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ABSTRACT 
 
Background: Atherosclerosis is an inflammatory disease. The process starts in 
childhood with the accumulation of lipid-laden macrophages (foam cells) onto the 
intima of the arteries. Atherosclerosis can be asymptomatic for decades, and the 
subsequent clinical manifestations of the disease vary from lower limb ischemia, 
myocardial infarction and stroke to sudden cardiac death (SCD). The subclinical 
development of atherosclerosis can be measured by carotid artery intima media 
thickness (IMT), carotid arterial elasticity (CAC) and brachial artery flow-mediated 
dilatation (FMD) which depicts the endothelial function. Within atherosclerotic 
plaques, antigen-presenting cells (i.e. macrophages) and T lymphocytes are the main 
players modifying the progression of the disease. Macrophages express interleukin 18 
(IL-18) in response to inflammatory stimuli, and IL-18 further activates other cells. The 
main targets of IL-18 are the CD4+ T lymphocytes. IL-18 in combination with IL-12 
stimulates the expression of the highly pro-atherosclerotic interferon-γ (IFN-γ). Both 
IL-18 and IFN-γ have been found to be expressed in human atherosclerotic lesions and 
linked with the development of atherosclerosis and unstable vulnerable atherosclerotic 
plaques in murine models and in humans. 
Aims: The present study aimed to investigate whether the variation of the IL-18 gene 
(SNPs rs1946519, rs360717, rs549908, rs4937100, rs5744292 and rs187238) affects 1) 
the development of subclinical atherosclerosis among a healthy Finnish population 
(Study I); 2) the expression of angiography-verified coronary artery disease (CAD) and 
the mortality for cardiovascular causes among a Finnish patient population (Study II); 
3) the occurrence of SCD and the artery wall areas of autopsy-verified coronary 
atherosclerotic lesions (Studies III and IV). Finally, the purpose was to examine 4) 
whether the traditional risk factors interact with IL-18 gene polymorphism and modify 
the risk of SCD (Study IV). 
Subjects and Methods: The study was based on three clinical and one autopsy study 
series comprising a total of over 5,000 subjects. In order to explore the frequencies of 
the most common haplotypes and 5 tag SNPs in the Finnish population, and to 
investigate the possible association between IL-18 gene polymorphism and the 
development of subclinical atherosclerosis, we used a study population of the 
Cardiovascular Risk in Young Finns Study comprising 2,282 young Finnish Caucasian 
adults selected randomly from the national population registry (Study I). In order to 
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investigate whether the same 5 IL-18 tag SNPs would affect the expression of CAD, 
we used a subpopulation of patients (n=461) who had undergone coronary angiography 
in the Finnish Cardiovascular Study. Follow-up data on the whole study population 
(n=2152) was used to investigate if these IL-18 gene polymorphisms associate with an 
altered risk of death due to cardiovascular causes (Study II). Furthermore, the material 
of an autopsy study of 663 men (The Helsinki Sudden Death Study, HSDS) was used 
to assess whether a known promoter region -137 G/C SNP (rs187238) affects the 
occurrence of SCD and CAD, and whether this effect is modulated by known risk 
factors (Studies III and IV). The Tampere Vascular Study, comprising 21 
atherosclerotic and 5 control samples obtained from live patients, was further utilized 
to verify the functional interaction in reference to the expression of IL-18 and IFN-γ 
(Study IV). 
Results: In the Cardiovascular Risk in Young Finns Study, one major haplotype 
(frequency, 0.24) associated significantly with lower IMT among young healthy 
Caucasian men. Among women there was no similar association. The sex-by-genotype 
interaction in relation to IMT was significant. Other polymorphisms or haplotypes were 
not seen to have any effect on IMT, CAC or FMD values (Study I). Among the patient 
population of the Finnish Cardiovascular Risk Study, the variation of the IL-18 gene 
was not observed to associate significantly with cardiovascular mortality. However, 
among patients who had undergone coronary angiography, one major haplotype 
(frequency, 0.27) had a different sex-dependent impact on the expression of CAD. 
Among men, the carriers of this haplotype had a lower occurrence of left main branch 
CAD, whereas among women the haplotype was not seen to associate with the 
expression of CAD (Study II). This major haplotype is also the only one carrying the 
minor T allele of the +127 C/T tag SNP. It is also the only haplotype carrying the minor 
C allele of the functional promoter region -137 G/C SNP (rs187238). 
In the HSDS, the minor C allele of the -137 G/C SNP (rs187238) associated 
with a lower occurrence of SCD (Study III). Furthermore, hypertension interacts with 
the -137 G/C SNP, affecting the risk of SCD due to CHD and the development of 
coronary atherosclerosis. Hypertension was a major risk factor for both the risk of SCD 
and the development of coronary atherosclerosis among GG homozygotes. Among C 
allele carriers, we did not find any significant effect. Hypertension also affected the 
mRNA expression of IL-18 and IFN-γ in human atherosclerotic plaques obtained from 
live patients. This effect was also seen to be modulated by IL-18 genotype (Study IV). 
[11] 
 
Conclusions: IL-18 gene polymorphism was observed to affect the development of 
subclinical atherosclerosis as well as the occurrence of angiography-verified CAD 
among men but not among women. Furthermore, a functional IL-18 gene polymor-
phism (rs187238) was found to associate with the risk of SCD among men. Hyperten-
sion interacted with this promoter region polymorphism and modulated the artery wall 
areas of coronary atherosclerotic plaques and the risk of SCD due to CHD. 
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TIIVISTELMÄ 
 
Tausta. Ateroskleroosi eli valtimonkovettumatauti on tulehduksellinen 
verisuonisairaus, joka alkaa nuoruusiässä rasvatäytteisten syöjäsolujen (vaahtosolujen) 
asteittaisella kertymisellä valtimoiden sisimpään kerrokseen (intimaan). 
Ateroskleroosilla on useita kliinisiä ilmenemismuotoja, joista tärkein, 
sepelvaltimotauti, voi johtaa sydänäkkikuolemaan. Taudin varhaisten, ei-kliinisten 
verisuonimuutosten kehittymistä voidaan seurata mittaamalla ultraäänitutkimuksen 
avulla kaulavaltimoiden sisäkerroksen (intima-media, IMT) paksuutta tai seinämän 
elastisuutta ja olkavaltimon laajenemisvastetta lisääntyneelle verenvirtaukselle. 
Olkavaltimon laajenemisvaste kuvastaa endoteelin toimintakykyä. Tärkeimpiä soluja, 
jotka vaikuttavat ateroskleroosin kehittymiseen suonen seinämässä, ovat sileiden 
lihassolujen ja endoteelisolujen ohella antigeenejä esittelevät solut (makrofagit) ja T-
lymfosyytit. Makrofagit tuottavat interleukiini (IL) 18:aa, joka aktivoi muita soluja ja 
CD4+ T-lymfosyyttejä. IL-18 yhdessä IL-12:n kanssa stimuloi T-lymfosyyttejä 
tuottamaan interferoni gammaa (IFN-γ). Ihmisen ateroskleroosimuutoksista on löydetty 
sekä IL-18:aa että IFN-γ:aa, ja niiden on havaittu lisäävän repeämisalttiiden, herkästi 
komplisoituvien ateroskleroosimuutosten kehittymistä. 
Tavoitteet. Tutkimuksen tarkoituksena oli tutkia, vaikuttaako IL-18-geenin 
polymorfismi eli monimuotoisuus (pistemutaatiot, single nucleotide -polymorfismit 
(SNP) rs1946519, rs360717, rs549908, rs4937100, rs5744292 ja rs187238): 1) edellä 
kuvattujen varhaisten ei-kliinisten valtimomuutosten kehittymiseen suomalaisilla 
nuorilla aikuisilla (tutkimus I, LASERI-tutkimus), 2) sepelvaltimoiden 
varjoainekuvauksella diagnosoidun sepelvaltimotaudin ilmenemiseen ja 
kardiovaskulaarikuolleisuuteen suomalaisilla sairaalapotilailla (tutkimus II, 
FINCAVAS-tutkimus) sekä 3) ruumiinavauksissa mitattuihin erityyppisten 
ateroskleroosimuutosten pinta-aloihin ja sydänäkkikuoleman riskiin (III ja IV, HSD-
tutkimus). Lisäksi selvitettiin, 4) onko IL-18-geenin ja riskitekijöiden interaktioilla 
(yhteisvaikutus) vaikutusta sydänäkkikuoleman riskiin ja geenien ilmenemiseen (IV). 
Aineisto ja menetelmät. Tutkimus perustui kolmeen kliiniseen (LASERI, TVS, 
FINCAVAS) ja yhteen ruumiinavausaineistoon (HSDS), joista tutkittiin yhteensä yli 
5000 henkilöä. IL-18-geenin yleisempien haplotyyppien ja 5 pistemutaation yleisyys 
suomalaisessa populaatiossa määritettiin Lasten sepelvaltimotaudin 
riskitekijät -tutkimuksen (LASERI) kansallisesta rekisteristä sattumanvaraisesti valitun 
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tutkimuspopulaation perusteella. LASERI-tutkimukseen kuuluu 2282 suomalaista 
tervettä aikuista (tutkimus I). LASERI-tutkimusaineistosta tutkittiin myös, vaikuttaako 
IL-18-geenin variaatio valtimonkovettumataudin varhaisten, ei-kliinisten muutosten 
kehitykseen. FINCAVAS (The Finnish Cardiovascular study) -tutkimuksessa on 
seurattu yliopistollisen sairaalan 2152 potilaan tilaa kliinisen rasituskokeen jälkeen. 
Osalle potilaista (n=461) on myös tehty sepelvaltimoiden varjoainekuvaus. 
FINCAVAS-aineiston avulla tutkittiin, vaikuttaako IL-18-geenin variaatio 
sepelvaltimotaudin ilmenemiseen ja kardiovaskulaarikuolleisuuteen (II). IL-18-geenin 
promoottorialueen funktionaalisen -137 G/C (rs187238) -pistemutaation vaikutus 
sydänäkkikuoleman esiintyvyyteen selvitettiin käyttäen oikeuslääketieteellistä 
ruumiinavausaineistoa (The Helsinki Sudden Death Study, HSDS) (III ja IV). HSDS 
koostuu 663 miehen ruumiinavauksesta saaduista tiedoista. Saman ruumiinavaussarjan 
avulla tukittiin, muokkaako ko. pistemutaatio (rs187238) perinteisten riskitekijöiden 
vaikutusta sydänäkkikuoleman esiintyvyyteen (IV) eli onko tällä IL-
18 -geenivaihtelulla interaktiota riskitekijöiden kanssa. Lisäksi tässä osatyössä tutkittiin 
IL-18 ja IFN-γ mRNA -ekspressiota pitkälle edenneissä ateroskleroosimuutoksissa 
(n=21) ja terveissä valtimonäytteissä (n=5). Näytteet ilmenemistutkimuksiin saatiin 
menossa olevasta TVS-tutkimuksesta (Tampere Vascular Study) . 
Tulokset. LASERI-tutkimuksessa havaittiin, että yhden yleisen haplotyypin 
(frekvenssi 0.24) mieskantajilla oli merkitsevästi pienempi karotisvaltimon sisäkalvon 
(IMT) paksuus verrattuna muihin miehiin. Naisilla ei vastaavaa yhteyttä havaittu. Tämä 
ero haplotyypin vaikutuksessa karotisvaltimon sisäkalvon paksuuteen naisten ja 
miesten välillä oli merkitsevä. Muuten IL-18-geenin variaatio ei merkitsevästi 
vaikuttanut valtimokovettumataudin subkliinisiin ilmenemismuotoihin (IMT, 
elastisuus, endoteelifunktio) (tutkimus I). FINCAVAS-tutkimuksessa ei havaittu 
yksiselitteistä yhteyttä tutkitun IL-18-geenin variaation ja 
kardiovaskulaarikuolleisuuden välillä. Kuitenkin yhden yleisen IL-18-geenin 
haplotyypin mieskantajilla (frekvenssi 0.27) oli merkitsevästi pienempi todennäköisyys 
sairastua sepelvaltimoiden päärungon (left main) tautiin. Naisilla ko. haplotyyppi ei 
vaikuttanut sepelvaltimotaudin ilmenemiseen. Interaktio sukupuolen ja IL-18-
haplotyypin kantajuuden välillä on merkitsevä (tutkimus II). Kyseinen haplotyyppi on 
ainoa IL-18-geenin haplotyyppi, joka sisältää +127 C/T -pistemutaation (rs360717) 
harvinaisemman T-alleelin. Samoin myös funktionaalisen IL-18 -137 G/C 
(187238) -promoottorialueen pistemutaation harvinaisempi C-alleeli esiintyy 
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ainoastaan tässä haplotyypissä. HSDS aineistossa C-alleelin kantajilla 
sydänäkkikuoleman esiintyvyys oli merkitsevästi alhaisempi verrattuna GG-
homotsygootteihin. Lisäksi tämän funktionaalisen pistemutaation havaittiin 
muokkaavan korkeaan verenpaineeseen liittyvää kohonnutta sydänäkkikuoleman riskiä 
ja sepelvaltimoiden ateroskleroosimuutosten kehittymistä. GG-homotsygooteilla 
korkea verenpaine lisäsi voimakkaasti sydänäkkikuoleman esiintyvyyttä ja edisti 
sepelvaltimoiden ateroskleroosimuutosten kehittymistä. C-alleelin kantajien 
keskuudessa vastaavaa vaikutusta ei havaittu. Lisäksi korkean verenpaineen havaittiin 
vaikuttavan IL-18:n ja IFN-γ:n mRNA-ekspressioon (ilmentymiseen) 
ateroskleroottisissa plakeissa, ja IL-18-genotyypin havaittiin muokkaavan tätä 
vaikutusta (IV).  
Johtopäätökset. IL-18-geenin variaatio vaikuttaa subkliinisen valtimonkovettumatau-
din kehittymiseen ja sepelvaltimotaudin ilmenemiseen miehillä. Lisäksi havaittiin 
merkitsevä yhteys funktionaalisen IL-18-polymorfian (rs187238) ja 
sydänäkkikuoleman riskin välillä. Tämä pistemutaatio (rs187238) muokkaa myös 
korkean verenpaineen vaikutusta sepelvaltimoiden ateroskleroosivaurioiden 
kehittymiseen ja sydänäkkikuoleman esiintyvyyteen. 
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INTRODUCTION 
Atherosclerosis is a multifactorial disease that develops from childhood and ultimately 
can lead to death. The clinical manifestations of atherosclerosis include myocardial 
infarction (MI), stroke and sudden cardiac death (SCD). The prevalence of the disease 
is high, and approximately 50% of all deaths globally can be attributed to 
atherosclerosis (Lusis 2000). 
The development of atherosclerosis begins with the accumulation of lipid 
particles into the intima, which is the innermost layer of the arteries. The intima is 
separated from the vessel lumen only by the endothelium. This process starts in early 
childhood and adolescence (Enos et al. 1953, Insull 2009, McGill and McMahan 1998, 
Newman et al. 1986). In the next phase, the accumulated lipids – or, more precisely, 
low-density lipoprotein (LDL) cholesterol – are oxidized and engulfed by the 
accumulating macrophages, forming lipid-filled foam cells. This denotes the formation 
of an early fibroatheroma. Fibroatheromas begin to form in persons in their teens and 
early twenties (Enos et al. 1953, Insull 2009, McGill and McMahan 1998, Newman et 
al. 1986). From this point on, the progression of the disease is marked by accumulating 
lipids and increasing inflammatory activity in the plaques. The inflammatory activity is 
caused by the interplay of accumulating macrophages, T lymphocytes, dendritic cells, 
and also by other cells capable of modulating the inflammatory reaction (Ross 1999). 
This process develops further, and generally by the 6
th
 decade of life, the arteries 
already contain fibroatheromas capable of causing clinical manifestations of the 
disease (Insull 2009). The whole disease process is driven by two main entities – the 
accumulation of lipids due to excessive concentrations of circulating LDL cholesterol 
and the inflammatory reaction within the atherosclerotic plaques (Ross 1999). 
Risk factors for atherosclerosis can be divided into those with a strong genetic 
component and environmental risk factors. Environmental risk factors have been 
estimated to account for approximately 50% of the disease burden, with estimates on 
the effect of the genetic component ranging from 20% to 60% (Kraus 2000, Smith et 
al. 2000a). In reality, hardly any risk factor is independent of genetic modulation. For 
example, the effect of smoking is modulated by genetic factors (Stephens and 
Humphries 2003). Traditional risk factors include hypertension, smoking, high LDL 
cholesterol levels, diabetes, obesity, physical inactivity, male sex and insulin resistance. 
Genetic research has many approaches. Genome-wide linkage studies and, more 
recently, genome-wide association analyses have provided novel ways of exploring 
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candidate genes. However, candidate gene studies are still needed to validate 
preliminary results and to elaborate the possible mechanism by which specific genetic 
factors could exert their influence (Kronenberg 2008). 
The present study is a candidate gene study. It was commenced to explore the 
atherogenic properties of the Interleukin (IL) 18 gene. IL-18 is a pleiotrophic and pro-
inflammatory cytokine. It is produced mainly by macrophages. The main function of 
IL-18 is to stimulate of the expression of interferon gamma (IFN-γ) by T lymphocytes 
(Arend et al. 2008). The IL-18 gene was selected, because IL-18 has previously been 
linked with the development of atherosclerosis in murine models and it has also been 
associated with the development of unstable plaques (Elhage et al. 2003, Mallat et al. 
2001a, Mallat et al. 2001b). Circulating IL-18 levels have also been found to predict 
the occurrence of acute coronary syndromes (Blankenberg et al. 2002, Espinola-Klein 
et al. 2007). Since the present study was commenced, a few studies have emerged on 
the relation between the variation of the IL-18 gene and the risk of MI as well as death 
due to cardiovascular causes (Bis et al. 2008, Kretowski and Kinalska 2003, Tiret et al. 
2005). 
The present study aimed to clarify whether the variation of the IL-18 gene would 
affect the expression of atherosclerosis in different phases of the disease and among 
different populations. This was accomplished by exploring the possible associations 
between IL-18 gene polymorphism and 1) the development of subclinical 
atherosclerosis among a healthy Caucasian population, 2) the expression of 
angiography-verified coronary artery disease and mortality among Finnish patient 
population, 3) the occurrence of sudden cardiac death among Finnish men, and, finally, 
4) the risk factors as well as the interactions of genotype and risk factors affecting the 
risk of SCD. 
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REVIEW OF THE LITERATURE 
 
1.1 The epidemiology of atherosclerotic diseases 
 
Atherosclerosis is a disease that affects large arteries, and it is the underlying cause of 
approximately 50% of all deaths in the Western world (Lusis 2000). Atherosclerosis 
has many clinical manifestations ranging from mild ischemia of the lower limb to SCD 
and stroke. Ischemic heart disease is a major complication of atherosclerosis. 
According to the statistics of the World Health Organization, it was the most frequent 
individual disease as a cause of death globally, accounting for 12.7% of all deaths in 
the year 2002 (WHO 2002). The second most frequent cause of death was 
cerebrovascular disease (9.6%). In developed countries, where fatal communicable 
diseases are less frequent, the problem is more evident when compared to the global 
situation. In the year 2008, ischemic heart disease alone claimed 11,761 lives in 
Finland, which accounts for 24.0% of all deaths, thus making it a major problem 
(StatisticsFinland 2008). 
 
1.2 Major atherosclerosis-related cardiovascular diseases  
 
Cardiovascular disease (CVD) is a large entity that contains many diseases. Not all of 
them are directly due to atherosclerosis, but many of the major diseases are intimately 
linked with the condition. 
 As stated before, ischemic heart diseases are the leading entity in global 
mortality statistics. The condition is basically chronic, but it can have severe acute 
complications. Chronic ischemic heart diseases include conditions such as coronary 
artery disease [CAD] (usually diagnosed by an angiography-verified narrowing of at 
least one of the coronary arteries) and ischemic cardiomyopathy. Acute diseases 
include, for example, stress-related stable angina pectoris (AP), unstable AP, acute MI 
and the subsequent complications of MI and other types of acute ischemic heart disease 
that can lead to heart failure (Boersma et al. 2003, Fuster et al. 1992, WHO 2007). 
Cerebrovascular disease is also a chronic condition that can have severe clinical 
implications. The acute complications related to atherosclerosis include cerebral 
infarction due to occlusion or thrombosis of the precerebral or cerebral arteries (e.g. 
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stroke). Transient ischemic attack can also be a manifestation on atherosclerotic 
cerebrovascular disease. 
Atherosclerosis also affects all other arteries such as the aorta, sometimes 
leading to the formation of an aortic aneurysm. Furthermore, the complications of 
peripheral artery disease can vary from chronic disability to acute ischemia of the 
lower limb. Hypertension, diabetes and hypercholesterolemia are considered diseases 
that intimately mediate the development of atherosclerosis (Boersma et al. 2003, Fuster 
et al. 1992). 
 
1.3 Risk factors for atherosclerosis 
 
In a concise review published in Nature in 2000, the risk factors associated with 
atherosclerosis and coronary heart disease (CHD) were divided into those with a strong 
genetic component and environmental risk factors (Lusis 2000). However, this division 
is not strict and some risk factors are strongly influenced by lifestyle factors as well as 
genetics. Another classification approved by the American Heart Association has 
emerged dividing risk factors into five main categories (Smith et al. 2000b). The first 
category includes causative risk factors such as smoking, elevated blood pressure, 
elevated serum cholesterol (or LDL cholesterol or, alternatively, elevated 
apolipoprotein B [ApoB]), low high-density lipoprotein cholesterol (HDL) and 
diabetes mellitus. The second category includes conditional risk factors such as 
triglycerides, small LDL particles, lipoprotein (a), homocysteine, coagulation factors 
(plasminogen activating factor inhibitor-1 and fibrinogen) and elevated C-reactive 
protein levels (CRP). All of these factors, except for CRP, are considered conditional 
when serum levels are abnormally high. The third group is classified as predisposing 
risk factors such as overweight and obesity, physical inactivity, male sex, family 
history of premature CHD, socioeconomic factors, behavioural factors (e.g. mental 
depression) and insulin resistance. The fourth category contains risk factors that are 
related to the coronary plaque burden. This category includes age and nonspecific ST 
segment changes in the resting electrocardiogram. Age is therefore a definitive risk 
factor, but its effect is mainly conveyed through the accumulation of other risk factors 
(Pencina et al. 2009, Smith et al. 2000b). The last risk factor, defined as a separate 
susceptibility factor, is left ventricular hypertrophy of the heart. 
 As noted earlier, many risk factors have a strong genetic component, although 
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they are also regulated by lifestyle factors. A good example of this is LDL cholesterol, 
which is associated with lifestyle (diet) but also controlled by genetic factors 
(Kathiresan et al. 2008, Roy et al. 2009). Other similar risk factors include, for 
example, HDL cholesterol, lipoprotein levels, elevated blood pressure, elevated 
homocysteine levels and diabetes. The strongest risk factor that may be considered 
environmental is a high-fat diet. Naturally, cigarette smoking can be classified into this 
category as well (Lusis 2000). 
It is difficult to estimate the contribution of genetic and environmental factors to 
the development of atherosclerosis, although a family history of premature CHD has 
been shown to be a very significant risk factor even after controlling for all other 
significant risk factors. Estimates of the overall effect of the genetic component in the 
development of CAD range from 20%–60%, and it is presumed to be more pronounced 
at a younger age (Kraus 2000). Supporting this, a large twin study conducted in 
Sweden revealed that the relative risk of a fatal CHD is markedly pronounced for a 
monozygotic twin after the other twin has died of CHD (the risk ratio for men whose 
twin had died under the age of 55 was 8.1 [2.7-24-5] and the risk ratio for women 
whose twin had died under the age 65 was correspondingly 15.0 [7.1-31.9]) 
(Marenberg et al. 1994). Furthermore, twin studies have revealed that the heritability 
(e.g. the statistical estimate of the degree to which genes contribute to a multifactorial 
trait) of an MI is 26% for males and 60% for females (Nordlie et al. 2005). As a 
reference, the major causal risk factors (smoking, elevated blood pressure, elevated 
serum total cholesterol [and LDL cholesterol in particular], low HDL cholesterol and 
diabetes) among asymptomatic high-risk patients account for approximately 50% of 
the variability in the risk of CHD (Smith et al. 2000a). In other populations, the 
explanatory value of major risk factors diminishes. For example, only 25% of the 
excess CHD risk for diabetic patients can be attributed to established risk factors 
(Pyorala et al. 1987). As both environmental and genetic risk factors fail to explain the 
whole disease process, it is obvious that the gene-environment interactions are also 
major players affecting the outcome of the disease. For example, smoking has been 
shown to interact with ApoE, lipoprotein lipase and IL-6 genotypes, affecting the risk 
of CHD (Stephens and Humphries 2003).  
Currently, it is also possible to use risk factor data (age, blood pressure, 
smoking, HDL cholesterol and total cholesterol) in order to approximate the individual 
risk of CVD. This method is called SCORE (= Systematic Coronary Risk Evaluation), 
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and the algorithm is based on the results of a large general population-based study 
(Graham et al. 2007). The calculator for individual risk assessment is freely available 
on the internet. In Finland the National Institute for Health and Welfare has also 
published a calculator for the risk assessment of CVD. The algorithm is based on the 
data of the Finnish FINRISK study (Jousilahti et al. 2005, Vartiainen et al. 1994). In 
addition to including the data of the above-mentioned variables used in the SCORE 
calculator, the FINRISK calculator also incorporates family history of CVD to the 
algorithm. This calculator has also been published on the internet and it is freely 
available. 
 
1.4 Manifestations of atherosclerosis 
 
1.4.1 Subclinical atherosclerosis 
Increased carotid artery intima-media thickness (IMT), carotid artery elasticity and 
flow-mediated dilatation (FMD) of the brachial artery are early subclinical markers of 
atherosclerosis and predict future coronary events (Lorenz et al. 2006, Schroeder et al. 
1999, Simons et al. 1999). Carotid IMT can be measured easily and non-invasively 
using ultrasound, and it has been recognized to be a valid method for evaluating the 
development of atherosclerosis (Greenland et al. 2000). Increases in carotid IMT 
associate with a higher risk of future cardiovascular vascular events independently of 
traditional risk factors (Bots et al. 1997, O'Leary et al. 1999). Furthermore, patients 
with cardiovascular disease have higher carotid artery IMT when compared to healthy 
controls (Burke et al. 1995). In a very recent article by Franks et al. published in the 
New England Journal of Medicine, it was also shown for the first time that 
hypertension, obesity and impaired glucose tolerance predict premature death for 
endogenous causes (Franks et al.). 
Carotid artery compliance (CAC) depicts the ability of the arteries to expand 
under the influence of pulse pressure. It can be evaluated by simultaneous ultrasonic 
measurement of carotid artery dilatation and measurement of pulse pressure from the 
brachial artery. Diminished arterial elasticity has been shown to be an independent 
predictor of cardiovascular events and mortality in high-risk individuals (Barenbrock et 
al. 2002, Blacher et al. 1998). 
FMD of the brachial artery quantifies the amount of vasodilatation in response 
to endothelial activation by an increase in local blood flow (Celermajer et al. 1992). It 
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is evaluated by first inflating a pneumatic tourniquet, placed around the forearm, up to 
a pressure of 250 mmHg and over. After 5 minutes, the pressure is released and the 
responding dilatation of the brachial artery measured. The dilatation can be attributed 
mainly to the nitric oxide released by endothelial cells (ECs) (Mullen et al. 2001). Even 
before the anatomical evidence of atherosclerosis appears, FMD is impaired in young 
symptom-free subjects with vascular disease risk factors. Impaired brachial endothelial 
function also associates with the prevalence and extent of clinically determined and 
angiography-verified coronary artery disease (CAD) (Neunteufl et al. 1997). 
 
1.4.2 Severe clinical manifestations of cardiovascular disease 
 
1.4.2.1 Myocardial infarction 
MI is a serious complication of coronary atherosclerosis. The term itself refers to death 
of cardiomyocytes due to prolonged ischemia (2000). This acute coronary syndrome is 
caused by a sudden decrease in blood flow due to an interruption in coronary artery 
circulation. This interruption is caused by intraluminal thrombi, inducing a total or 
severe occlusion of the artery, and the situation might be further complicated by 
vasoconstriction and microembolisation of the thrombi (Fuster et al. 1992). Sometimes 
an acute coronary event is provoked by a heavy stenosis without thrombi due to an 
advanced fibrocalcific plaque (Virmani et al. 2000a). If the occlusion of the artery lasts 
for more than 30 minutes, the myocardium can suffer irreversible damage (Hermens et 
al. 1992). If the occlusion persists longer, the damaged area increases in size, and after 
6 hours the affected area of the myocardium becomes necrotic. This can lead to serious 
loss of function in the myocardium, and the most severe possible end point resulting 
from this is death (Boersma et al. 2003). 
 The cause of intraluminal coronary thrombi is the disruption of the vessel wall. 
In MIs resulting in death, the underlying cause is most often the disruption of a thin-
cap fibroatheroma (50%–60% of all deaths). The other two causes with thrombotic 
aetiology are thrombosis due to erosion of the endothelium (20% of deaths) and 
thrombosis due to the protrusion of a calcified nodule into the arterial lumen (2% of 
deaths). As mentioned before, heavy coronary stenosis without thrombi, due to 
advanced fibrocalcific plaque formation, can also provoke an MI resulting in death 
(20%–30% of all deaths) (Insull 2009, Virmani et al. 2000a). However, not all plaque 
ruptures lead to acute coronary syndrome. A smaller plaque rupture can also happen 
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with no clinical manifestations (Falk et al. 1995). According to autopsy data, 
approximately 9% of healthy individuals have disrupted plaques in their coronaries, 
and this proportion can rise up to 22% among people with hypertension and diabetes 
(Davies et al. 1989). Smaller plaque ruptures with superimposed thrombus can be 
repaired by new formation of a fibrous cap, and this can also lead to increased 
narrowing of the lumen (Mann and Davies 1999). The results of an autopsy study by 
Burke et al. showed that among sudden cardiac death victims, 61% had healed ruptures 
in coronary arteries and that many of the deceased had multiple healed ruptures at the 
same sites. Furthermore, multiple healed ruptures were associated with increased 
coronary narrowing (Burke et al. 2001). According to an extensive review by Falk et al. 
in 1995, which summarized the results of four independent autopsy studies, the 
majority of culprit lesions are identified in sites with less than 50% stenosis, although 
increased narrowing may result in higher disability and certainly incurs a great risk for 
acute coronary syndrome. The authors concluded that this is due to the fact that the 
number of sites with less severe stenosis is overwhelmingly greater and the smaller
 
plaques are probably more likely to lead to acute
 
clinical events, because they are
 
less 
frequently associated with protective collateral circulation (Falk et al. 1995). 
According to the European Society of Cardiology and the American College of 
Cardiology (ESC and ACC), an MI can be diagnosed if the patient has ischemic 
symptoms (typical chest pain) or changes in the electrocardiogram indicative of 
myocardial infarction (ST elevation or depressions or pathological Q waves indicating 
of transmural myocardial infarction) and, at the same time, the patient presents with a 
typical rise in the troponin levels or creatine kinase-MB. If the patient has typical chest 
pain but no ST elevations or Q waves are found in the electrocardiogram, and the 
troponin levels or creatine kinase-MB levels in the serum do not demonstrate the 
typical rises, the condition is diagnosed as unstable angina pectoris (UAP)(ESC/ACC 
2000) 
 
1.4.2.2 Sudden cardiac death 
Sudden cardiac death (SCD) is caused by cardiac arrest leading to the termination of 
effective cardiac function. According to the World Health Organization, SCD is defined 
as death from cardiac causes within 1 hour of symptom onset if the death is witnessed. 
If not witnessed, the patient has had to have be observed alive and asymptomatic 
within the previous 24 hours. Most often the events leading to SCD are ventricular 
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tachycardia accelerating into ventricular fibrillation and, ultimately, to asystole or 
pulseless electrical activity (Huikuri et al. 2001, Winslow et al. 2005). In rare cases, 
mechanical defects caused by a previous MI, such as ventricular or papillary muscle 
rupture, pericardial tamponade, septal defects and ischemic valvular dysfunction, may 
also lead to SCD in the absence of ventricular tachycardia (Bunch et al. 2007). The 
underlying cause of SCD is most often (~80%) coronary atherosclerosis. Hypertrophic 
and dilated cardiomyopathy account fo approximately 10%–15% of the cases. These 
conditions can be attributed to genetic predisposition combined with hypertension and 
infections as well as other yet unknown factors. The underlying cause for SCD can also 
be primary electrical ion channel abnormality and valvular or genital heart disease 
(<5%) (Huikuri et al. 2001). Men have a higher risk for SCD. Currently, 75% of all 
SCD victims are men (Zipes and Wellens 1998). A positive family history also clearly 
increases the risk of SCD independently of risk factors. The results of previous studies 
indicate that if one first-degree relative has died of SCD, the risk is increased by 50%–
80% and a parent’s SCD increases the risk 9-fold for the offspring (Friedlander et al. 
1998, Jouven et al. 1999). In developed countries, SCD accounts for over 50% of all 
cardiac deaths (Zipes and Wellens 1998). 
 Coronary atherosclerosis is not only the biggest risk factor for SCD, but SCD is 
often the first manifestation of the disease. It is also the most common manifestation of 
the condition (Schatzkin et al. 1984). As mentioned before, SCD can be caused by 
acute MI resulting from the occlusion of the coronary artery by a thrombus. This is the 
case in more than half of the cases, but the estimate varies due to different study 
settings (Farb et al. 1995, Mehta et al. 1997). In the rest of the cases, no thrombosis can 
be found. The recent
 
MI can also have been caused by progressive arterial narrowing, 
or SCD may be due to arrhythmias arising from old myocardial infarction
 
scars in the 
absence of a recent MI (Farb et al. 1995, Mehta et al. 1997). This conclusion is backed 
up by the fact that old infarction scars of the myocardium, a known history of ischemic 
heart disease and three-vessel disease all inversely associate with the presence of 
coronary arterial thrombus at autopsy (Davies et al. 1989). 
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1.5 Normal arteries 
 
The pathogenesis of atherosclerosis starts in childhood and the disease aetiology is 
complex (McGill et al. 2000, Ross 1999). It affects large arteries and its clinical 
manifestations are usually not seen until middle age. The normal artery has three layers 
(intima, media adventitia). In atherosclerosis, the mainly affected layer is the intima 
whose luminal side is normally covered by endothelial cells, thus forming an 
endothelial layer resting on a basement membrane. The internal elastic lamina, which is 
considered a part of the media, denotes the outside border between the intima and 
media. There are two main layers in the intima: the proteoglycan layer subjacent to the 
lumen (composed mainly of proteoglycan, sparse smooth muscle cells and isolated 
macrophages) and the musculoelastic layer (composed of smooth muscle cells [SMC], 
elastic fibres and collagen) (Stary et al. 1992). The media consists mainly of SMCs 
and extracellular matrix (elastic fibres and collagen). The SMCs of this layer are 
responsible for vasoconstriction and vasodilatation (Ross and Glomset 1976). The 
media is normally much thicker than the intima, but the ratio between these can vary 
anywhere between 0.1 and 1 (Stary et al. 1992). The media is separated from the 
adventitia by an external elastic lamina. The adventitia consists of fibroblasts (loose 
connective tissue), SMCs, mast cells, collagen fibres and proteoglycan as well as the 
vaso vasorum which is responsible for the blood supply to the adventitia and 
approximately 2/3 of the outer layer of the media. The oxygen supply to the intima and 
the inner third of the media is provided via diffusion from the luminal blood flow. 
Through the adventitia comes also lymphatic drainage and small nerves innervating the 
SMCs of the media, thus controlling the contractile function of the arteries. Lymphatic 
vessels do not reach the intima (Ross and Glomset 1976). 
 
1.6 Classification of atherosclerotic lesions 
 
Perhaps the most commonly used classification of atherosclerotic lesions is the one 
recommended and updated by the American Heart Association (Stary 2000, Stary et al. 
1995, Stary et al. 1994). It classifies lesions into: initial change lesions (I), minimal 
change lesions (fatty streak) (II), intermediate lesion pre-atheromas (III), atheromas 
(IV), fibroatheromas (V), haemorrhagic/thrombotic lesions (VI), calcified lesions (VII) 
and fibrotic lesions (VIII). In the previous AHA classification, lesion types VII and 
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VIII were classified as subtypes of type V lesions (Vb and Vc correspondingly). The 
current AHA-recommended classification is presented in Table 1. An alternative 
classification of atherosclerotic plaques has been presented by Virmani et al., but 
although this classification is based on autopsy data and contains an extensive 
description of lesions prone to rupture, it has not been adopted and the Stary 
classification remains the standard (Virmani et al. 2000b). The classification by 
Virmani et al. is presented in Table 2. 
 
Table 1. The classification of atherosclerotic lesions according to the American Heart 
Association. 
Lesion type Cellular composition 
  I     Initial change Isolated macrophage foam cells 
II     Minimal change Multiple layers of foam cells 
IIa: Progression-prone; Abundant 
SMCs 
Few lymphocytes 
IIb: Progression resistant; Few SMCs Isolated mast cells 
III     Preatheroma Isolated pools of densely packed 
extracellular lipids 
SMCs accumulate lipid droplets 
IV     Atheroma Confluent core of extracellular lipids 
Increased number of lymphocytes 
SMCs decrease in numbers 
V      Fibroatheroma Fibrous tissue and collagen added 
Intimal SMCs increase in number 
VI     Hemorrhagic/thrombotic lesion Lesion becomes fissured and/or thrombotic 
 
VII    Calcified lesion (Previously type Vb) Calcification predominates 
VIII   Fibrotic lesion (previously type Vc)  Fibrous tissue changes predominate 
Lipid core is nearly absent 
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Table 2. Classification of autopsy-verified atherosclerotic lesions by Virmani et al. 
Lesion name Lesion description by histopathology Thrombosis 
Non-atherosclerotic 
intimal lesions 
  
1. Intimal 
thickening 
Normal accumulation of SMCs in the intima 
with the absence of lipid or macrophage 
foam cells 
Thrombus is absent 
2. Intimal 
xhantoma of 
fatty streaks 
Subendothelial accumulation of foam cells 
in the intima with no necrotic core or fibrous 
cap; animal and human data show that such 
lesions usually regress 
Thrombus is absent 
Progressive lesions   
   3a. Pathologic intimal 
thickening 
SMCs in a proteoglycan-rich matrix with 
areas of extracellular lipid accumulation 
without necrosis 
Thrombus is absent 
   3b. With erosion Luminal thrombosis, plaque the same as 
above 
Thrombus most 
often mural and 
infrequently 
occlusive 
   4a. Fibrous cap 
atheroma 
Well-formed necrotic core with overlying 
fibrous cap 
Thrombus is absent 
   4b. With erosion Luminal thrombosis; plaque the same as 
above, no communication of thrombus with 
necrotic core 
Thrombus most 
often mural and 
infrequently 
occlusive 
   5. TCFA A thin fibrous cap infiltrated with 
macrophages and lymphocytes, rare SMCs, 
and an underlying necrotic core 
Absent, with 
intraplaque 
haemorrhage/fibrin 
       a. With rupture Fibroatheroma with cap disruption; luminal 
thrombus communicates with underlying 
necrotic core 
Thrombus usually 
occlusive 
  6. Calcified nodule Eruptive nodular calcification with 
underlying fibrocalcific plaque 
Thrombus usually 
non-occlusive 
  7. Fibrocalcific plaque Collagen-rich plaque usually with 
significant stenosis; contains large areas of 
calcification with few inflammatory cells; 
necrotic core may be present 
Thrombus is absent 
Abbreviations: SMC = smooth muscle cell; TCFA = thin-cap fibroatheroma (Virmani 
et al. 2000b) 
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1.7 The development of atherosclerosis 
 
1.7.1 Initial change, minimal change lesions, pro-atheroma and atheroma 
In the beginning of the process of atherosclerosis, LDL particles accumulate onto the 
intima. This early fatty streak development begins in childhood and adolescence (Enos 
et al. 1953, Insull 2009, McGill and McMahan 1998, Newman et al. 1986). The 
accumulation is positively correlated with circulating levels of LDL. The preferred 
sites for LDL accumulation are those were the blood flow is disturbed due to branching 
or curvature of the artery. In these sites the endothelium has an altered morphology (the 
cells are polygonal in shape and have no particular orientation) and thus have increased 
permeability for macromolecules such as LDL (Gimbrone 1999). Furthermore, the 
disturbed blood flow in these sites has been shown to reduce the activity of 
atheroprotective molecules such as nitric oxide and increase the production of vascular 
cell adhesion molecule 1 (VCAM-1) which enables the recruitment of monocytes and 
lymphocytes (Jongstra-Bilen et al. 2006, Packard and Libby 2008). The retention of 
LDL within the intima involves interaction between matrix proteoglycans and apoB 
located on the surface of lipoproteins (Boren et al. 1998a, Boren et al. 1998b). In 
addition, lipoprotein a (Lp(a)), which also contains apoB, can accumulate in the intima 
(Grainger et al. 1994). If the trapped lipoprotein particles are not processed from the 
intima rapidly, they undergo progressive oxidation and are subsequently internalized by 
phagocytes through the function of scavenger receptors (scavenger receptor A and 
CD36) (Hajjar and Gotto 2003, Moore and Freeman 2006). However, even before the 
LDL particles are oxidized sufficiently for recognition by scavenger receptors, they can 
have pro-inflammatory properties. This ‘minimally oxidized’ LDL can stimulate the 
ECs to produce adhesion molecules such as VCAM-1, chemotactic proteins such as 
monocyte chemotactic protein 1 (MCP-1), and growth factors such as the macrophage 
colony stimulating factor (M-CSF) (Lusis 2000).  
Within the vessel wall, monocytes are transformed mainly into macrophages 
(but also to dendritic cells [DC]), and they engulf the oxidized LDL particles, forming 
foam cells. It is noteworthy that SMCs can also uptake oxidized LDL and thus form 
foam cells (Young et al. 2002). However, as noted earlier, the LDL cholesterol particles 
must first be oxidized. The enzymes involved in this process are reactive oxygen 
species (ROS) produced by macrophages and ECs in addition to other enzymes found 
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in atherosclerotic lesions, such as myeloperoxidase, sphingomyelinase, and secretory 
phosfolipase (Lamon and Hajjar 2008). The appearance of oxidized LDL within the 
intima further propagates the inflammatory response, as pro-inflammatory cytokines 
(such as IL-8 tumour necrosis factor α [TNF-α] and IL-1β) promote the attachment, 
rolling and infiltration of leukocytes to the site (Boudjeltia et al. 2006, Martin-Fuentes 
et al. 2007). During the chemotactic process, T cells are also accumulated onto the site. 
This creation of foam cells together with the accumulation of T cells stipulates the 
formation of a fatty streak. 
 In these early phases of atherosclerotic plaque development, medial SMCs 
begin to migrate to the scene (Bentzon et al. 2006). This is most likely due to direct 
mitogenic activities of cytokines or cytokine-induced production of mitogenic factors 
such as the platelet-derived growth factor (PDGF) (Myllarniemi et al. 1997). 
Meanwhile, the increasing amounts of foam cells within the plaque contribute to the 
process by secreting numerous cytokines (IL-1β, IL-6, IL-12, IL-18, TNF-α, TNF-β, 
IFN-β and IFN-γ), chemokines (MCP-1, IL-8), growth factors (PDGF and tumour 
growth factor β [TGF-β]), colony stimulating factors (M-CSF and GM-CSF), and 
proteolytic enzymes (matrix metalloproteinases [MMP] and cathepsins). As more foam 
cells form in response to the lipid accumulation, the plaque begins to grow, and this 
orchestra of different inflammatory factors begins to influence the form of the plaque. 
The accumulation of macrophages and foam cells denote the formation of an early 
fibroatheroma. This process begins in persons in their teens and early twenties (Enos et 
al. 1953, Insull 2009, McGill and McMahan 1998, Newman et al. 1986, Stary et al. 
1994). 
 
1.7.2 The formation of the atheroma and fibroatheroma 
As noted earlier, PDGF is a strong stimulator of SMC migration. The importance of 
this factor is even more underlined by the fact that it has also been shown to inhibit 
SMC apoptosis (Newby and George 1996). The over-expression of factors such as IL-
1, TNF-α and CD40L in the plaque are known to enhance the PDGF production by 
SMCs and ECs, allowing the indirect contribution of these cytokines to the migration 
of SMCs. The migration and proliferation of SMCs is also provoked by matrix 
metalloproteinase 9 (MMP-9)(Mason et al. 1999). At the site, SMCs can also produce 
many other pro-atherosclerotic cytokines (TGF-β, IFN-γ and MCP-1) (Doran et al. 
2008). The increasing numbers of SMCs migrated from the media through the internal 
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lamina to the intima and subendothelial space begin to produce extracellular matrix 
(ECM), which marks the formation of a fibrous cap onto the plaque (Libby 1995, Ross 
1999). The ECM in atherosclerotic plaques is formed mostly by proteoglycans with 
scattered type I collagen fibrils and fibronectin (Ross 1999). Furthermore, PDGF not 
only affects the migration and survival of SMCs but also augments, along with TGF-β, 
the production of the ECM. Interestingly, IFN-γ, produced mainly by T cells, has been 
shown to inhibit this basal IL-1β- and TGF-β-stimulated collagen synthesis (Amento et 
al. 1991b). 
 
1.7.3 Formation of the necrotic and pro-thrombotic core of the fibroatheroma and 
haemorrhagic/thrombotic lesions  
An atherosclerotic plaque may have numerous fates, and all depends on the amount 
and speed of the lipid accumulation and the nature of the cytokine environment 
produced by the cells within the plaque. If enough lipids are accumulated within the 
plaque and given the right cytokine environment, the foam cells inside the plaque may 
undergo apoptosis or oncosis, thus forming a necrotic and pro-thrombotic core within 
the plaque (Cai et al. 1997, Majno and Joris 1995). For example, cytokines such as IL-
1β, IFN-γ and TNF-α can augment the production of ROS to the extent of causing 
apoptosis and oncosis (Geng et al. 1996, Li et al. 1999). In addition, macrophages may 
be sensitized by IFN-γ and TNF-α to die through apoptosis induced by Peroxisome-
Proliferator-Activated Receptor (PPAR) α and γ ligands (Chinetti et al. 1998). The Fas 
ligand produced by T cells can also induce Fas-mediated apoptosis in SMCs and ECs 
(Fukuo et al. 1997). 
 
1.7.4 The complicated vulnerable plaque, thin fibrous cap and plaque rupture 
When the atherosclerotic plaque develops further, it begins to transform. Normally, the 
core of an atherosclerotic plaque is formed by foam cells and extra-cellular lipid 
droplets and surrounded by a cap of SMCs and ECM (Hansson 2005, Stary et al. 1995, 
Virmani et al. 2000b). However, the cap can also contain inflammatory cells which are 
most often macrophage foam cells. The thickness of the fibrotic cap is crucial for the 
development of the plaque. If the fibrous cap transforms into a thin cap, it becomes 
more prone to rupture, which can lead into either accelerated plaque development or an 
ischemic event (Falk 1985, Fuster 1995, Fuster et al. 1992). The thinning of the cap is 
most likely due to decreased ECM synthesis by the decreasing number of SMCs 
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residing in the cap and to matrix degradation by infiltrating macrophages (Thim et al. 
2008). In fact, it has been shown that ruptured caps of human atherosclerotic plaques 
have increased macrophage and decreased SMC density when compared with intact 
caps (Davies et al. 1993). In the most rupture-prone shoulder regions of the plaques, T 
cells, mast cells and macrophages can be found abundant (Jonasson et al. 1986, 
Kovanen et al. 1995). Hence, the changing inflammatory environment in the shoulder 
regions can lead to plaque rupture (Packard and Libby 2008). It is believed that the 
increased inflammatory stimuli cause macrophages to excrete MMPs, which leads to 
the loss of ECM. 
MMPs have been identified to cause matrix degradation through their 
proteolytic activity. There are 23 different types of MMPs, and collectively they can 
completely degrade collagen and other ECM components (Nagase et al. 2006). Besides 
macrophages, various other cells, such as ECs, SMCs and macrophages, can also 
produce MMPs. Agonists for MMP expression include cytokines such as IL-1β and 
TNF-α, extracellular MMP inducer and bacterial lipopolysaccharide (LPS). MMPs also 
have antagonists called tissue inhibitors of matrix metalloproteinases (TIMPs), and the 
activity of MMPs is therefore not directly related to their expression within the plaques 
(Newby 2008). Furthermore, IFN-γ derived mainly from T lymphocytes has been 
shown to greatly inhibit the ability of SCMs to synthesize new collagen, making the 
cap even more vulnerable (Amento et al. 1991a). Calcification and neovascularization 
also occur in complicated plaques, representing a further feature linked with plaque 
instability (Harvey and Ramji 2005). If the conditions within the plaque lead to rupture, 
the outcome is not always an ischemic event. A clinically silent rupture is healed by 
SMCs that immediately begin to secrete ECM with a high glycosaminoglycan content 
and collagen (Mann and Davies 1999). This can lead to rapid narrowing of the afflicted 
artery, as the residual thrombus is organized within the newly reforming plaque (Burke 
et al. 2001). Endothelial eruption can also lead to the formation of a thrombus and thus 
contributes to the further formation of an advanced plaque (Hansson 2005). 
 
1.8 The role of T lymphocytes in atherosclerosis 
Atherosclerotic plaques contain T lymphocytes, and the majority of them are CD4+ T 
lymphocytes. CD4+ lymphocytes are the main target of IL-18 within the plaques. The 
activation of T lymphocytes by IL-18 leads to the production of highly pro-
atherosclerotic INF-γ (Okamura et al. 1995, Okamura et al. 1998). Other T cells that 
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can be found in atherosclerotic lesions are CD8+ cytolytic T cells and CD1+ Natural 
Killer T (NKT) cells (Jonasson et al. 1986, Tupin et al. 2004). The majority of the T 
cells are formed by memory T cells in late or chronic state of activation (Stemme et al. 
1992), and most of them can be found in clusters in the shoulder regions of 
atherosclerotic plaques (Jonasson et al. 1986, van der Wal et al. 1989). Usually, they 
are surrounded by major histocompatibility (MCH) class II-expressing macrophages 
and dendritic cells (Bobryshev and Lord 1995, Jonasson et al. 1985, Kishikawa et al. 
1993). 
A large body of evidence suggests (presented below) that CD4+ T cells have a 
more prominent role in the disease process than CD8+ T cells and NKT cells. 
However, clear evidence also exists of the involvement of other T cells. For example, 
the presence of NKTs in human lesions has been proven (Melian et al. 1999), and the 
results of several studies conducted on mice have established the pro-atherosclerotic 
role of NKT cells possibly through the production of atherogenic IFN-γ (Aslanian et al. 
2005, Major et al. 2004, Nakai et al. 2004, Tupin et al. 2004). Furthermore, activated 
CD8+ cells can kill neighbouring cells via cell–cell contact, and several mediators 
produced in atherosclerotic lesions can propagate CD8+ cells to kill SMCs and 
macrophages (Ludewig et al. 2000). The role of T lymphocytes in atherosclerosis in 
described in Figure 1. 
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Figure 1. Main functions of T lymphocytes and antigen presenting cells (APCs) in atherosclerotic lesions. 
Antigens presented by macrophages and dendritic cells trigger the activation of antigen-specific T cells in 
the artery. Most of the activated T cells produce Th1 cytokines (e.g., interferon-γ) in response to concomi-
tant stimulation with IL-18 and IL-12. This leads to the activation of macrophages and vascular cells, 
leading to inflammation. Regulatory T cells modulate the process by secreting anti-inflammatory cyto-
kines (such as interleukin-10 and transforming growth factor β). Picture adopted from the article by 
Hansson et al. 2005; reproduced with permission of the publisher. 
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1.8.1 T lymphocytes, antigen presenting cells (macrophages) and adaptive 
immunity  
The T cell response, e.g. adaptive immunity, is elicited when an antigen-presenting cell 
(APC) presents an antigenic peptide to a naïve T cell. Each naïve T cell is specific for a 
certain type of antigen, and the presented antigen must therefore be correct for the 
activation to occur (Huppa and Davis 2003). In atherosclerosis, the initial antigen 
presentation most likely happens in regional lymph nodes in the adventitia by DCs 
(APCs), and from there on the T cell homes to the site for secondary activation (e.g. 
plaque) (Bobryshev 2005, Galkina et al. 2006, Grabner and El-Matbouli 2009) (see 
Figure 2.). Within the plaque itself, many different types of cells aside from DCs, such 
as macrophages and possibly even ECs and SMCs, can act as APSs and be responsible 
for the secondary activation of T cells (Bobryshev and Lord 1998, Hansson et al. 1986, 
Jonasson et al. 1985, Murray et al. 1995). However, the most prominent agents for 
secondary activation of T cells are mature DCs. In fact, clusters of mature DCs and T 
cells have been identified in rupture-prone regions of the arteries, thus further linking T 
cell activation to unstable plaque formation (Bobryshev and Lord 1998, Yilmaz et al. 
2004). Culprit plaques responsible for acute coronary syndromes have a high 
proportion of activated T cells (Hosono et al. 2003, van der Wal et al. 1994).  
The CD4+ T lymphocytes recognize protein antigens presented by major-
histocompatibility-complex (MHC) class II molecules. The CD4+ T cells that are 
found in the human atherosclerotic plaques can react to oxidized LDL, heat-shock 
protein 60, and Chlamydia pneumoniae elementary bodies  (de Boer et al. 2000, 
Stemme et al. 1995, Xu 2002). The importance of T cells is underlined by the fact that 
approximately 10% of all T cells in human atherosclerotic plaques recognize oxidized 
LDL in MHC class II restricted manner (Stemme et al. 1995). Once the CD4+ T cell is 
activated, the inflammatory reaction in the cell is modulated either towards T helper 
(Th) 1 cell response or Th2 cell response. Within the human atherosclerotic plaque, the 
inflammatory environment usually promotes specialization to a Th1 response, but Th2 
cells have also been identified to take part in the disease process (Frostegard et al. 
1999, Uyemura et al. 1996). Recently, other types of CD4
+ 
T cells (T regulatory) have 
also been found within the plaques. These cells seem to have anti-atherogenic 
properties, possibly acting via the indoleamine 2,3-dioxygenase (IDO) or IDO-induced 
tryptophan degradation-dependent pathways which might suppress other T cells (Ait-
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Oufella et al. 2009, Niinisalo et al. 2010). 
 The activation by antigens in itself is not sufficient to mount a strong T cell 
mediated immunity response. Cross-talk and co-stimulation between the players of the 
inflammatory cascade are also important, and in atherosclerosis they have been linked 
with primary as well as secondary activation of the T cells in the atherosclerotic 
lesions. As a result of co-stimulation, T cells can activate macrophages to produce more 
inflammatory cytokines, MMPs and tissue factor. 
Despite the fact that only a small proportion (less than 10%) of the CD3+ T 
cells do express CD28+ in human atherosclerotic plaques, one of the co-stimulatory 
pairs could be the CD28+ expressed by T cells and the CD80/CD86 expressed by APCs 
(de Boer et al. 1997, de Boer et al. 1999). Similarly, at least in advanced plaques (Stary 
classes V-VI), the CD28+ surface markers have been shown to be clearly up-regulated 
(Niinisalo et al. 2010). However, the actual function of this pair in atherosclerosis is 
still unclear (Buono et al. 2004). CD4+ CD28null cells, on the other hand, are potent 
players, vividly expressing IFN-γ and TNF-α (Robertson and Hansson 2006). They are 
also believed to be able to lyse ECs and trigger apoptosis in SMCs (Nakajima et al. 
2003, Pryshchep et al. 2006). 
Another pair for co-stimulation is the one formed by CD40, which is expressed 
by APCs, and CD40L (CD154), expressed by CD4+ T cells. The activation of this pair 
leads to priming and expansion of antigen-specific CD4+ T cells (Xu and Song 2004). 
In mice, the interruption of CD40 signalling has been demonstrated to reduce 
atherosclerosis and promote the expression of a more stable plaque phenotype (Lutgens 
et al. 2000, Mach et al. 1998, Schonbeck et al. 2000). Ligation between CD40 and 
CD40L increases the expression of CD80 and CD86, and the stimulation of these two 
results in an increased expression of CD40L (Buono and Lichtman 2004, Xu and Song 
2004). 
The CD40/CD40L pair is also linked with the progression of atherosclerosis 
independently of leukocytes (Smook et al. 2005), and both CD40 and CD40L are 
expressed by many other cells, such as platelets, macrophages, SMCs and ECs, 
providing the pair with other evident pro-atherosclerotic mechanisms alongside the co-
stimulation between leukocytes (Andersson et al. 2009, Schonbeck and Libby 2001). 
For example, EC ligation of the CD40/CD40L leads to increased expression of 
chemokines and adhesion molecules, thus provoking leukocyte recruitment (Karmann 
et al. 1995), and CD40L ligation has also been linked with platelet activation and 
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thrombosis (Henn et al. 1998, Inwald et al. 2003). All in all, the CD40/CD40L is 
associated with increased pro-inflammatory cytokines, chemokines, adhesion 
molecules, metalloproteinases and tissue factor, which is a pro-coagulant (Karmann et 
al. 1995, Schonbeck and Libby 2001). 
Ox40, expressed by T cells, and its ligand OX40L, which in turn is expressed 
by activated APCs, form another pair for co-stimulation. The ligation to OX40 
facilitates the survival of the immune response, and inhibits T regulatory cell 
development and function (anti-inflammatory). Alongside atherosclerosis, this pair has 
also been linked with other autoimmune diseases (Martin-Orozco et al. 2003, Ndhlovu 
et al. 2001, Wang et al. 2005). APCs of human atherosclerotic plaques have been 
shown to express Ox40, but most of the evidence linking Ox40 with the development 
of atherosclerosis on vessel wall level has arisen from experiments with mice (van 
Wanrooij et al. 2007, Wang et al. 2005). 
Furthermore, other potential co-stimulatory pairs affecting the development of 
atherosclerosis have been identified (ICOS/ICOSL, CD137/CD137L, PD1/PD-L1 and 
PDL2), but as of yet, the data is sparse (Gotsman et al. 2007, Gotsman et al. 2006, 
Olofsson et al. 2008). 
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Figure 2. Antigen presentation in an inflammatory environment favourable for Th1 cell differentiation. 
Antigen presentation with co-stimulation further stimulates the expression of major histocompatibility 
class II molecules used in antigen presentation and co-stimulatory molecules. The activation of Th1 cells 
leads to the activation of transcription factors (NK-κB, STAT4, GATA3) resulting to the expression of 
Th1 cell cytokines such as IFN-γ. Picture adopted and modified from the article by Greenwood et al. 
2006. Reproduced with permission of the publisher. 
 
 
1.8.2 Th1 cell-related immunological responses in atherosclerosis 
As mentioned before, most of the CD4+ T cells in atherosclerotic plaques are Th1 
cells. These cells induce macrophage activation and produce IFN-γ and TNF-α which 
have many atherosclerotic properties (Hansson et al. 2006) (see Figure 1). To underline 
this fact, local expression of IFN-γ dominates over the expression of Th2-related 
cytokines (IL-4 and IL-5) in human lesions (Hansson et al. 2006). In fact, IFN-γ is 
produced by the majority of T cells in human atherosclerotic plaques (Hansson et al. 
1989b, Stemme et al. 1995). IL-12 and IL-18 synergistically act to promote the Th1 
response and IFN-γ production (Benagiano et al. 2003, Uyemura et al. 1996). 
Furthermore, in genetically altered mice, lineages with Th1 predominance have been 
associated with increased development of atherosclerosis when compared to lineages 
with Th2 predominance (Schulte et al. 2008). 
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 IFN-γ is involved in the recruitment of T cells and macrophages, increased 
expression of MCH class II, increased macrophage lipid up-take to and therefore the 
formation of foam cells, in addition to increased activation of APCs and enhanced 
secretion of Th1-promoting cytokines (Leon and Zuckerman 2005). IFN-γ plays a 
major role in regulating macrophage involvement and, supporting this, roughly 25% of 
the macrophage transcriptome is regulated by IFN-γ (Ehrt et al. 2001). Murine studies 
have shown that IFN-γ is associated with increased atherosclerosis. IFN-γ has also 
been associated with the development of unstable plaques (Andersson et al. 2009). 
IFN-γ is associated with the recruitment of inflammatory cells to the lesions. 
First of all, it induces the expression of chemokines, one of the most important of 
which is MCP-1, a potent chemotactic for monocytes and T-cells (Harvey and Ramji 
2005, Valente et al. 1998). In addition, MCP-1 causes the adhesion of recruited cells to 
ECs and potentiates the polarization towards a Th1 response in T cells. IFN-γ also 
induces the expression of VCAM-1 and intracellular adhesion molecule (ICAM) -1 
from ECs and SMCs (Chung et al. 2002, Li et al. 1993). It is recognized to promote 
both, the differentiation of monocytes to macrophages and causes the activation of both 
macrophages and T cells (Boehm et al. 1997, Schroder et al. 2004). Furthermore, lipid 
accumulation onto macrophages and the formation of foam cells are known to increase 
due to IFN-γ (Panousis and Zuckerman 2000, Reiss et al. 2004). As noted above, the 
apoptosis of the foam cells results in the formation of the necrotic core of the lesion 
and, consequently, IFN-γ has also been shown to promote apoptosis of macrophage-
derived foam cells and vascular SMCs (Geng et al. 1996, Inagaki et al. 2002). 
Furthermore, IFN-γ is a very prominent factor causing plaque destabilization by 
inhibiting the expression of collagen genes (e.g. collagens I and III) and the 
proliferation of SMCs. These effects contribute to the formation of the ECM (discussed 
earlier). Not surprisingly, IFN-γ has also been directly linked with the weakening of the 
protective fibrous cap of the lesions (Buono et al. 2003, Gupta et al. 1997). 
Furthermore, IFN-γ has been found to reduce proliferation on ECs and SMCs and to 
reduce the differentiation and collagen synthesis of vascular SMCs (Amento et al. 
1991a, Friesel et al. 1987, Hansson et al. 1989a). 
In atherosclerotic lesions, IFN-γ can also be secreted by numerous other cell 
types, such as CD8+ lymphocytes, activated macrophages, NK cells, B cells and 
vascular SMCs (Bancroft et al. 1991, Flaishon et al. 2000, Gerdes et al. 2002a, Munder 
et al. 1998, Sad et al. 1995). NK T cells have also been shown to secrete high amounts 
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of IFN-γ (Aslanian et al. 2005, Tupin et al. 2004). Interestingly, despite the fact that 
IFN-γ is considered to associate with increased atherosclerosis, it has been related to 
some anti-atherogenic functions such as the inhibition of macrophage lipoprotein lipase 
(aids the up-take of modified LDL) and that of the oxidation of LDL (McLaren and 
Ramji 2009). 
 
1.8.3 Other CD4+ T cells 
Other CD4+ T cells identified in atherosclerotic lesions are Th2 cells, Th17 cells and T 
regulatory cells. The role of the Th2 cells is not clear. According to studies conducted 
with mice, cytokines related with Th2 response (IL-4 and IL-5) seem to have different 
effects. IL-4 would seem to have a pro-atherogenic influence, and IL-5 would appear to 
associate with decreased lesion formation (Binder et al. 2004, Davenport and Tipping 
2003, King et al. 2002). T regulatory cells, which characteristically express 
transcription factors FoxP3 and CD25, are immunosuppressive cells, and their presence 
has been verified in atherosclerotic lesions of both mice and men (Heller et al. 2006, 
Niinisalo et al. 2010, Shevach et al. 2006, Veillard et al. 2004). T regulatory cells have 
been related to decreased lesion formation in murine models, and the suppressive effect 
is thought to be attributable at least partly to their expression of TGF-β and IL-10 
(Andersson et al. 2009), and possible throughout the indoleamine 2,3-dioxygenase 
(IDO)-related tryptophan depletion-mediated T-cell depression (Niinisalo et al. 2010). 
Th17 cells are involved in the recruitment of neutrophils, and they elaborate IL-17, but 
their role in atherosclerosis remains unclear (Andersson et al. 2009). 
 
1.9 Interleukin 18  
 
IL-18 was initially identified as an IFN-γ-inducing factor, and it was observed to be 
involved in orchestrating the Th1 response (Okamura et al. 1995). It is a pleiotrophic 
cytokine influencing both the innate and the acquired immune system (Okamura et al. 
1998). IL-18 is part of the IL-1 family (alongside with IL-1 and IL-33), which means 
that it has structural similarities with the other members of the family. The involvement 
of IL-18 has been identified in several inflammatory and autoimmune diseases such as 
multiple sclerosis, arthritis, inflammatory bowel diseases and psoriasis (Arend et al. 
2008). It also seems to play an important role in atherosclerosis 
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1.9.1 The production and secretion of interleukin 18 
IL-18 is produced mainly by monocytes and macrophages, but it can also be produced 
by many other cell types, such as DCs, Kupffer cells, keratinocytes, chondrocytes, 
synovial fibroblasts and osteoblasts (Gracie et al. 1999, Horwood et al. 1998, Olee et 
al. 1999, Zepter et al. 1997). IL-18 is initially produced as a 24 kDa precursor peptide, 
and it has to be cleaved to its mature form (18 kDa) before it can be secreted. The pre-
cursor mRNA has a stable structure and is constitutively and intracellulary stored (Gu 
et al. 1997). The cleavage of pro-IL-18 to its active form and its secretion is believed to 
be influenced strongly by the activity of the intracellular cysteine protease known as 
caspase-1 (Casp-1) (Arend et al. 2008). However, it has also been shown that ECs, for 
example, secrete mature IL-18 independently of Casp-1 activity (Kolinska et al. 2008). 
One possible alternative for IL-18 processing is the serine proteinase known as 
protease-3 (PR-3), which can cleave precursor IL-18 into active mature IL-18. PR-3 
can be found on the surface membranes of macrophages, neutrophils and ECs, and it 
can also be released in response to inflammatory stimuli (Fantuzzi and Dinarello 1999). 
The caspase-3 enzyme can cleave precursor IL-18 and mature IL-18, but this leads to 
accumulation of biologically inactive products, suggesting a scavenger function for 
Casp-3 (Arend et al. 2008, Fantuzzi and Dinarello 1999). 
 The excretion of IL-18 is stimulated by several agonists that activate the 
pattern-recognition receptors (PPRs) of monocytes/macrophages. PPRs, such as Toll-
like receptors (TLR) which are found mainly on cell membranes, are an important part 
of the innate immune system (Liew et al. 2005). At least two agonists for TLRs 
(lipopolysaccharide [LPS] and flagellin) have been identified to stimulate IL-18 
expression (Bachmann et al. 2006, Grobmyer et al. 2000, Seki et al. 2001). 
Interestingly, also IFN-γ and TNF-α may provoke the expression of mature IL-18 in 
cultured epithelial cells (Kolinska et al. 2008). The fact that peripheral blood 
monocytes can also express IL-18 in response to stimulation by Chlamydia pneumonia 
(independently of TLR2 and TLR4) quite clearly links IL-18 with an innate immune 
response (Netea et al. 2004). C-reactive protein can also activate the release of IL-18 in 
human endothelial cells. 
Furthermore, cardiomyocytes can express IL-18 in response to stimulation by 
TNF-α, aldosterone, endothelin-1 and angiotensin II. These responses have been 
attributed to the stimulation of nuclear factor-kappa B, which has a binding site in the 
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IL-18 gene (Chandrasekar et al. 2003, Doi et al. 2008). 
 
1.9.2 IL-18 receptor (IL-18R) and IL-18 binding protein (IL-18BP) 
The IL-18 receptor complex comprises two chains of IL-18 receptor (R) α and IL-
18Rβ. IL-18Rα is a binding chain, and it is expressed on most of the key players 
associated with atherosclerosis (naïve T cells, mature Th1 lymphocytes, NK cells, 
macrophages, B cells, neutrophils, mast cells, ECs and SMCs) (Arend et al. 2008, 
Gerdes et al. 2002b, Nakamura et al. 2000, Yoshimoto et al. 1998). IL-18Rβ is an 
accessory protein, which binds with ligated IL-18Rα, resulting in the activation of the 
complex. This leads to the activation of intracellular adapter molecules (myeloid 
differentiation factor 88, IL-1R-associated kinase, TNF-α associated kinase 6), thus 
resulting in the activation of signal transduction pathways such as nuclear factor-kappa 
B, c-Jun N-terminal kinase and p38 mitogen-associated protein kinase (Thomassen et 
al. 1998). The expression of the IL-18 receptor complex, and especially that of the IL-
18Rβ, are influenced by many cytokines, and the effects of IL-18 are therefore also 
regulated by the expression of its receptors in response to inflammatory stimuli (Arend 
et al. 2008). In addition, angiotensin II can enhance the expression of IL-18Rα on 
SMCs (Sahar et al. 2005). 
 IL-18BP is a soluble protein with four naturally occurring human isoforms, two 
of which have a high affinity for binding to mature IL-18 (Kim et al. 2000). The 
binding of IL-18BP to IL-18 results in the neutralization of IL-18 and therefore 
prevents its further interaction with IL-18R. The two isoforms can neutralize over 95% 
of IL-18 at a molar excess of 2 (Kim et al. 2000). IL-18BP is produced constitutively in 
the human spleen (Novick et al. 1999). In addition, monocytes/macrophages, ECs and 
epithelial cells are also known to express IL-18BP (Corbaz et al. 2002). The expression 
IL-18BP in endothelial cells is enhanced by the release of IFN-γ, thus suggesting a 
negative feedback loop for IL-18 signalling (Paulukat et al. 2001). 
 
1.9.3 The biological functions of IL-18 
One of the main functions of IL-18 is to induce IFN-γ production and promote the Th1 
response (Okamura et al. 1995). However, despite the fact that IL-18 is a very potent 
inducer of IFN-γ production from Th1 cells and clearly promotes the Th1 response, 
synergy with IL-12 is important for these responses (Robinson et al. 1997, Takeda et al. 
1998). Interestingly, IL-18 in synergy with IL-12 also promotes the expression of IFN-
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γ in macrophages and SMCs (Darwich et al. 2009, Gerdes et al. 2002a) The interplay 
between IL-18 and IL-12 is clear, as IL-12 can induce the expression of IL-18Rβ 
(Neumann and Martin 2001). In fact, three different cytokines (IL-15, IL-21, and IL-
23) have been identified to act in synergy with IL-18, inducing the production of IFN γ 
from T cells (Hoeve et al. 2003, Strengell et al. 2003, Strengell et al. 2002). IL-21 has 
also been demonstrated to augment the expression of the IL-18R gene (Strengell et al. 
2002). 
Alone, IL-18 stimulates the expression of IL-6 (pro-atherosclerotic cytokine), 
IL-8 (chemokine), ICAM-1 and MMPs (MMP-1/-9/-13) in cultured human SMCs, ECs 
and mononuclear phagocytes (Chandrasekar et al. 2006, Gerdes et al. 2002a). It also 
promotes human coronary SMC migration through the increased production of MMP9 
(Chandrasekar et al. 2006). Interestingly, IL-18 can also act as a chemoattractant for T 
CD4+ cells (Komai-Koma et al. 2003) and enhance the IFN-γ production as well as the 
cytolytic capability and proliferation of CD8+ T cells (Okamoto et al. 1999, Tough et 
al. 2001). The expression of IFN-γ can also have a positive feedback on the production 
of IL-18. It was recently demonstrated that IL-18 is expressed by DCs upon antigen 
presentation to T cells, and this expression of IL-18 was stimulated by IFN-γ (Iwai et 
al. 2008). IL-18 can also increase the OX40 and OX40L expression on T cells and 
APCs, therefore further facilitating the interaction between these two cell types via co-
stimulation (Maxwell et al. 2006). Furthermore, it has been shown that the priming of 
NK T cells by IL-18 leads to ligand-activated IFN-γ production (Uchida et al. 2007). 
Not surprisingly, when combined with IL-12, it leads to the secretion of IFN-γ 
(Fujibayashi et al. 2007). 
IL-18 also seems to have a strong role in regulating the activity of NK cells. It 
was shown quite recently that priming of NK cells with IL-18 in vivo enhances the IL-
12 induced translation of IFN-γ mRNA (Chaix et al. 2008). Previous studies have 
demonstrated that IL-18 augments the NK cell activity and, in combination with IL-15, 
NK cell proliferation and IFN-γ expression (French et al. 2006, Hyodo et al. 1999, 
Strengell et al. 2003, Takeda et al. 1998). IL-18 can also enhance the Fas ligand on NK 
cells (as well on T cells) and induce apoptosis in cells that express Fas (Faggioni et al. 
2001). 
  Additionally, IL-18 yields diverse effects on monocytes and macrophages. 
Therefore, it also directly influences innate immunity. For example, IL-18 can cause 
peripheral blood mononuclear cells to express GM-CSF, TNF-α, IL-1β and IL-8, in 
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addition to other chemokines such as MCP-1(Puren et al. 1998). Preconditioning of 
macrophages with IL-18 and IL-12 increases the IFN-γ-dependent nitric oxide 
response and the TNF-α response to inflammatory stimuli in vivo (Bastos et al. 2007). 
In addition, the treatment of monocytes with IL-18 and IL-12 prevents spontaneous 
apoptosis and promotes differentiation to macrophages as well as the expression of 
chemokines (CXC chemokine ligands -8/-9/-10, which activate chemokine receptors 
on granulocytes, T cells and monocytes) (Coma et al. 2006, Moser et al. 2004, Nold et 
al. 2003). Human neutrophils also express IL-18R and can be activated by IL-18 
(Leung et al. 2001). 
 Although IL-18 is a potent inducer of Th1 responses and has been related to 
them in atherosclerosis, it can also, under certain conditions, promote Th2 responses 
(Nakanishi et al. 2001). In combination with IL-2, it can stimulate the production of IL-
13, a cytokine related to the Th2 response, by T cells and NK cells (Fujibayashi et al. 
2007, Hoshino et al. 2001). Furthermore, IL-18 in synergy with IL-23 has been 
associated with the polarization and activation of Th17 cells, but as mentioned before, 
even the role of Th17 cells is unclear in atherosclerosis, rendering the importance of 
the link between these two factors in regard to atherosclerosis an issue to be clarified 
(Arend et al. 2008). 
 
1.9.4 The role of IL-18 in atherosclerosis 
According to several murine models, IL-18 clearly associates with increased 
atherosclerosis measured in plaque sizes (Elhage et al. 2003, Mallat et al. 2001b). IL-
18 is also connected with plaque instability (less T cells, lipids, cell death, 
macrophages and increased collagen and SMC content) (Elhage et al. 2003, Mallat et 
al. 2001b) One of the models has also indicated that the pro-atherogenic effect of IL-18 
is IFN-γ-dependent (Whitman et al. 2002). Interestingly, the IFN-dependency is not 
dependent on T cells, and the potent pro-atherosclerotic response can also be obtained 
from macrophages, NK cells and vascular cells (Tenger et al. 2005). 
 In humans IL-18 has also been associated with the development of 
atherosclerosis on the vessel wall level. In a study by Mallat et al., IL-18 and IL-18Rα 
were found to be highly expressed in atherosclerotic samples obtained from carotid 
arteries when compared to normal arteries. Furthermore, unstable plaques had higher 
levels of IL-18 mRNA when compared to stable plaques (Mallat et al. 2001a). Another 
study has also confirmed the higher expression of IL-18 in atherosclerotic plaques 
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when compared to normal arteries (Graebe et al. 2009). 
Further evidence of the link between IL-18 and the development of 
atherosclerosis is presented in studies that depict the development of the disease using 
other end-points than the vessel wall level plaque development. One previous study 
associated plasma IL-18 levels with intima media thickness (IMT), a marker of 
subclinical atherosclerosis, among patients with obstructive sleep apnoea-hypopnoea 
syndrome (Li et al. 2009). Another study that associated higher IL-18 plasma levels 
with IMT revealed that circulating IL-18 levels also correlate with decreased carotid 
femoral pulse wave velocity (a marker depicting the stiffness of arteries) among men 
with no manifestations of cardiovascular disease (Vlachopoulos et al.). Two other 
studies have confirmed the finding concerning IMT among healthy populations, but 
whether this association is independent of traditional risk factors remains unclear 
(Chapman et al. 2006, Yamagami et al. 2005). 
The relation between the polymorphism of the IL-18 gene and carotid IMT has 
been studied, but the results obtained were not clear. Although some major haplotypes 
of the IL-18 gene associated with circulating IL-18 levels, IL-18 gene polymorphism 
did not seem to affect carotid atherosclerosis. However, among a subpopulation of 
CHD patients, one major haplotype seemed to associated with a higher risk of 
developing a carotid artery plaque (Thompson et al. 2007a). Furthermore, circulating 
IL-18 levels have been associated with coronary plaque areas in patients suffering from 
MI as assessed by quantitative coronary angiography (Hulthe et al. 2006), and another 
study reported a positive association between IL-18 levels and the extent of coronary 
atherosclerosis among patients with unstable AP (Chen M. C. et al. 2007). In one 
previous study, the atherosclerotic burden was assessed using combined angiography 
measurements and ultrasound evaluation from the femoral and carotid artery. In this 
study setting, IL-18 levels were associated with the over-all atherosclerotic burden 
(Espinola-Klein et al. 2007). 
Among healthy men, plasma levels of IL-18 also have a predictive value for 
acute coronary syndromes (Blankenberg et al. 2003). One later study confirmed that 
baseline IL-18 concentrations predict the occurrence of MI during follow-up, but this 
result did not hold after adjustment for risk factors (Thompson et al. 2007b). In line, 
patients with unstable angina pectoris and MI have higher plasma concentrations of IL-
18 when compared to controls (Hulthe et al. 2006, Mallat et al. 2002, Rosso et al. 
2005). In patients with CAD, serum levels of IL-18 predict the occurrence of 
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cardiovascular mortality independently of risk factors (Blankenberg et al. 2002, 
Espinola-Klein et al. 2007, Tiret et al. 2005). 
The variation of the IL-18 gene has also been linked with a higher risk of MI 
and cardiovascular mortality. In 2005 Tiret et al. linked the polymorphism of the IL-18 
gene with cardiovascular mortality among CAD patients (Tiret et al. 2005). A few years 
later, another study was published revealing that among a combined population of 
hypertensive patients and postmenopausal women, the risk for MI, but not for stroke, 
also associates with IL-18 gene polymorphism (Bis et al. 2008). 
  
1.9.5 Polymorphism of the IL-18 gene 
In 2005, Tiret et al. published a comprehensive analysis of the variability of the IL-18 
gene in a Caucasian population, and they reported that the variation of the IL-18 gene 
can be covered with 6 haplotypes accounting for 99.0% of all chromosomes (Tiret et al. 
2005). The gene was found to have three major haplotypes (minor allele frequencies 
approximately: 0.306, 0.286 and 0.247) and three minor haplotypes (minor allele 
frequencies approximately: 0.103, 0.027 and 0.024). These 6 haplotypes can be 
constructed using 5 tag single nucleotide polymorphisms (SNPs). Obviously, the whole 
IL-18 gene contains more SNPs, but they can be organized into five clusters or BINs 
because the majority of them are inherited in complete association (Tiret et al. 2005). 
 Few individual SNPs of the IL-18 gene have been shown to have functional 
properties. Giedraitis et al. showed that a haplotype carrying the minor allele of two 
promoter region SNPs (rs1946518, position -607[C/A], and rs187238, position -137 
[G/C]) are associated with lower transcriptional activity of the gene in vitro using HeLa 
cells (Giedraitis et al. 2001). The latter (rs187238) also seemed to associate with the 
production of mature IL-18, and it was therefore speculated to be responsible for the 
observed significant change in the transcriptional activity. Subsequently, the same 
polymorphisms were associated again with similar patterns in transcriptional activity in 
cultured HepG2 cells (Liang et al. 2005). Further evidence of the functionality of 
the -137 (G/C) SNP has been presented in two independent studies, both showing that 
this particular SNP also associates with the production of mature IL-18 from 
monocytes constitutively as well as under stimulation, with the minor C allele 
associating with decreased transcriptional activity (Arimitsu et al. 2006, Khripko et al. 
2008). The other study reported that the rs1946518 (-607 [C/A]) also associates with 
the transcriptional activity of the gene, but the effect seemed weaker compared to the 
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effect of -137 (G/C) (Khripko et al. 2008). Two other studies have also reported 
positive associations between two new SNPs (rs360716 and rs5744247) and the 
expression of IL-18 mRNA, but these results have not been confirmed in other studies 
(Harada et al. 2009, Sanchez et al. 2009). Furthermore, as the rs360716 is in complete 
association with the -137 (G/C) SNP, it is impossible to assume that the observed 
association would be independent. The minor C allele of the -137 (G/C) SNP has been 
associated with lower circulating levels of IL-18 (Liu et al. 2009) 
 Haplotype studies have also revealed interesting results of the functionality of 
the IL-18 gene polymorphism. The study by Tiret et al. demonstrated that two major 
haplotypes are associated with circulating IL-18 levels (Barbaux et al. 2007, Tiret et al. 
2005). Both haplotypes associated with lower IL-18 concentrations in serum. The other 
haplotype is the only one carrying the minor C allele of the -137(G/C) SNP. The other 
major haplotype is the only one carrying the minor A allele of the rs5744292 SNP 
(+183[A/T]). In a further functional haplotype study using lymphoblastoid cell lines, 
the haplotype carrying this SNP (rs5744292) was shown to clearly associate with a 
lower expression level of the gene. The association between the haplotype carrying the 
-137 G/C SNP and expression levels was also significant but did not seem so evident 
(Barbaux et al. 2007). Subsequently, two other haplotype studies have further proved 
that these two major haplotypes associate with lower circulating IL-18 levels 
(Thompson et al. 2007a, Thompson et al. 2007b). 
 
1.10 The methodology of genetic studies 
 
Genetic studies can basically be divided into two bigger entities: candidate gene 
association studies and genetic linkage studies (genome-wide linkage studies, genome-
wide association studies, GWAS). The present study utilizes the candidate gene 
approach, because IL-18 and the variation in the IL-18 have already been identified to 
affect the development of atherosclerosis. 
Genome-wide linkage studies are used to find quantitative trait loci (QTL) 
within chromosomes that regulate atherogenesis. QTLs, however, can contain hundreds 
of genes. Therefore, even after one QTL has been identified repeatedly in independent 
populations as regulating atherogenesis, the testing of all of the genes in the specific 
chromosomal region is a daunting task. However, genome-wide linkage studies have 
been very efficient in finding genes with simple Mendelian inheritance (Chen Y. et al. 
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2007). Atherosclerosis is a common disease with a complex aetiology, and it is not easy 
to find common variants that would have a strong effect on disease progression using 
the QTL approach. 
The completion of the human genome sequence and the international HapMap 
project a few years ago, in addition to the lowering costs of genotyping and 
sequencing, have lead to the submersion of a new method known as GWAS (Manolio 
et al. 2007). GWAS can be used to find SNPs or haplotypes associating strongly or 
moderately with common disease traits, such as those related to atherosclerosis. Over 
20 million SNPs are available at www.ncbi.nlm.nih.gov/SNP. In 2007 the HapMap 
project had genotyped more than 3 million SNPs, and the sequence data has confirmed 
that the vast majority of the SNPs are strongly correlated with nearby proxies. 
Therefore, it is not generally required to genotype all SNPs in GWAS. In an African 
population, where the genetic diversity is broad, approximately 1 million SNPs suffice, 
whereas in non-African populations, 500.000 SNPs guarantee excellent power to 
determine more than 90% of the common SNP variation (2005, Altshuler et al. 2008). 
Despite the high costs, GWAS seems to be a good way of establishing new associations 
between common polymorphisms and disease traits. Nevertheless, the power for 
detecting associations has thus far been relatively low. Detecting a common allele with 
a frequency of 20% and a factor of 1.2 for the effect requires 8,600 samples. This is 
due to the fact that a genome-wide scan usually means testing approximately 1 million 
independent hypotheses, and in order to correct for type I error, a very stringent 
significance level must be assumed (P=5 x 10
-8
) (Altshuler et al. 2008). GWAS reports 
of significant associations with CAD, coronary disease, MI (also early onset), and 
CVD are listed in Table 3, and for other atherosclerosis-related traits, such as lipids, 
CRP and diabetes, lists can be found in the Catalog of Published Genome-wide 
Association Studies (www.genome.gov/gwastudies) 
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Table 3. Genome-wide association studies presently reporting significant associations 
with CAD, coronary disease, MI (also early onset) and CVD. The Odds Ratios (ORs) 
for each risk factor range from 1.08 to 1.91 and the reported P-values for the ORs from 
7 x10
-7
 to 3 x10
-44
. Data was extracted from Catalog of Published Genome-Wide 
Association Studies. Available at: www.genome.gov/gwastudies 
Publication Disease/Trait Gene Region Platform 
[SNPs] 
Erdmann et al. 
08 February 2009  
Nat Genet 
CAD MRAS 
 HNF1A,C12orf43 
3q22.3  
12q24.31 
Affymetrix 
[567,119] 
Kathiresan et al. 
08 February 2009 
Nat Genet 
MI (Early onset) CDKN2A, CDKN2B 
 CELSR2, PSRC1, SORT 
SLC5A3, MRPS6, KCNE2  
MIA3 
 PHACTR1 
LDLR 
CXCL12 
 PCSK9  
9p21.3,  
1p13.3  
21q22.11  
1q41  
6p24.1  
19p13.2  
10q11.21  
1p32.3  
Affymetrix  
[~2.500.000] 
(imputed) 
Tregouet et al. 
08 February 2009  
Nat Genet 
CAD Two Four SNP haplotypes 
formed by  
SLC22A3, LPAL2 and LPA 
6q25.3 Affymetrix  
[~500,000] 
Larson et al. 
19 September 2007  
BMC Med Genet 
Major CVD Intergenic 6p24.1 Affymetrix  
[70,897] 
Samani et al. 
18 July 2007 
N Engl J Med 
Coronary disease intergenic  
PSRC1 
MTHFD1L 
CXCL12 
SMAD 
 pseudogene 
9p21.3 
1p13.3 
6q25.1 
10q11.21 
15q22.33 
2q36.3 
Affymetrix  
[377,857] 
WTCCC 
07 June 2007 
Nature 
Coronary disease CDKN2A,CDKN2B 
Intergenic  
Intergenic 
Intergenic 
9p21.3 
1q43 
22q12.1 
16q23.3 
Affymetrix  
[469,557] 
Helgadottir et al.,  
03 May 2007 
Science 
MI CDKN2A,CDKN2B 9p21.3 Illumina  
[305,953] 
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AIMS OF THE STUDY 
 
The pro-atherogenic and plaque-destabilizing role of IL-18 has been established with 
murine models, and some evidence also exists that it has the same properties in human 
atherosclerotic plaque development. Circulating levels of IL-18 seem to be associated 
with the development of subclinical atherosclerosis and the occurrence of acute 
coronary syndromes. Although the IL-18 gene has functional SNPs affecting IL-18 
expression, the role of the variation in the IL-18 gene in the development of subclinical 
atherosclerosis is not clear due to a lack of studies and conflicting results. Furthermore, 
only one previous study has associated the polymorphism of the IL-18 gene with 
cardiovascular mortality among patients with CAD, and the role of IL-18 gene 
variation in the development of different stages of atherosclerosis and with SCD 
remains unclear. 
 The present study focuses on the possible role of IL-18 gene variation in the 
development of different stages of atherosclerosis by using autopsy-verified 
atherosclerotic lesions and the manifestation of atherosclerosis over the course of life 
in different populations. 
 
The specific aims of the present study are: 
 
1. To study the possible association between the polymorphism of the IL-18 
gene and the development of sub-clinical atherosclerosis, as measured by 
carotid artery intima media thickness, carotid arterial elasticity and 
endothelial function, among young asymptomatic and healthy Caucasian 
adults (Study I) 
2. To study whether IL-18 gene polymorphisms or their haplotypes have any 
effect on cardiovascular mortality among a Finnish patient population at an 
intermediate risk of death due to cardiovascular causes; and to investigate 
the possible effect of IL-18 gene polymorphism on the occurrence of 
angiography-verified coronary artery disease (Study II). 
3.  To explore whether a functional IL-18 promoter polymorphism associates 
with the risk of SCD due to coronary heart disease and SCD caused by non-
coronary diseases among Caucasian men (Study III). 
4. To explore the possible interactions between traditional risk factors and IL-
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18 gene functional SNPs affecting the risk of SCD and the expression of 
autopsy-verified coronary artery disease. We also wanted to study the 
possible effect of these interactions on the expression of IL-18 as well as 
IFN-γ mRNA in atherosclerotic samples obtained from live patients 
subjected to vascular surgical procedures (Study IV). 
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MATERIALS AND METHODS 
 
1.1 Clinical series 
 
1.1.1 The Cardiovascular Risk in Young Finns Study 
 
1.1.1.1  Subjects 
The Cardiovascular Risk in Young Finns Study is an ongoing prospective multicentre 
cohort study, with a study population of 2,282 young adults. Details of the cohort have 
been published previously (Åkerblom et al. 1985). The study began in 1980. The 21-
year follow-up was carried out in 2001. All of the data used in the present study was 
collected in the year 2001, and participants with type 1 diabetes were excluded from 
further analyses. The Ethical Review Committee of Turku University Hospital ap-
proved the research plan, and the study was conducted according to the tenets of the 
Declaration of Helsinki. Patients gave an informed consent before entering the study. 
 
1.1.1.2  Clinical and biochemical characteristics 
A standardized questionnaire was used to assess cardiovascular risk factors (smoking, 
alcohol consumption, geographical origin and familial history of coronary heart 
disease). The classification of these variables has been described earlier in more detail 
(Hernesniemi et al. 2008). The study subjects’ height and weight were used to calculate 
their body mass index (BMI = weight, kg/(height, m)
2
), and their blood pressure (BP) 
was recorded. Fasting venous blood samples were used to determine C-reactive protein 
(CRP), insulin, glucose, serum lipids, apolipoprotein A-1 (ApoA-1), apolipoprotein B 
(ApoB), and homocysteine concentrations. Total cholesterol, high-density lipoproteins 
(HDL) and triglycerides were determined enzymatically. Low-density lipoprotein 
(LDL) was calculated with the Friedewald formula. Standardized methods were 
employed in all determinations (Juonala et al. 2004a, Raitakari et al. 2003). 
Information on geographical origin was also recorded, because the Eastern Finnish 
population is genetically more predisposed to the development of atherosclerosis than 
the population of Western Finland (Juonala et al. 2005). 
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1.1.1.3 Measurements of subclinical markers of atherosclerosis  
Carotid artery IMT was measured by ultrasound, and in order to determine CAC, the 
concomitant brachial blood pressure was also monitored. The brachial artery FMD was 
assessed by measuring the left brachial artery diameter both at rest and during reactive 
hyperaemia (after five minutes of comprimation). Ultrasound examinations were 
performed using Sequia512 mainframes (Acuson, Mountain View, California) with a 
13.0 MHz linear array transducer. The procedures have been discussed earlier in more 
detail (Raitakari et al. 2003). 
To determine the intra-individual reproducibility of the measurements, the 
ultrasound measurements were replicated for a small random sample of participants 
(n=57, 2,5%) 3 months after the initial visit. The between-visit coefficient of variation 
was 6.4% for IMT, 16.3% for CAC and 26% for FMD measurements. 
 
1.1.2 The Finnish Cardiovascular Study 
 
1.1.2.1  Study cohort 
FINCAVAS is a cohort study with the purpose of constructing a risk profile to identify 
individuals at a high or low risk of cardiovascular diseases, events and deaths by using 
genetic, hemodynamic and electrocardiographic (ECG) markers (Nieminen et al. 
2006). The participant pool consists of patients (n=2152) who underwent an exercise 
stress test at Tampere University Hospital between October 2001 and December 2004 
and were willing to participate in the study. Indications for the exercise test were: 
suspicion of coronary heart disease (CHD, n=959), testing vulnerability to arrhythmia 
during exercise (n=465), evaluation of working capacity (n=387) and adequacy of drug 
therapy (n=330), as well as obtaining an exercise profile prior to surgery (n=284) and 
post-MI (n=171). In some cases, the patients had more than one indication. 
Angiography was performed on a subsample of patients for interventional and 
diagnostic indications (n=461). The coronary angiographies were performed before 
June 2005. The study protocol was approved by the Ethical Committee of the Hospital 
District of Pirkanmaa, Finland, and all patients gave informed consent prior to study 
initiation, according to the Declaration of Helsinki. 
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1.1.2.2  Collection of risk factor data 
Data on demographics, classical cardiovascular risk factors, lifestyles, medications and 
medical history were gathered using a computer-based questionnaire before the 
exercise stress test was performed. Blood samples were drawn for DNA analyses after 
the exercise test. The definition of risk factor data has been described previously in 
detail (Fan et al. 2006).  
 
1.1.2.3  Angiography-verified CAD 
The same dedicated cardiologist analysed all coronary angiographies, and the 
percentages of stenosis in the different parts of the coronary arteries were registered. 
Angiography was performed on 461 patients. Based on the angiographies, 255 (34%) 
patients had main branch CAD (defined as over 50% stenosis in at least one of the 
major coronary arteries, including the left main, left anterior descending, right, and left 
circumflex coronary artery). In addition, 37 (8%) patients had a side branch stenosis of 
50% or more, while none of the patients had concomitant main branch disease. 
 
1.1.2.4 Mortality data collection 
Death certificates were received from the Causes of Death Register, maintained by 
Statistics Finland, in September 2009; this source has been proven reliable (Pajunen et 
al. 2005). The certificates included causes of death according to the tenth revision of 
the International Classification of Diseases (ICD-10). Diagnosis numbers and 
certificate texts were used to determine if the diseased had died of cardiovascular 
causes or due to other causes. The autopsy rate was 40% for all deaths and 60% for 
patients with SCD. 
 
1.1.3  The Tampere Vascular Study 
 
1.1.3.1  Samples 
The Tampere Vascular Study (TVS) material comprises arterial samples of 
atherosclerotic lesions (types IV–VI) (Stary et al. 1995) from the carotid arteries (n=9), 
femoral arteries (n=4) and aortas (n=7) of 20 patients subjected to vascular surgical 
procedures, in addition to healthy control samples of the left interior thoracic artery and 
the left interior mammary artery of patients (n=6) undergoing coronary artery bypass 
surgery at the Divisions of Vascular and Cardiothoracic Surgery, Tampere University 
[53] 
 
Hospital. The details of this study have been described previously in more detail 
(Oksala et al. 2009). Genome-wide expression analysis (GWEA) was performed on all 
samples. The expression levels of IL-18 receptor α (IL-18Rα), IFN-γ, and IL-12 have 
been previously measured using real-time polymerase chain reaction (PCR) for a 
separate publication, and these measurements were incorporated into the data to obtain 
more accurate results (Oksala et al. 2009). 
 
1.1.3.2 RNA isolation and genome-wide expression analysis (GWEA) 
The fresh tissue samples (n=26) were immediately soaked in RNALater solution 
(Ambion Inc., Austin,TX, USA), and total-RNA was isolated with TRIzol reagent 
(Invitrogen, Carlsbad, CA, USA) and the RNAEasy Kit (Qiagen, Valencia, CA, USA). 
The GWEA Microarray experiments were performed by using Sentrix® Human-8 
Expression BeadChips analyzing over 23,000 known genes and gene candidates 
(Illumina, San Diego, CA, USA) according to the manufacturer’s instructions. 
BeadChips were scanned with the Illumina BeadArray Reader. The method has been 
more accurately described previously (Oksala et al. 2009). The accuracy of the 
Illumina Sentrix® Human-8 Expression BeadChips microarray methodology in 
measuring gene expression was verified by real-time quantitative TaqMan PCR 
through quantifying the expression of 20 genes with both methods. (Laaksonen et al. 
2006) 
 
1.2 Autopsy series 
1.2.1 The Helsinki Sudden Death Study 
1.2.1.1 Subjects 
The Helsinki Sudden Death study (HSDS) is based on the autopsy data of 700 Finnish 
Caucasian men who had died suddenly out of hospital in the area of Helsinki (Mean 
age 53 years, range 33 to 70 years). The material includes two independent autopsy 
series. They were collected in 1981–1982 (A series, n=400) and 1991–1992 (B series, 
n=300). All the men were subjected to a medicolegal autopsy, because of their 
unexpected sudden death occurring outside a hospital and often unwitnessed, unless the 
deceased had suffered from a clinically diagnosed condition with a high probability of 
causing an untimely and sudden demise, such as severe chronic heart failure. The 
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HSDS material covers 25.3% of all the 2,850 deaths of 33–70-year-old males during 
the study period, covering 35.0% of all deaths which occurred due to ischemic heart 
disease in the area of Helsinki. The leading cause of death within this study population 
was cardiac causes (41%, n=288). Other causes of death were verified as other diseases 
(20%, n=140) and unnatural deaths resulting from accidents or suicides (39%, n=272). 
All medicolegal autopsies were performed according to the same protocol at the 
Department of Forensic Medicine at the University of Helsinki, and the study was 
approved by the Ethics Committee of the department/university. 
 
1.2.1.2 Post-mortem verification and classification of varying causes underlying 
SCD and MI 
The deaths caused by cardiac diseases were divided into two main categories by the 
autopsy findings – SCDs caused by CHD (80%, n = 220) and SCDs caused by non-
coronary diseases in the absence of CHD (20%, n = 55). Most of the men with CHD 
died of SCD due to an MI (n = 154) (death due to acute M [n = 101], or/and 
arrhythmias associated with the scar of a prior MI [n = 53]), or CHD with no 
acute/prior MI (n = 64). Non-coronary SCDs were due to cardiomyopathy, hypertrophy 
or dilatation of the heart, or valvular diseases. MI was verified by a macroscopic and 
histological examination of the myocardium. Fibrous scar tissue of the myocardium 
was considered the diagnostic criterion for old MI and the presence of neutrophil 
granulocytes for an acute MI. When coronary arteries were opened longitudinally, the 
presence of a coronary thrombus was recorded.  
 
1.2.1.3 Autopsy measurement of coronary stenosis and atherosclerosis 
A silicon rubber cast was made from the three main epicardial coronary arteries (the 
left anterior
 
descending, left circumflex and right coronary artery). The degree of 
coronary stenosis was determined from these rubber models. The cut-off value for the 
classification of CAD was over 50% stenosis in any part of one or several main 
coronary arteries. In order to analyze the areas of different types of atherosclerotic 
lesions and overall atherosclerosis, the coronary arteries were fixed in 10% buffered 
formalin and stained for fat by the Sudan IV staining method. The methods of these 
measurements have been described previously. (Mikkelsson et al. 2001)  
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1.2.1.4 Collection of risk factor data in the HSDS 
A close friend, spouse or relative of the deceased was interviewed by means of a ques-
tionnaire to obtain risk factor data. Complete interview data on risk factors was avail-
able in 402 (60.6%) of the 663 cases whose IL-18 genotype was successfully deter-
mined. (Mikkelsson et al. 2001) Risk factor data included the following variables: hy-
pertensive (yes/no), diabetic (yes/no), smoker (yes/no; smokers and ex-smokers were 
combined in to the category of smokers for the statistical analysis), daily alcohol con-
sumption and body mass index (BMI). BMI was calculated from the autopsy data. The 
victim was determined hypertensive if his hypertension had been diagnosed clinically 
by a physician and/or he had been medically treated for hypertension, or if it was 
known that hypertensive blood pressure values had been measured from the subject 
prior to his death. 
 
1.3 DNA isolation and genotyping methods 
 
1.3.1 DNA isolation 
In the clinical series, genomic DNA was extracted from peripheral blood leukocytes by 
using the QIAampDNA Blood Minikit and automated biorobot M48 extraction 
(Qiagen, Hilden, Germany). In the HSDS, the cardiac muscle tissue samples collected 
for the A series were stored as paraffin-embedded blocks, and the samples from the B 
series were stored frozen. The DNA extraction method from these samples has been 
described earlier (Isola et al. 1994). 
 
1.3.2 Genotyping methods 
Within a Caucasian population, 99% of the genetic variation of the IL-18 gene is 
covered by six haplotypes formed by five common tag SNPs (rs1946519, rs360717, 
rs549908, rs4937100 and rs5744292), or SNPs existing within the same bin with these 
five common haplotypes (SNPs in nearly complete association with each other) (Tiret 
et al. 2005). In the Cardiovascular Risk in Young Finns Study, and in the Finnish 
Cardiovascular Study, we genotyped the same polymorphisms. Genotyping of four 
SNPs (rs4937100, rs549908, rs360717, and rs1946519) was performed using Taqman 
SNP Genotyping assays, as well as the ABI Prism 7900HT Sequence Detection System 
(Applied Biosystems, Foster City, CA, USA). For the SNP rs5744292, the genotyping 
was performed using a custom Taqman assay designed according to the Custom 
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TaqMan® Assays instructions and manufactured by Applied Biosystem’s Custom 
TaqMan® Assays Service. In the HSDS and TVS, the promoter region SNP (rs187238) 
was genotyped using the same protocol, and the nucleotide sequences of the primers 
and the fluorogenic allele-specific oligonucleotide probes
 
used in PCR were deduced 
from published sequences in the GenBank database; they were chosen and synthesized 
in co-operation with Applied Biosystems. 
PCR reaction containing genomic DNA, 2  TaqMan Universal PCR Master 
Mix, 900 nM of each primer, and 200 nM of each probe was performed in 384-well 
plates according to a standard protocol in a total volume of 5 l. Water controls and 
random duplicates were used as a quality control. Parallel samples were genotyped to 
monitor genotyping errors. No errors were detected. A description of the principles of 
the 5’nuclease assay method can be found in a previous publication by Livak et al. 
(1999) (Livak 1999). 
In the Cardiovascular Risk in Young Finns Study, the genotyping was 
successful in 94.8%–98.8% of the cases depending on genotype. Genotyping of the IL-
18 SNP (rs187238) was successful for 663 (94.7%) of the 700 tissue samples (A series, 
382 cases; B series, 281 cases) in the HSDS and 25 (96.2%) of the 26 blood samples in 
the TVS. 
 
1.4 Statistical Analyses and methods 
Haplotype analyses. The haplotype reconstructions were performed by PHASE 
software (Version 2.0.2) (Stephens and Donnelly 2003, Stephens et al. 2001) in studies 
x-y. The THESIAS software was used to analyze the risk factor-adjusted global 
association between the variation of the IL-18 gene and cardiovascular mortality as 
well as the occurrence of main branch CAD and all CAD in the Finnish Cardiovascular 
Risk Study (Tregouet and Garelle 2007). A p-value of < 0.05 was considered 
statistically significant. The computations were carried out with SPSS for Windows 
software (Version 14.0, SPSS Inc, USA). Values of significance on all non-parametric 
tests are presented as asymptomatic and 2-tailed. In all study settings (I–IV), analysis 
of variance (ANOVA) was used to evaluate the possible association between risk 
factors and the polymorphism of the IL-18 gene. Non-parametric tests such as the 
Mann-Whitney U and Kruskall-Wallis H test were applied if the continuous variable 
was not normally distributed. Categorical variables and Hardy Weinberg equilibrium 
were tested using the χ2-test. 
[57] 
 
 
In study I (the Cardiovascular Risk in Young Finns Study), in order to investigate the 
possible association between IL-18 gene polymorphism and the subclinical markers of 
atherosclerosis, we applied adjusted analysis of variance (ANCOVA). Only significant 
covariates were accepted into the models (the procedure has been previously described 
in more detail) (Hernesniemi et al. 2008). First we studied the possible factor-by-sex 
interactions. If the interaction between the haplotype or SNP and sex was found 
significant, we proceeded to analyze the effect of the haplotype or SNP among men and 
women separately, and the results from the level of the whole study population were 
not interpreted. To study the effect of haplotypes, we divided the population into 
carriers and non-carriers. The effects of individual genotypes were studied without 
pooling the genotypes. Previously, pregnancy has been associated with changes in 
serum values of IL-18, and this tendency has been found to be modulated by IL-18 
genotype (Ida et al. 2000, Kashef et al. 2008). For this, the analyses were performed 
before and after the exclusion of the 61 women who were pregnant during the time of 
the study. However, the results remained almost unchanged, and we therefore only 
present the results obtained from the whole study population. Variables with skewed 
distributions (insulin, glucose and CRP) were log10-transformed for the analyses. 
The Li & Ji method was applied in order to correct for multiple testing (Li and 
Ji 2005). This method is the improved version of the method originally introduced by 
Nyholt et al. for adjusting for multiple testing in multilocus analyses (Nyholt 2004). 
This correction method was used because of the high linkage disequilibrium between 
the SNPs.  
 
In study II (the Finnish Cardiovascular Study), Cox regression analysis was used to 
study mortality among different genotypes and haplotypes over the follow-up period. 
The analysis was adjusted with age, sex, use of beta-blockers, percentage of age-
adjusted maximal heart rate reached as well as prior diagnoses of CHD, MI and 
diabetes. All covariates fulfilled the proportionality assumption based on correlations 
of survival rankings with Schoenfeld residuals. When studying the possible association 
between IL-18 gene variation and the expression of CAD, we used binary regression. 
We first studied whether the effect of specific genotypes would be sex-dependent. If a 
significant interaction was observed, the study population was stratified by sex. 
Otherwise, no stratification by sex was performed. The risk factors preliminarily 
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considered as covariates in each regression model were age, sex, diabetes, smoking, 
resting systolic blood pressure and hypercholesterolaemia. In all adjusted analyses, 
only significant covariates were accepted in the final models, as insignificant 
covariates were filtered out by backward elimination.  
One of the IL-18 genotype distributions (533T>C, rs4937100) was not in 
Hardy Weinberg equilibrium in the study population of the Cardiovascular Risk in 
Young Finns Study (p<0.001). Nevertheless, we included it into our haplotype 
reconstruction in order to verify whether our haplotype frequencies were in line with 
those observed in previous studies (Tiret et al. 2005). This SNP was responsible for 
dividing one common haplotype (haplotype aCTA with a frequency of 0.173) into two 
smaller haplotypes (aCTAT, frequency 0.132 and aCTAc, frequency of 0.041) (See 
Table III below). Because the genotype distributions of the 533T>C SNP were not in 
Hardy Weinberg equilibrium, this SNP was excluded from further analyses, and only 
the effect of the combined aCTA haplotype was studied. 
 
In the HSDS (Studies III and IV), due to the small number of CC homozygotes (n = 
43, 6.5%), they were combined with the GC heterozygotes to form a group of C allele 
carriers for statistical analyses. However, the analyses were also repeated without 
pooling the genotypes. 
Logistic regression analysis was used to calculate the odds ratios (OR) for de-
pendent variables according to genotype groups. Analyses were carried out with and 
without adjustment for autopsy data (body mass index [BMI] and age) and interview 
data (daily alcohol consumption, smoking, diabetes and hypertension). The control 
group consisted of men who had died of other diseases and men who had died of un-
natural causes. This was included because the IL-18 genotype group did not associate 
with the rate of deaths caused by non-cardiac-related diseases or unnatural causes. 
Binary logistic regression analysis was used to calculate the IL-18 genotype-by-
risk-factor interactions. Analyses for each genotype group by risk factor interaction 
were carried out with and without adjustment for autopsy data (BMI and age) and 
interview data (alcohol consumption, smoking, diabetes and hypertension). If the 
interaction between IL-18 genotype group and a risk factor was found significant, the 
effect of the risk factor on the occurrence of SCD was studied separately using 
unadjusted and adjusted binary logistic regression analysis, stratifying the population 
by IL-18 genotypes. In all analyses, covariates were included in the model in a 
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stepwise manner. Only statistically significant (p < 0.05) covariates were accepted in 
the final adjusted model 
 
In study IV (the Tampere Vascular study), the patients were divided into two groups: 
GG homozygotes and C allele carriers. This was done because only one patient carried 
two copies of the minor C allele of the promoter region -137 G/C SNP. The expression 
levels of IL-18 mRNA and IFN-γ mRNA were compared over IL-18 genotype groups, 
and patients with or without hypertension using ANCOVA. The study population was 
divided into two groups by median systolic arterial pressure (140 mmHg) in order to 
study the effect of hypertension on the dependent variables. All ANOVAs were 
adjusted with the mRNA expression of surface structures expressed by APCs (CD80 
and CD86 transcript variant 1 [ v1 ] and CD86 transcript variant 2[ v2 ]) and by T cells 
(CD4, CD28, and CTLA-4) (Sansom 2000). This allowed us to compare the expression 
of IL-18 and IFN-γ between samples with different inflammatory background, and it 
was necessary because the current material consist of atherosclerotic samples from 
different vascular beds with variation in inflammatory background. The expression of 
the mRNA of these factors is subject to inflammatory stimuli (Sansom 2000). 
Therefore, they do not directly represent the quantity of the T cells or APCs in the 
samples. However, at the same time, they provide some adjustment on the 
inflammatory activity within the samples. These covariates were selected because 
macrophages, which also act as APCs, are major producers of IL-18, and T cells are 
major producers of IFN-γ (Okamura et al. 1995). Only significant covariates were 
selected into the model by means of a backward elimination procedure. All analyses 
were repeated with log-transformation of the continuous variables, but this did not 
improve the predictive value of the analyses (measured by pseudo R
2
-value), which is 
why the results of the analyses performed with crude values are reported.  
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RESULTS 
 
1.1 Genotype distributions of the IL-18 gene in different study populations 
In the Finnish Cardiovascular Risk Study and the Cardiovascular Risk in Young Finns 
Study, we determined 5 tag SNPs (rs1946519, rs549908, rs360717, rs5744292, 
rs4937100. All of the genotype distributions were in accordance with the Hardy-
Weinberg equilibrium, except for the rs4937100 SNP which, in both series, showed a 
significant deviation from the equilibrium (p<0.0001). Nevertheless, it was included it 
in the haplotype reconstruction in order to verify whether our haplotype frequencies 
were in line with those observed in previous studies, but it was excluded from further 
analyses. This SNP was responsible for dividing one common haplotype (haplotype 
ACTA with a frequency of 0.17, see table 5.) into two smaller haplotypes (see original 
publication I for more details). The haplotypes constructed from these tag SNPs as well 
as their frequencies were in accordance with the results of previous studies (Barbaux et 
al. 2007, Tiret et al. 2005). In brief, we found that the IL-18 gene has 5 common 
haplotypes (CTCA, AGTA, CTCG, ATCA and CGCA [underlined letters denote minor 
alleles of the specific SNP]). The haplotype AGTA was the only one carrying the 
minor T allele of the +127 (C/T) polymorphism (rs36017), and only the CTCG 
haplotype carried the minor G allele of the +415 (A/G) polymorphism (rs5744292). 
 In the HSDS, only the promoter region -137 (G/C) (rs187238) SNPs were 
genotyped due to the quality and quantity of the tissue samples. This polymorphism is 
in complete association with the +127 (C/T) polymorphism (rs360717), which was 
genotyped in the clinical series. Of all the men, 359 (54.1%) had the wild-type GG 
genotype, 261 (39.4%) were heterozygotes (CG), and 43 (6.5%) were CC 
homozygotes. The allelic frequency of the C allele was 0.262 and of the G allele 0.738. 
The genotype distributions in the TVS were: 15 (60%) GG homozygotes, 9 (36%) GC 
heterozygotes and 1 (14%) CC homozygote. In both studies, the genotype distribution 
was in line with the Hardy-Weinberg equilibrium. 
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Table 4. The genotype distributions among the study populations of the Cardiovascular 
Risk In Young Finns Study (I) and The Finnish Cardiovascular Risk Study (II). The 
topmost line of each genotype denotes the percentage of the population (number of 
subjects in brackets) with two copies of the wild-type allele. The following line denotes 
heterozygotes and the lowest line homozygotes carrying two mutated copies of the 
gene. 
 Single Nucleotide Polymorphism 
Study rs1946519            
-656 (C/A)* 
rs549908          
+35 (T/G) 
rs360717       
+127 (C/T)* 
rs5744292      
+415 (A/G) 
rs4937100   
+533 (T/C)** 
      
 
I 
30.0% 
47.1% 
22.5% 
(673) 
(1065) 
(506) 
47.2% 
42.9% 
9.9% 
(1062) 
(966) 
(223) 
50.8% 
40.6% 
8.5% 
(1125) 
(899) 
(189) 
57.6% 
36.6% 
5.8% 
(1204) 
(766) 
(121) 
53.4% 
31.4% 
15.2% 
(1195) 
(704) 
(340) 
II 32.1% 
48.7% 
19.2% 
(683) 
(1037) 
(410) 
50.1% 
41.1% 
8.8% 
(1058) 
(868) 
(185) 
54.2% 
38.7% 
7.1% 
(1151) 
(821) 
(150) 
54.6% 
38.8% 
6.6% 
(1156) 
(823) 
(140) 
52.6% 
31.3% 
16.0% 
(1076) 
(640) 
(328) 
*Genotype distribution significantly different (p<0.05) between the two study 
populations. **Genotype distributions not in Hardy-Weinberg equilibrium. 
 
 
Table 5. The IL-18 gene haplotypes and their observed frequencies among the study 
populations of the Cardiovascular Risk in Young Finns Study (I) and The Finnish 
Cardiovascular Risk Study (II). Underlined letters denote the minor allele of the 
individual SNPs. 
  Frequency 
Study I Study II 
        CTCA-haplotype  0.270 0.275 
    AGTA- haplotype  0.288 0.266 
    CTCG-haplotype  0.244 0.261  
    ATCA-haplotype  0.173 0.171  
    CGCA-haplotype   0.024 0.027 
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1.2 IL-18 gene polymorphism and subclinical markers of atherosclerosis (Study I) 
 
According to adjusted ANOVA, there was a significant difference between men and 
women in the ways in which the CCTG haplotype associated with carotid artery IMT 
(p=0.011 after correcting for multiple testing). This analysis was adjusted with sex, 
BMI, age, smoking and geographical origin. The population was therefore stratified by 
sex. Among men, carriers of the CCTG had a significantly lower mean IMT when 
compared to the non-carriers (adjusted difference in means: -0.016mm 95% CI 
from -0.028 to -0.004, p=0.014 after correcting for multiple testing). The adjusted 
mean values by haplotype group were: 0.601mm (standard error [S.E.] 0.004mm) for 
non-carriers, 0.585mm (S.E. 0.005mm) for heterozygous carriers and 0.596mm (S.E. 
0.014mm) for homozygous carriers of the CCTG haplotype. The difference in mean 
IMT between heterozygous and homozygous male carriers of this haplotype was not 
significant (corrected p=1.00). As the carriers of the CTCG haplotype are the only ones 
carrying the minor G allele of the +415 C/g SNP (rs5744292), it is clear that this allele 
is responsible for the significant difference between the haplotype groups. Among 
women we did not observe any significant differences (0.005 mm, 95% CI from -0.004 
to 0.014, corrected p=0.498) between carriers and non-carriers of the CTCG haplotype.  
None of the other haplotypes or SNPs associated significantly with IMT 
among the whole study population, and no other significant haplotype-by-sex-
interactions were seen. None of the haplotypes or studied SNPs associated significantly 
with CAC or brachial artery FMD in the whole study population, and we did not 
observe any significant haplotype-by-sex-interactions.  
We also found that the frequencies of the minor alleles of the +35 (T/g) SNP 
(p=0.005) and +127 (C/t) SNP (p=0.040) were higher among subjects with Eastern 
Finnish origin when compared to those originating from Western Finland. As 
geographical origin in Finland has been previously associated with the development of 
atherosclerosis, we also repeated all the analyses after excluding geographical origin 
form the covariates. The exclusion did not alter the results, and the observed 
associations remained significant. 
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1.3 IL-18 gene polymorphism and the expression of angiography-verified CAD 
(Study II) 
 
According to the adjusted global association analysis, the genetic variation did not 
associate significantly with the occurrence of main branch CAD, when all five of the 
most common haplotypes were considered in the analysis (p=0.772), or with CAD 
defined as over 50% stenosis in any part of the coronary arteries (p=0.847). However, 
according to the interaction analyses executed with the binary regression method, one 
haplotype seemed to associate differently among men and women in the occurrence of 
main branch CAD (adjusted p=0.033 for the interaction). Among men, the carriers of 
the AGTA haplotype had a lower risk for main branch CAD (adjusted OR 0.576, 95% 
CI 0.340–0.978, p=0.041). Among women no significant difference was observed in 
the occurrence of main branch CAD (adjusted OR 1.562, 95% CI from 0.669–3.648, 
p=0.303). Other significant interactions were not found, and none of the haplotypes or 
SNPs were found to associate significantly with main branch CAD or with CAD in any 
part of the coronary arteries in the whole study population. 
 
1.4 IL-18 gene polymorphism and cardiovascular mortality in a Finnish patient 
population (Study II) 
 
According to the global association analysis, mortality from cardiovascular causes 
during the follow-up was not associated with IL-18 gene polymorphism, when all the 
five most common haplotypes were accounted for (p=0.344). Consistently, none of the 
studied SNPs or haplotypes associated individually with mortality during the follow-up 
according to Cox-regression analysis. The hazard ratios corresponding to the carriage 
of the haplotypes were (in comparison to the non-carriers): HR 1.122 for CTCA 
(p=0.588), HR 0.806 for AGTA (p=0.307), HR 1.355 for CTCG (p=0.144), HR 0.803 
for ATCA (p=0.353), and HR 0.928 for CGCA (p=0.924). 
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1.5 IL-18 gene polymorphism and the occurrence of SCD (Study III) 
 
According to the results of the autopsy series, the C allele carriers had a lower risk of 
SCD than GG homozygotes (50.3% of the men in the control population where C allele 
carriers, whereas the corresponding proportion among SCD victims was 36.9%; crude 
OR 0.65; 95% CI 0.48–0.89, p=0.007; and adjusted OR 0.49; 95% CI 0.31–0.77; p = 
0.002). Furthermore, the C allele carriers had a significantly lower risk of both SCD 
due to CHD (adjusted odds ratio, 0.51; 95% CI 0.32–0.82; p = 0.005) and SCD caused 
by non-coronary heart diseases (adjusted odds ratio, 0.34; 95% CI 0.13–0.90, p = 
0.030) when compared to the GG homozygotes. The results persisted when the analysis 
was limited to different sub-types of SCD caused by coronary atherosclerosis (Table 6). 
In order to test whether the risk of SCD was age-dependent, we used 
regression analysis to analyze the possible age-by-genotype interactions affecting the 
risk of different subtypes of SCD. Most of these associations were independent of age 
(data not shown). However, there was a significant age-by-genotype interaction with 
the risk of SCD due to MI (crude and adjusted interactions p = 0.028/0.037). Therefore, 
we formed two categories of equal size by dividing the overall study population by the 
mean age (53 years). In the younger age group (age < 53 years), the C allele was 
strongly protective against SCD due to MI: of the 35 died men, 26 (74.3%) were GG 
homozygotes and only 9 were (25.7%) C allele carriers (crude odds ratio, 0.34; 95% CI 
0.14–0.68; p = 0.004; and adjusted odds ratio, 0.16; 95% CI 0.05–0.51; p = 0.002). In 
the older age group, 68 (57.1%) of the 119 men who had suffered an SCD due to MI 
were GG homozygous and 51 (42.9%) were C allele carriers. This difference was not 
statistically significant. 
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Table 6. IL-18 -137 G/C (rs187238) genotype group frequencies among men who had 
suffered different subtypes of SCD or died of other causes, with corresponding adjusted 
odds ratios (OR) 
 n CG/CC GG Adjusted OR (95% CI)
***
 p Value 
      
Controls
*
 388 50.3% 49.7%   
SCD not due to CHD
**
 55 32.7% 67.3% 0.34 (0.13-0.90) 0.030 
CHD 220 41.4% 58.6% 0.51 (0.32-0.82) 0.005 
   MI aetiology 154 39.0% 61.0% 0.48 (0.28-0.81) 0.006 
   AMI 101 36.6% 63.4% 0.50 (0.28-0.90) 0.021 
   AMI with thrombus 58 32.8% 67.2% 0.40 (0.18-0.87) 0.021 
      *Death due to non-cardiac diseases or unnatural deaths.  
**Death due to cardiomyopathy, cardiac hypertrophy or dilatation, or to valvular 
disease in the absence of CHD. 
***model adjusted with age, body mass index, smoking, hypertension, diabetes and 
daily alcohol consumption 
Abbreviations: IL-18, interleukin 18; CHD, coronary heart disease; SCD, sudden 
cardiac death; (A)MI, (Acute)myocardial infarction. 
 
To verify our results, we studied the association between IL-18 genotype and SCD 
separately in both of the independent autopsy series which formed the entire study 
population. These autopsy series were collected ten years apart (please see the Material 
and Methods section for the description of the autopsy series). The C allele carriers 
seemed to be underrepresented among SCD victims in both independent autopsy series.  
In the A series, the difference was statistically significant (p = 0.039 by two-sided ex-
act Pearson’s chi-square test). In the B series, there was a similar but not significant 
trend (p = 0.085 by two-sided exact Pearson’s chi-square test) (Figure 3.). IL-18 geno-
type associated with the occurrence of various phenotypes of SCD similarly in both 
series, but the associations were not significant due to smaller sample sizes. The major 
conclusions are therefore based on combined data from series A and B. 
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1.6 The interactions between risk factors and IL-18 gene polymorphism on the 
risk of SCD and CAD (Study IV) 
 
According to unadjusted binary logistic regression analysis, IL-18 genotype group in-
teracted significantly with hypertension (crude p = 0.009 and adjusted p = 0.011) as 
regards the effect on the risk of SCD, and this association persisted even after applying 
the Bonferroni correction (crude p = 0.045 and adjusted p = 0.055). When the IL-18 
genotype information was entered in the analysis without pooling CG heterozygotes 
and CC homozygotes, the result remained significant (crude p = 0.022 and adjusted p = 
0.029). Interactions with daily alcohol consumption (p = 0.600), BMI (p = 0.075), 
smoking (p = 0.998), or diabetes (p = 0.943) were not statistically significant.  
 Similarly, in unadjusted binary regression analysis of the occurrence of CAD, 
there was a statistically significant interaction between IL-18 genotype group and hy-
pertension (p = 0.020), which remained significant after adjustment for other risk fac-
tors (p = 0.026). After Bonferroni correction, the interaction was no longer significant 
(crude p = 0.100 and adjusted p = 0.130). Interactions with daily alcohol consumption 
(p = 0.701), BMI (p = 0.833), smoking (p = 0.805), and diabetes (p = 0.316) were not 
statistically significant. 
Because of the statistically significant genotype-group-by-hypertension inter-
action, we divided the study population according to IL-18 genotype in order to study 
the effect of hypertension separately by IL-18 genotype. 
  
1.7 The effect of hypertension on the expression coronary atherosclerosis among 
IL-18 genotypes (Study IV) 
 
In order to study how hypertension affects atherosclerotic plaque formation and 
composition among IL-18 genotype groups, we focused on the control group. This was 
done to avoid the evident selection bias presented by the significantly different 
mortality due to CHD-related SCD among the different IL-18 genotype groups. Among 
GG homozygotes, according to ANOVA adjusted with autopsy data (BMI and age), the 
coronary arteries of hypertensive men were more afflicted by overall atherosclerosis, 
and the relative surface areas of both fatty streaks and fibrotic plaques were larger 
when compared to normotensive men (Table 7). According to adjusted regression 
analysis, hypertension was also a significant risk factor for the occurrence of 
complicated plaques (OR 8.38 with 95% CI 2.39–29.33, p < 0.001; covariates: BMI 
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and age). Among C allele carriers, hypertension was not associated with the overall 
atherosclerotic burden (Table 7). In addition, when the groups of GC heterozygotes and 
CC homozygotes where analyzed separately, hypertension did not associate 
significantly with plaque areas or the occurrence of complicated plaques. 
Furthermore, hypertension was a major risk factor of CAD among GG 
homozygotes (adjusted OR 3.08; 95% CI 1.48–6.41, p < 0.003) but not among the 
combined group of C allele carriers (OR 0.78; 95% CI 0.32–1.89, p = 0.581), nor 
among GC heterozygotes (OR 0.83; 95% CI 0.32-2.11, p=0.687) or CC homozygotes 
(p=1.00 evaluated by Fisher’s exact χ2-test because only 5 men had suffered from 
hypertension, and only two of them had CAD). 
 
 
 
 
Table 7. The effect of hypertension on the relative surface area of the coronary arteries 
covered by atherosclerotic lesions among different IL-18 genotype groups. P-values 
were determined by using analysis of variance adjusted with age and body mass index.  
 GG homozygotes p-value C allele carriers p-value 
 SBP <140 SBP <140  SBP <140 SBP >140  
Fatty streak 7.1% (1.3) 4.2% (0.4) 0.026 6.8% (1.0) 5.2% (0.5) 0.268 
Fibrotic plaque 4.6% (0.7) 2.0% (0.2) <0.001 2.5% (0.6) 3.2% (0.4) 0.268 
Overall lesion  
area 
11.7% (1.7) 6.2% (0.5) 0.002 9.3% (1.1) 8.4% (0.7) 0.701 
       
Abbreviations: SBP, systolic blood pressure. 
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1.8 The effect of hypertension on the risk of SCD among IL-18 genotypes (Study 
IV) 
Hypertension was a major risk factor for SCD and CAD among GG homozygotes, but 
not among the combined group of C allele carriers, nor among GC heterozygotes or CC 
homozygotes, when the genotypes were analyzed separately. Among GG homozy-
gotes, hypertension associated significantly with SCD due to CHD (adjusted OR 3.75; 
95% CI 1.78–7.91, p = 0.0005), SCD due to old or acute MIs (sudden cardiac death 
due to arrhythmias caused by an old MI scar and/or AMI) (adjusted OR 4.56; 95% CI 
2.05–10.11, p = 0.0002), and with fatal acute MI (adjusted OR 4.69; 95% CI 2.01–
10.95, p = 0.0004). Among C allele carriers, hypertension was not associated with 
higher risk of SCD due to CHD (adjusted OR 0.78; 95% CI 0.32–191, p = 0.583), SCD 
due to old or acute MIs (sudden cardiac death due to arrhythmias caused by an old MI 
scar and/or AMI) (adjusted OR 0.88; 95% CI 0.32–2.40 p = 0.805), and fatal acute MI 
(adjusted OR 1.14; 95% CI 0.39–3.37, p = 0.814). 
 
 
Figure 3. The effect of hypertension on the risk of Sudden Cardiac Death (SCD) and 
Coronary Artery Disease (CAD) among GG homozygotes and C allele carriers of the 
IL-18 gene -137G/C polymorphism. Odds ratios (OR) are derived by logistic regres-
sion adjusted with traditional risk factors for CAD. 
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1.9 The effect of IL-18 genotype and hypertension among IL-18 genotype groups 
on the expression of IL-18 and IFN-γ mRNA in atherosclerotic arterial sam-
ples (Study IV) 
 
According to adjusted ANOVA, the effect of hypertension on the expressions of IL-18 
mRNA and IFN- γ mRNA were modulated by the IL-18 genotype (p = 0.030 [IL-18] 
and p = 0.004 [IFN- γ] for the interactions). Among GG homozygotes, hypertension 
did not associate with the expression level of intracellular precursor IL-18 mRNA (0.89 
fold increase, p = 0.217), whereas among C allele carriers hypertension augmented the 
expression of intracellular precursor IL-18 mRNA (1.31 fold increase, p = 0.001). 
Almost inversely, among GG homozygotes, hypertension associated with a higher 
expression level of pro-atherosclerotic IFN-γ (1.58 fold increase, p = 0.006), whereas 
hypertension in C allele carriers seemed to associate with a lower expression level of 
IFN-γ (0.58 fold increase, p = 0.047).  
In the atherosclerotic samples obtained from GG homozygotes, the expression 
levels of the intracellular precursor IL-18 mRNA were lower (0.68 fold increase, p < 
0.001), but the expression levels of IFN-γ mRNA were higher (1.85 fold increase, p < 
0.001), when compared to the atherosclerotic samples of the C allele carriers. 
Furthermore, according to the unadjusted Mann-Whitney U-test, the expression levels 
of IL-18 mRNA seemed to be significantly higher in the healthy control samples when 
compared to the atherosclerotic samples (1.33 fold increase, p = 0.052). 
Significant covariates associating with the expression of IL-18 mRNA were: 
CD80 (p = 0.006), CD86v1 (p = 0.012), CD4 (p = 0.013), CD86v2 (p = 0.010), 
Caspase-1 variant α (p = 0.023), and Caspase-1 variant ε (p = 0.009). The expression 
levels of Caspase-1 (Casp-1) variants were also introduced to this model, because 
Casp-1 cleaves the IL-18 precursor protein into biologically active IL-18, resulting in 
the secretion of mature IL-18 protein. This intrinsic processing is likely to affect the 
amount of intracellular IL-18 precursor mRNA, which has a stable mRNA structure 
and is constitutively and intracellularly stored (Nakanishi et al. 2001). 
Significant covariates associating with the expression of IFN-γ mRNA were: 
CD80 (p < 0.001), CD86v1 (p < 0.001), CD4 (p = 0.014), CTLA-4 (p = 0.010), IL-12 
(p = 0.004), and IL-18Rα (p = 0.003). The expression levels of IL-12 and IL-18Rα 
were also included in this model, because IL-12 in synergy with IL-18 augments the 
production of IFN-γ, and IL-18Rα plays an important role in IL-18 signalling 
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(Nakanishi et al. 2001). The expressions of IL-18 binding protein, Casp-1vα and Casp-
1vε were also added to the analysis, but these covariates were not significant in the 
model and were not used for further adjustment. 
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DISCUSSION 
 
1.1 Study populations 
 
1.1.1 The Cardiovascular Risk in Young Finns Study 
In the Cardiovascular Risk in Young Finns Study, the original population was randomly 
selected from the national population register to include different parts of Finland 
(from urban areas as well as from rural areas) and equal numbers of participants from 
both sexes. The initial sampling consisted of 4,320 subjects aged 3, 6, 9, 12, 15 and 18. 
A total of 3,596 subjects (83.2%) participated. In 2001, data was collected for a 21-year 
follow-up. A total of 2,283 subjects participated (63.5% of the original study cohort). 
Both the sample of participants in 1980 and the follow-up sample of 2001 were 
concluded to be representative of the original randomly selected population because of 
the high participation rate, and because there did not seem to be any systematic reason 
of for non-participation in 1980 and, finally, because there was no difference in the 
baseline risk factors (measured in 1980) between dropouts and participants (Akerblom 
et al. 1985, Juonala et al. 2004b). 
Based on the fact that the study population can be considered a good 
representative of a population of Caucasian healthy adults, this multicentre study 
provides a good population for genetic studies. Also, the relatively large study 
population (n=2,283) secures enough power for the study. We can also presume that the 
genotypic distributions obtained from this population represent the genotypic 
distribution of the general population in Finland. Furthermore, within this population, 
the effect of other risk factors has been very extensively studied, and it is therefore easy 
to size the associations between the genetic risk factors and the end-points.  
 
1.1.2 The Finnish Cardiovascular Study 
In the Finnish Cardiovascular Study, the population comprises patients (men and 
women) who have undergone a clinical exercise stress test for diagnostic indications at 
Tampere University Hospital. This ongoing study is designed to construct a risk profile 
of individuals at high risk of cardiovascular diseases, events and deaths. The results of 
the present study are based on the data collected between October 2001 and December 
2004. By the end of 2004, 2,152 patients had been included in the study population. 
The study population in itself is fairly heterogeneous due to the selection criteria. The 
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indications for the clinical exercise stress test were diagnosis of CHD (frequency 
44.6%), testing vulnerability to arrhythmia during exercise (21.6%), evaluation of 
working capacity (n=18.0%) and adequacy of drug therapy (15.3%), as well as 
obtaining an exercise profile prior to surgery (13.2%) and post MI (n=7.9%). Some of 
the patients had multiple indications. Furthermore, the patients in the study population 
come from different backgrounds with varying lifestyles. They also have different 
medical histories and the age spectrum is wide. For this reason, the study setting is 
challenging for the study of associations between individual genetic factors and 
mortality to cardiovascular causes. A genetic factor may be a clear risk factor for one 
set of patients but not for others. Unfortunately, the study population is still relatively 
small for division into subpopulations. However, as the study is ongoing, more patients 
are being recruited and the follow-up time is increasing. Eventually, the study will 
provide a clear setting for genetic risk stratification also in sub-populations. In the 
present study population, the mortality rate was also not very high, weakening the 
power of the study (during a follow-up of 6.3 years, 5.3% of the patients had died of 
cardiovascular causes). 
Coronary angiography was performed on a subset of patients (21.4%) for 
clinical and interventional indications. This patient population is highly selected, and 
the expression of CAD is thus likely to be similar despite the differences in the genetic 
background of the patients. However, as the number of patients in this sub-population 
increases, significant genetic factors will most likely become evident, and the risk 
factor profile should be different between patients with different backgrounds. 
 Despite these limitations, the Finnish Cardiovascular Study is unique, because 
it incorporates extensive exercise data with other clinical variables and genetic 
markers. It includes extensive data on the demographics (i.e. age, sex, body mass 
index), lifestyle factors and, most importantly, the exposure to classical cardiovascular 
risk factors, such as smoking, hypertension, diabetes, occurrence of hyperlipidemia and 
family history. Medications and prior diagnoses of CHD and MIs are also recorded. In 
conclusion, the study setting allows adjustment of all the analyses with extensive risk 
factor data.  
 
1.1.3 The TVS 
The TVS comprises atherosclerotic samples from different arteries (carotid arteries, 
femoral arteries and the aorta). The healthy control samples were obtained from 
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different arteries (interior mammary arteries and interior thoracic arteries) during 
coronary artery bypass surgeries. The study is limited due to the fact that the patients 
were of different sexes and had very different backgrounds and medications. 
Furthermore, the vascular samples were obtained from different arteries, which limits 
the power of the study not only because the hemodynamic environments are different, 
thus possibly modifying the atherosclerotic process, but also because it is clear that 
lesions in different sites may have different properties. In fact, within the samples of 
the present study, the expression levels of the mRNA of factors expressed on T cells 
and APCs were very different (data not shown). However, we were able mitigate this 
problem by adjusting the statistical analyses with these factors, allowing us to provide 
some adjustment of the inflammatory activity in the samples. Currently, this study 
material is being expanded to include more samples, and in the future the diversity of 
the samples will become an advantage, as it will be possible to explore the expression 
patterns of candidate pathways in different vascular beds. The fact that all 
atherosclerotic samples were of advanced plaques with similar histology (Classes IV 
and V according to the AHA/Stary classification) is another advantage. Furthermore, it 
is important to bear in mind that the study data allows us to observe the expression 
patterns directly on the human artery wall level. 
 
1.1.4  The Helsinki Sudden Death Study 
The HSDS provides a good material for studying the possible associations between 
genetic and environmental factors and the occurrence of SCD among men, as well 
associations with autopsy-verified atherosclerotic lesion areas in different arterial beds 
(coronaries, aorta). This is due to the fact that this study includes nearly all SCDs 
which occurred in the Helsinki area during the time of the autopsy series and, 
therefore, the study population is quite representative of the population at risk of SCD. 
Also, the proportion of SCD among the entire study population is extremely high 
(41%), thus making the study sensitive for candidate gene studies. The study setting 
also provides an opportunity to study the effects of different factors on the development 
of coronary atherosclerosis in a population with no survival bias. Furthermore, by 
studying the development of coronary atherosclerosis among the control group (men 
who had died of unnatural causes or diseases unrelated to cardiac causes), we can 
circumvent the obvious selection bias if the suspected risk factor has also affected the 
occurrence of SCD. As the study population only comprises men, the results are not 
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directly applicable to women. 
One obvious limitation, besides the fact that there are no measurements of the 
cholesterol levels of the deceased, is that we were unable to obtain interview data on all 
subjects. The risk data concerning diabetes, hypertension, smoking and alcohol 
consumption therefore did not cover the entire population. We also lack data on 
possible pre-mortem medications of the deceased. Furthermore, the validity of the risk 
factor data derived by interviewing a close friend, spouse or relative cannot be 
considered as high as that of clinical measurements or an interview of the subject 
himself. Fortunately, though, the validity of interview data concerning, for example, 
hypertension is high (Wu et al. 2000). 
Although the study setting is challenging, its strength lies in the unambiguous 
post-mortem verification of the cause death and the accuracy of the data concerning the 
development of coronary atherosclerosis on the vessel wall level. By using vulcanized
 
rubber models of the arteries, we were able to determine the degree of stenosis 
accurately. The presence of thrombus in the coronary arteries was also verified, and we 
were able to ascertain the presence of old infarction scars and the presence of AMI 
reliably by examining the myocardium.  
 
1.2 IL-18 gene variation and subclinical atherosclerosis 
 
The genetic variation of the IL-18 gene was not found to associate with CAC or FMD 
in a population of young healthy adults. The present study is the first one to explore the 
possible connection. One recent study linked circulating IL-18 levels inversely with 
carotid femoral pulse wave velocity but not with FMD among men. The observed 
association was independent of risk factors (Vlachopoulos et al.). We did not perform 
any sex stratification, because we did not observe any significant interactions with IL-
18 genotype and sex influencing CAC or FMD. Furthermore, the mean age of the 
previous study population was significantly higher (58 years). If, indeed, there were 
any connection between IL-18 gene polymorphism and CAC, it could perhaps present 
itself in a risk population with higher sub-clinical atherosclerotic burden. 
 Interestingly, we did find that one major haplotype of the IL-18 gene (also the 
only one carrying the minor G allele of the +415 C/G SNP) associated with lower IMT 
values. The scale of the difference was comparable or even more evident than that of 
many traditional risk factors (such as the 1 standard deviation [14.4mmHg] in systolic 
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blood pressure, sex and smoking). Among women, we observed no significant 
association. Although many studies have already linked circulating IL-18 levels with 
IMT, only one has examined the possible association between IL-18 gene 
polymorphism and carotid atherosclerosis (Chapman et al. 2006, Li et al. 2009, 
Thompson et al. 2007a, Vlachopoulos et al., Yamagami et al. 2005). In a recent report 
by Thompson et al., the authors suggested that haplotypes of the IL-18 gene did not 
associate with carotid IMT, but they did find that one haplotype, which also associated 
with higher IL-18 levels among men with CHD, seemed to associate with a higher risk 
of the presence of a carotid artery plaque in ultrasound (Thompson et al. 2007a). Based 
on the carriage of SNPs inherited in the same BINs, and on the frequency of this 
haplotype, we can deduct that it most likely corresponds with the ATCA haplotype 
(frequency 0.13 in Study I and 10% in the study by Thompson et al.). We did not 
observe any significant findings related to this haplotype. However, the observed 
association by Thompson et al. was of borderline significance, and even they did not 
find this haplotype to associate significantly with circulating levels of IL-18 among 
healthy adults. 
 
1.3 IL-18 gene polymorphism and mortality from cardiovascular causes 
 
In the present study, we did not observe any significant association between 
cardiovascular mortality and IL-18 gene polymorphism among a Finnish patient 
population. One previous study has linked IL-18 gene polymorphism with the CV 
mortality among CAD patients and the occurrence of MI among a combined group of 
hypertensive patients and postmenopausal women (Bis et al. 2008, Tiret et al. 2005). 
The haplotype linked with lower risk for cardiovascular mortality by Tiret et al. is the 
only one that carried the minor G allele of the +183 A/G SNP. However, our results are 
not necessarily contradictory. Unfortunately, our study lacks the power to conclude that 
there is no association between IL-18 gene polymorphism and cardiovascular mortality 
among a Finnish patient population. The whole study population is very heterogeneous 
comprising patients with different indications for exercise test, and many of the 
patients in our study population were not high-risk individuals. The overall mortality 
from cardiovascular causes was therefore not high. This reduces the power of the 
current study, and we cannot conclude that the variation in the IL-18 gene indeed does 
not associate with cardiovascular mortality. For example, in comparison to our study, 
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the mortality for cardiovascular causes was clearly higher in the study by Tiret et al. 
They followed 1,299 CAD patients for a median follow-up period of 5.9 years. During 
that time, the mortality rate was 11% (Tiret et al. 2005). Our follow-up time was 
similar, but the mortality rate reached only 5%. 
 
1.4 IL-18 polymorphisms and the expression of angiography-verified CAD 
 
In Study II we found that the AGTA haplotype associated, independently of risk 
factors, with lower risk of angiography-verified main branch disease among men. This 
haplotype is the only one carrying the minor T allele of the +127 C/T polymorphism. 
Furthermore, it is the only one carrying the minor C allele of the -137 G/C SNP, 
because these two are inherited simultaneously in the same haplotype. Previous studies 
have repeatedly shown that the -137 G/C SNP is functional. Therefore, it is most likely 
that the observed significant association between the AGTA haplotype is due to the 
promoter region -137 G/C polymorphism. As the C allele is associated with diminished 
transcriptional activity of the gene and diminished production of mature IL-18, it is 
plausible to suggest that the carriers of the C allele are less prone to develop occlusions 
in the main branches of their coronary arteries. However, we did not find that the 
variation in the IL-18 gene is associated with the occurrence of angiography-verified 
CAD. This is due to the fact that none of the haplotypes showed significant deviation 
from the occurrence of CAD in reference to the most common haplotype among the 
entire study population. Even if the variation in the IL-18 gene did affect the 
development of CAD, the effects would have to be very specific in order for them to be 
seen among angiography patients who have been selected to the procedure according to 
a strict diagnostic evaluation. In a sub-population such as this one, the effect expression 
of CAD is likely to be similar, despite the differences in the genetic background of the 
patients. 
 
1.5 IL-18 gene promoter region functional -137 G/C SNP and the risk of SCD 
 
In Study III we found that a functional IL-18 gene promoter region -137 (G/C) SNP 
(rs187238) associates with the occurrence of sudden cardiac death among men. The 
minor C allele of the SNP associated with lower risk of SCD due to CHD and with 
SCD due to other causes in the absence of CHD. A large haplotype study Tiret et al. 
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showed that the variation in the IL-18 gene associates with CV mortality during 
follow-up (Tiret et al. 2005). Our findings support the result. However, in the study by 
Tiret et al. found that only one haplotype associates independently with CV mortality. 
The same haplotype also associated with decreased circulating IL-18 levels. This 
haplotype is the only one carrying the minor G allele of the +183A/G polymorphism. 
The authors hypothesized that this polymorphism, located in the 3'untranslated region, 
potentially affected mRNA stability, thus exerting its effect. In the present study, we 
did not genotype this SNP and are therefore unable to ascertain whether it is related to 
the occurrence of SCD. What we do know is that the minor G allele of the SNP does 
not co-exist in the same major haplotype with the minor C allele of the -137 
polymorphism. Therefore, as the haplotype carrying the minor G allele of the +183 
(A/G) SNP is also associated with attenuated production of IL-18, it only emphasizes 
our results because among GG homozygotes of the -137G/C polymorphism, there are 
more G allele carriers of the +183A/G polymorphism than among the C allele carriers 
(Barbaux et al. 2007, Tiret et al. 2005). 
The association between the -137 (G/C) SNP and the risk of SCD due to 
causes not related to CHD (cardiomyopathy, hypertrophy, or dilatation of the heart) is 
first of its kind to be reported. Although there is no prior evidence of the involvement 
of IL-18 genetics in this field, it has been previously shown that patients with 
congestive heart failure have higher circulating IL-18 levels when compared to 
controls, and that higher IL-18 levels associate with the clinical outcome of heart 
failure (Mallat et al. 2004, Naito et al. 2002, Seta et al. 2000). One possible source for 
IL-18 in the myocardium alongside macrophages is cardiomyocytes. Cardiomyocytes 
can produce IL-18 in response to stimulation by TNF-α, aldosterone, endothelin-1 and 
angiotensin II (Chandrasekar et al. 2003, Doi et al. 2008). In the myocardium, IL-18 
has many possible ways for aggravating the situation. IL-18 induces the production of 
anti-natriuretic peptide from myocytes and can thus also stimulate hypertrophy of the 
myocardium (Chandrasekar et al. 2005, Seta et al. 2000). 
 
1.6 The interplay between IL-18 gene polymorphism and hypertension 
 
In Study IV we showed that the promoter region -137 G/C SNP significantly modulates 
the effect of hypertension on the risk of SCD due to CHD. The study aimed to clarify 
the possible mechanism by which this promoter region polymorphism affects the risk 
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of SCD as observed in our previous study. Other risk factors were not seen to interact 
with IL-18 polymorphism, which is why further investigation was focused on the effect 
of hypertension in different IL-18 genotype groups. As we divided the study population 
into wild-type GG homozygotes and carriers of the C allele, we found that 
hypertension was a major risk factor among GG homozygotes for SCD due to CHD, as 
well as for CAD and the development of coronary atherosclerosis. Among C allele 
carriers, hypertension did not associate with any of these end-points. In publication IV, 
we have already discussed the possible mechanisms by which this promoter region 
polymorphism interacts with hypertension. In brief, many factors intimately associated 
with hypertension, such as β2-receptor activation, aldosterone and angiotensin II, may 
induce IL-18 expression and modulate the whole IL-18 pathway (causing changes in 
IL-18mRNA stability and IL-18 receptor expression) (Chandrasekar et al. 2004a, 
Chandrasekar et al. 2004b, Doi et al. 2008, Sahar et al. 2005). It is also possible that the 
simple overall pro-atherogenic properties of hypertension have less severe effects on 
those with impaired IL-18 response (e.g. C allele carriers of the -137 G/C SNP) (Ross 
1999).  
We also observed, in an independent material, that hypertension has very 
different effects on the expression of IL-18 and IFN-γ mRNA in human atherosclerotic 
vascular samples when comparing GG homozygotes to C allele carriers. Among GG 
homozygotes, hypertension associated significantly with higher expression of IFN-γ 
mRNA, whereas among C allele carriers the effect seemed contrary. Interestingly, in 
the samples obtained from hypertensive GG homozygotes, the expression levels of IL-
18 did not significantly differ from those of the corresponding samples obtained from 
GG homozygous subjects with no hypertension. Among C allele carriers, hypertension 
associated with higher expression of IL-18. Based on this data, it is impossible to 
deduct a causative mechanism between these two findings. IL-18 mRNA must be 
processed before it is secreted in an active form, and although we controlled for Caps-1 
mRNA expression levels, the results remained the same. However, Casp-1 must also be 
cleaved into active form before it becomes biologically active, and this adjustment does 
not guarantee that this confounding factor is completely controlled for. Protease 3 can 
also cleave IL-18 into active form, which was unfortunately not accounted for in our 
analyses. Nevertheless, the whole pathway leading to the secretion of mature IL-18 is 
still unknown, making it impossible to take all factors into account. Although our 
results leave room for further elaboration, they do show that hypertension affects, in an 
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IL-18 genotype-dependent manner, the inflammatory environment as regards IL-18 and 
IFN-γ mRNA expression in human atherosclerotic plaques. 
The combined results derived from the Helsinki Sudden Death Study and 
Tampere Vascular Study provide strong evidence of the link between IL-18 gene 
polymorphism and hypertension in the development and manifestation of 
atherosclerosis. The fact that we observed the same interplay affecting the occurrence 
of SCD in the whole study population, and in the expression of coronary 
atherosclerosis among men who had died of other causes (e.g. controls), adds further 
weight to this finding. By limiting the analysis to the control population, we were able 
to circumvent the possible confounding effect of selection bias. Furthermore, the 
results of an independent study material supported the findings. 
Although our study is the first one to present a significant interaction between 
hypertension and IL-18 genotype affecting the risk of a major clinical end-point, one 
previous study has reported a significant interaction between IL-18 gene polymorphism 
and smoking impacting on the risk of CVD. Recently, Grisoni et al. reported, in a very 
accomplished paper, that the IL-18 gene -105 C/T SNP (rs360719), and a major 
haplotype carrying the minor T allele, interacts significantly with smoking, thus 
modulating the risk of CVD disease. Similar analyses were performed treating CHD 
stroke events separately and excluding cases with CVD at baseline. The interaction was 
confirmed in all of the analyses. The study was based on combined study populations 
of five separate sub-cohorts from Finland, Sweden, Ireland and France, and the 
combined number of subjects was 2,271.  
Two facts make the results of the study very interesting from the point of view 
of our study. Firstly, the -105 C/T SNP is in nearly complete association with the 
promoter region -137 G/C SNP (e.g. inherited in the same BIN). Secondly, Grisoni et 
al. observed that while none of the SNPs genotyped in the study, nor the variation of 
the IL-18 gene globally, associated with the occurrence of CVD, IL-18 gene variation 
and especially the -105 C/T genotype among smokers did. The authors observed that in 
smokers the carriage of the minor T allele was significantly higher among cases than 
among controls. They also found that among non-smokers, this association was inverse 
but not as strong. When they studied the effect of smoking on the risk of CVD among 
IL-18 genotype groups, they found that smoking was associated with an almost two 
times higher risk among T allele carriers. The significance of this finding was evident 
(p=3.5 x 10
-8
).  Among CC homozygotes, the effect of smoking on the risk of CVD 
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was not as strong (OR 1.25, p=0.05). Grisoni et al. concluded that the minor T allele, or 
at least some related factor (e.g. another SNP), was associated with increased risk of 
CVD in smokers. This conclusion is hardly wrong but could certainly be elaborated 
further. 
In the combined study population of the MORGAM project (on which the 
study by Grisoni et al. is based), the frequencies of the minor T allele (of the -105 C/T 
SNP) among non-smoking controls and cases were 0.29 and 0.27, respectively. This 
difference between the groups reflects the previously hypothesized protective property 
associated with the T allele. Nevertheless, these frequencies are not extremely different 
from the 0.28 observed previously in a large study population of Caucasian CAD 
patients. In the study population of the Finnish Cardiovascular Risk Study, formed by 
patients selected for a clinical exercise test, the frequency of the minor T allele of the 
+127 C/T SNP (inherited in almost complete association) was 0.27. The corresponding 
frequency in the Cardiovascular Risk in Young Finns study population, which 
represents the normal Finnish population, was 0.29. However, in the MORGAM 
project, the corresponding frequencies for smoking controls and cases were 0.24 and 
0.28, respectively. If we assume that the T allele does not provide any protection 
against CVD, the frequency of the T allele carriers among smoking CVD cases should 
be clearly higher than their frequency within the normal population. This should then 
also apply to the frequency of CC homozygotes, but the difference would not be as 
dramatic. The frequencies presented in the MORGAM study reveal that this is not the 
case. An alternative hypothesis is that the T allele is associated with a protective effect 
but that the effect is efficiently abolished by smoking. This would explain the fact that 
although smoking is associated with a higher risk of CVD among T allele carriers than 
CC homozygotes, the frequency of T allele carriers among smoking patients with CVD 
is lower than the corresponding frequency of CC homozygotes.  
 
1.7 Methodological considerations and limitations of the study 
 
We did not measure circulating IL-18 concentrations for any of the study populations 
of the present study. This is a clear limitation. Although previous studies have already 
reported some evidence on the matter, it could have provided us additional information 
on the association between IL-18 gene polymorphism and circulating IL-18 levels. 
Given the robust study setting, the Cardiovascular Risk in Young Finns Study would 
[81] 
 
probably have provided us valid information on the connection between these two. 
Most haplotype studies that have connected IL-18 gene polymorphism and circulating 
levels of IL-18 have shown that the variation of the gene explains 1.7%–5.2% of the 
variation in the circulating IL-18 levels, independently of risk factors (Thompson et al. 
2007a, Thompson et al. 2007b, Tiret et al. 2005). 
However, some separate haplotypes have been identified with more dramatic 
changes in circulating IL-18 levels. Tiret et al. found that among CAD patients, two 
major haplotypes corresponding to the haplotypes AGTA and CTCG identified in our 
study associated with significant decreases in circulating IL-18 levels. The haplotype 
corresponding to the CTCG haplotype had the most dramatic effect, lowering the IL-18 
levels by up to 9% in reference to the most frequent haplotype (Tiret et al. 2005). 
Another study also found that a haplotype related to CTCG was associated with 15% 
lower IL-18 levels among subjects carrying 2 copies of the haplotype when compared 
to non-carriers (Thompson et al. 2007a). The study population was based on adults 
without CHD, and the effect of the haplotype seemed to be linear (i.e. IL-18 values of 
heterozygotes fell between the values of the other two genotypes). In a population of 
men with premature CHD, the same haplotype associated with decreases of 12% and 
22% among heterozygotes and homozygotes carrying two copies in reference to non-
carriers (Thompson et al. 2007a). Interestingly, one smaller haplotype with a haplotypic 
frequency of 0.10 (corresponds to the ATCA haplotype in the present study) was 
associated with a corresponding increases of 15% and 55% when compared to non-
carriers. Furthermore, a third haplotype study showed that among patients selected for 
coronary artery bypass surgery, baseline levels of IL-18 were approximately 25%–30% 
lower among carriers of haplotypes corresponding to the haplotypes AGTA and CTCG 
identified in our study. It seems that study populations with heavier disease burden 
have a greater IL-18 genotype-dependent response with regard to the circulating IL-18 
levels. This suggests that inflammatory stress augments the IL-18 genotype-dependent 
systemic IL-18 response. 
Another confounding factor is that IL-18 levels seem to be very positively and 
strongly correlated with risk factors such as age, metabolic syndrome traits (BMI, waist 
circumference, triglyceride concentrations, HDL concentrations [inverse correlation], 
fasting glucose levels, insulin levels and hyperglycaemia) and blood pressure (Esposito 
et al. 2002, Evans et al. 2007, Hung et al. 2005, Thompson et al. 2007c). Fortunately, 
we were able to adjust the analyses in the present study in reference to most major risk 
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factors. Furthermore, it is not clear that circulating IL-18 levels is responsible for 
conveying the risk of atherosclerosis and its end-points. Circulating levels of IL-18 
might only reflect the overall inflammatory status or the burden of the disease, 
rendering the observed association a result of reverse causality. The local production of 
IL-18 in atherosclerotic plaques modulated by genetic factors is also a very probable 
factor causing aggravation of the disease. 
The results of the present study rely on the candidate gene approach. The 
obvious pitfall of many candidate gene approaches has been their poor reproducibility 
of the results (Plump and Lum 2009). This is often due to the fact that the candidate 
genes have not been selected with enough scrutiny or the associations have been tested 
in very heterogeneous populations. Atherosclerosis is a multifactorial disease, and it is 
therefore very unlikely that a single genetic factor would have dramatic effects on 
major end points. The candidate gene (IL-18) selected for the present study is very 
promising, and this is emphasized by the fact that IL-18 has been previously linked 
with the development of atherosclerosis on the vessel wall level as well as with major 
clinical end points (see the Review of the literature). Furthermore, previous association 
studies have shown a connection between IL-18 gene variation and severe clinical end 
points. Therefore, our study aimed to clarify the possible effects of IL-18 gene 
variation on different end points of atherosclerosis among different populations. We 
also wanted to explore whether IL-18 interacts with some of the known risk factors. 
This was done to elucidate the possible mechanisms behind the associations.  
GWAS is another possible approach for genetic research. The technological 
improvements made during the past few years have made GWAS a reality. However, 
while GWAS might be a powerful tool for recognizing possible loci associating with 
major clinical end points, the approach only provides a starting point for the search of 
functional SNPs and genes (Plump and Lum 2009). Basically, GWAS provides a 
hypothesis-free approach for exploring candidate genes. The subsequent validation and 
replication of results must be carried out by means of association studies (Kronenberg 
2008). 
 
1.8 Future Prospects 
 
The need for more specific studies concerning gene-environment interactions is 
evident. In a multifactorial disease such as atherosclerosis, it is very unlikely that one 
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specific common mutation would have a dramatic response with regard to clinically 
significant end points. This fact is underlined by the vast number of genetic association 
studies failing to replicate the borderline results of previous studies. Genetic research 
of common variants in common diseases is not likely to produce much direct clinical 
value in the sense of risk prediction. This is emphasized by the fact that, as most 
common variants hardly ever greatly augment the risk of any trait and as the 
development of diseases such as atherosclerosis is dependent on multiple factors, it is 
very unlikely that any given individual would bear the brunt of more than the average 
number of such genetic risk factors.  
Even if risk prediction were not the primary aim, genetic research is required 
in clarifying the mechanisms of the diseases. The IL-18 pathway should be studied 
further on a vessel wall level.  The results of the present and previous studies have 
shown that IL-18 is most likely associated with the expression of the unstable plaque 
phenotype and thus also the occurrence of severe complications. Genome-wide 
expression studies are most likely to clarify this issue further. They can provide 
interesting data directly from the vessel wall level concerning the development of 
atherosclerosis, facilitating further study of candidate pathways.  
Identification of strong gene-environment interactions would also be useful to 
identify specific populations for targeted drug prevention. More studies are therefore 
needed, as much is still unknown. In the present study, we have shown that IL-18 gene 
polymorphism interacts with hypertension. This could be an interesting prospect for 
targeted treatment of hypertension. However, this interaction still requires further study, 
and the results must be replicated. Investigations of gene-gene interactions (e.g. 
epistasis) are also likely to provide much needed insight into the pathogenesis of 
common but deadly diseases such as atherosclerosis.  
In conclusion, as the technology for genome-wide association and expression 
studies advances and the availability of such technologies imroves, it is highly likely 
that more interesting interacting pathways are discovered and the study of the present 
candidate pathways, such as the IL-18 pathway, is facilitated. 
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SUMMARY AND CONCLUSIONS 
 
This candidate gene study explored the possible effects of IL-18 gene polymorphism 
on the expression of atherosclerosis in different study settings. We also searched for 
possible interactions between the variation of the IL-18 gene and risk factors. The main 
findings and conclusions were as follows: 
1. The minor T allele of the +415 A/G SNP and also the only major haplotype car-
rying the G allele associated significantly with lower IMT among young 
healthy Caucasian men. Among women there was no association to be seen. 
This interaction was significant. Other polymorphisms or haplotypes were not 
observed to have any effect on IMT values (Study I). 
2. The variation in the IL-18 gene was not seen to associate significantly with CV 
mortality among a Finnish patient population. Among patients who had coro-
nary angiography, one major haplotype had a different sex-dependent impact on 
the expression of CAD. This major haplotype is also the only one carrying the 
minor T allele of the +127 C/T SNP and the minor C allele of the functional 
promoter region -137 G/C SNP. Among men, the carriers of this AGTA haplo-
type had a lower occurrence of severe CAD, whereas among women the haplo-
type was not seen to associate with the expression of CAD (Study II). 
3. In an autopsy study of Caucasian men who had died suddenly out of hospital, 
the functional promoter region -137 G/C SNP was seen to associate with the 
occurrence of SCD due to CHD and due to other causes in the absence of CHD. 
The minor C allele was associated with a lower risk of both causes of death 
(Study III). 
4. Hypertension interacts with the -137 G/C SNP, affecting the risk of SCD due to 
CHD and the development of coronary atherosclerosis. Hypertension was a ma-
jor risk factor for both the risk for SCD and the development of coronary 
atherosclerosis among GG homozygotes. Among C allele carriers, we did not 
see any significant effect. Hypertension also affected the expression of IL-18 
and IFN-γ mRNA in human atherosclerotic plaques obtained from live patients. 
This effect was also seen to be modulated by IL-18 genotype. (Study IV) 
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In conclusion, IL-18 gene variation seemed to associate with the development of 
subclinical atherosclerosis and the expression of CAD among men but not among 
women. Among men, IL-18 associates with the risk of SCD. Hypertension seems to 
affect the risk for SCD due to CHD in an IL-18 genotype dependent manner. 
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Abstract 
Background and Aim. Interleukin 18 (IL-18) is a pro-atherosclerotic cytokine. We 
wanted to evaluate whether IL-18 gene polymorphism associates independently of risk 
factors, with early subclinical markers of atherosclerosis (intima media thickness [IMT], 
coronary artery compliance [CAC] and flow mediated dilatation [FMD]) in a population 
of young healthy Caucasian adults. 
Methods. This study was based on the ongoing Cardiovascular Risk in Young Finns 
Study consisting of 2260 young adults, mean age being 31.7 (range 24-39years) (1247 
women and 1013 men).  
Results. Five studied tagSNPs formed six major haplotypes, which accounted for 99.9% 
of all variation of the IL-18 gene. According to adjusted analysis of variance the IL-18 
gene polymorphism didn’t associate with subclinical atherosclerosis in the whole study 
population. However, one major haplotype associated differently among men and women 
with IMT (p=0.011). Male carriers of a major CCTgT haplotype (n=441) seemed to have 
a lower IMT when compared to the non-carriers (-0.016mm, 95% CI -0.028 to - 0.004, 
p=0.014). Among women no significant association were observed. 
Conclusions. Among all study subjects, the polymorphism of the IL-18 gene is not 
associated with subclinical markers of atherosclerosis. However, among men one major 
IL-18 haplotype seemed to associate with substantially lower IMT values. 
Key words: arterial elasticity, intima media thickness, genetics, atherosclerosis, 
inflammation 
 
 
To be published in ANNALS OF MEDICINE 
Key messages:  
Interleukin 18 (IL-18) gene polymorphism has been previously associated with severe 
clinical end-points such as sudden cardiac death and the occurrence of myocardial 
infarctions. 
 
According to the results of the present haplotype study, the IL-18 gene polymorphism 
doesn’t associate significantly with subclinical markers of atherosclerosis among a 
population of healthy young adults. 
 
However, among men one major haplotype seems to associate significantly with lower 
intima media thickness of the carotid artery. 
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Abbreviations: 
1. IL-18  = Interleukin 18  
2. MI  = Myocardial infarction 
3. CAD  = Coronary artery disease 
4. SCD  = Sudden cardiac death 
5. SNP  = Single nucleotide polymorphism 
6. IMT  = Intima media thickness 
7. FMD  = Flow mediated dilatation 
8. CAC  = Carotid artery compliance 
9. BMI  = Body mass index 
10. BP  = Blood pressure 
11. CRP  = C-reactive protein 
12. ApoA-1 = Apolipoprotein A-1 
13. ApoB  = Apolipoprotein B 
14. HDL  = High density lipoprotein 
15. LDL  = Low density lipoprotein 
16. ANOVA = Analysis of variance 
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Introduction 
 
Atherosclerosis is an inflammatory disease which progresses through decades (1, 2). 
Interleukin 18 (IL-18), a pro-inflammatory and pro-atherosclerotic cytokine is produced 
mainly by monocytes and macrophages (3, 4). It seems to play a crucial role in the 
development of more vulnerable atherosclerotic plaques (5, 6) through inducing the 
production of interferon-γ (7). 
In-vitro models have shown that the genetic variation of the IL-18 gene affects the 
monocyte´s production of IL-18 (8-11). Likewise, the expression of IL-18 in humans is 
regulated by the genetic variability of the IL-18 gene and according to several studies IL-
18 gene polymorphism associates with circulating IL-18 levels (12-15). 
Previously IL-18 levels have been shown to correlate with the extent of coronary 
atherosclerosis among patients with previous myocardial infarction (MI) and with 
unstable angina (16, 17) and also predict the mortality in patients with coronary artery 
disease (CAD) (18, 19). Genetic studies have revealed similar results: Polymorphism of 
IL-18 gene is associated with cardiovascular mortality among CAD patients and MI risk 
among hypertensive patients and postmenopausal women (12, 20). 
Increased carotid artery intima-media thickness (IMT), elasticity and flow-
mediated dilatation (FMD) are early subclinical markers of atherosclerosis and predict 
future coronary events (21-23). Carotid artery compliance (CAC) depicts the ability of 
the arteries to expand under the influence of pulse pressure. Diminished arterial elasticity 
has been shown to be an independent predictor of cardiovascular events in high-risk 
individuals (24, 25). FMD of the brachial artery quantifies the amount of vasodilatation 
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in response to endothelial activation by an increase in local blood flow (26). Even before 
anatomical evidence of atherosclerosis appears, FMD is impaired in young symptom-free 
subjects with risk factors for vascular disease (27). Carotid IMT has been showed to 
independently predict future vascular events especially among young subjects (21). 
The increased circulating levels of IL-18 seem to be associated with greater 
carotid artery IMT (28, 29). Whether this association is independent of traditional risk 
factors is still unclear (28, 29). To the best of our knowledge the relation of FMD and 
CAC to IL-18 concentrations or IL-18 genotypes have not been previously studied. 
Lately the reports have concentrated on studying the IL-18 levels/polymorphism 
and their association to the advanced atherosclerotic end-points e.g., acute MI, CAD. 
Thus we wanted to study, whether known IL-18 haplotypes or single-locus tagSNP 
polymorphisms affect, independently of risk factors, the early (subclinical) markers of 
atherosclerosis (IMT, CAC and FMD) in a population of young healthy Caucasian adults. 
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Materials and methods 
 
Subjects 
 
The Cardiovascular Risk in Young Finns Study is an ongoing prospective multicentre 
cohort study, which provided us the study population of 2282 young adults. Details of the 
cohort have been published previously (30-32). The study began 1980 and the 21 year 
follow-up was carried out in 2001. All of the data used in the present study was collected 
in the year 2001. Participants with type 1 diabetes were excluded from further analyses. 
The Ethical Review Committee of Turku University Hospital approved the research plan, 
and the study followed the tenets of the Declaration of Helsinki. Patients gave an 
informed consent before entering to the study. 
 
Clinical and biochemical characteristic  
 
Standardized questionnaire was used to assess cardiovascular risk factors (smoking, 
alcohol consumption, geographical origin and familial history of coronary heart disease). 
The classification of these variables has been described earlier in more detail (33). Study 
subjects height and weight were used to calculate their body mass index (BMI=weight, 
kg/(height, m)
2
) and their blood pressure (BP) was recorded. Fasting venous blood 
samples were used to determine C-reactive protein (CRP), insulin, glucose, serum lipids, 
apolipoprotein A-1 (ApoA-1), apolipoprotein B (ApoB), and homocysteine 
concentrations. Total cholesterol, high-density lipoprotein (HDL) and triglycerides were 
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determined enzymatically. Low-density lipoprotein (LDL) was calculated by Friedewald 
formula. Standardized methods were used in all determinations (31, 32). The information 
of geographical origin was included as a covariate because the population originating 
from Eastern Finland is genetically more predisposed to the development of 
atherosclerosis than the population of Western Finland (34). 
 
DNA isolation and genotyping of the IL-18 polymorphism 
 
Genomic DNA was isolated from peripheral blood leukocytes by using QIAampDNA 
Blood Minikit and automated Biorobot M48 (Qiagen, Hilden, Germany) extraction. The 
five IL-18 SNPs (rs1946519, rs360717, rs549908, rs5744292, rs4937100) and haplotypes 
were genotyped by using the 5´ nuclease assay for allelic discrimination and fluorogenic 
TagMan MGB probes with the ABI Prism 7900HT Sequence Detection System (Applied 
Biosystems, Forster City, CA, USA) (35). The nucleotide sequences of the primers and 
fluorogenic allele-specific oligonucleotide probes used in PCR were deduced from 
published sequences in the Gene Bank database. They were chosen and synthesized in 
co-operation with Applied Biosystems. PCR reaction containing genomic DNA, 2  
TaqMan Universal PCR Master Mix, 900 nM of each primer, and 200 nM of each probe 
was performed in 384-well plates according to standard protocol in a total volume of 5 
l. Water controls and random duplicates were used as a quality control. 
 
 
Measurements of subclinical markers of atherosclerosis (IMT, CAC and FMD) 
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Carotid artery IMT was measured by ultrasound and for determining CAC the 
concomitant brachial blood pressure was also monitored. The brachial artery FMD was 
assessed by measuring the left brachial artery diameter both at rest and during reactive 
hyperemia. Ultrasound studies were performed using Sequia512 mainframes (Acuson, 
Mountain View, California) with 13.0 MHz linear array transducer. The procedures have 
been earlier discussed in more details (32). 
To determine the intra-individual reproducibility of the measurements, the 
ultrasound measurements were replicated for small random sample of the participants 
(n=57, 2,5%) 3 months after the initial visit. The between-visit coefficient of variation 
was 6.4% for IMT, 16.3% for CAC and 26% for FMD measurements.  
 
 
Statistical analyses 
 
The statistical analysis was performed using the SPSS 14.0 for Windows (SPSS Inc., 
Chicago, IL, USA). In order to study the possible association between IL-18 gene 
polymorphism and the subclinical markers of atherosclerosis, we applied adjusted 
analysis of variance (ANOVA). Only significant covariates were accepted into the 
models (the selection criteria and procedure has been previously described in more detail) 
(33). First we studied the possible factor-by-sex interactions. If the interaction between 
the haplotype or SNP and sex was found significant we proceeded to analyze the effect of 
the haplotype or SNP among men and women separately and the results from the level of 
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the whole study population were not interpreted. To study the effect of haplotypes, we 
divided the population into carriers and non-carriers. The effects of individual genotypes 
were studied without pooling the genotypes. Previously pregnancy has been associated 
with changes in serum values of IL-18 and this tendency has been found to be modulated 
by IL-18 genotype (36, 37). For this, the analyses were performed before and after the 
exclusion of the 61 women who were pregnant during the time of the study. However, the 
results remained almost unchanged and thus we only present the results obtained from the 
whole study population. 
ANOVA was used to evaluate the possible association between risk factors and 
the polymorphism of the IL-18 gene. Variables with skewed distributions (insulin, 
glucose and CRP) were log10-transformed for the analyses. Categorical variables and 
Hardy Weinberg equilibrium were tested using the χ2-test. 
A value of P < 0.05 was considered statistically significant. In order to correct for 
multiple testing we applied the Li & Ji method (38). This method is the improved version 
of the method originally introduced by Nyholt et al. for adjusting for multiple-testing in 
multilocus analyses (39). This correction method was used because of the high linkage 
disequilibrium between the SNPs. Frequencies of the most common haplotypes and the 
most probable haplotypes for each study subjects were determined using the PHASE 
program (Version 2.0.2) (40). 
One of the IL-18 genotype distributions (533T>C, rs4937100) was not in Hardy 
Weinberg equilibrium in our study population (p<0.001). Nevertheless, we included it 
into our haplotype reconstruction in order to verify whether our haplotype frequencies 
would be in line with those observed in previous studies (12). This SNP was responsible 
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for dividing one common haplotype (haplotype aCTA with a frequency of 0.173) into 
two smaller haplotypes (aCTAT, frequency 0.132 and aCTAc, frequency of 0.041) (See 
Table III below). Because the genotype distributions of the 533T>C SNP was not in 
Hardy Weinberg equilibrium, this SNP was excluded from further analyses and only the 
effect of the combined aCTA haplotype was studied. 
 
Results 
 
General Characteristics 
 
The mean age of the study population was 31.7±5.0 (S.D) years and there were more 
women than men (n=1247 vs. n=1013, respectively). The average BMI of the study 
population was 24.9 ±4.2 S.D. Other general characteristics are presented in Table I. 
Genotyping was successfully performed in 92.6% to 99.6% of the cases depending on the 
genotype. Genotype distributions are presented in Table II. 
 
Haplotype analyses 
 
The five studied IL-18 SNPs (rs1946519, rs360717, rs549908, rs5744292, rs4937100) 
formed six major haplotypes: CCTAc, atgAT, CCTgT, aCTAT, CCgAT and aCTAc. 
The haplotype frequencies, presented in table III, were in line with the results of the 
earlier haplotype study by Tiret et al.(12). These haplotypes accounted for 99.9% of all 
variation in the IL-18 gene. The CCTgT haplotype was the only haplotype carrying the 
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G allele of the 415A>G polymorphism (rs5744292) and the atgAT haplotype was the 
only one to carry the T allele of the 127C>T polymorphism (rs360717). 
 
IL-18 gene polymorphism and cardiovascular risk factors 
 
None of the studied SNPs (Table II) or haplotypes (Table III) of the IL-18 gene 
associated with the clinical or biochemical risk factors of atherosclerosis measured in our 
study (variables in Table I) after correcting the analysis for multiple testing. Some 
significant differences were observed between the populations originating from Eastern 
and Western Finland before correcting for the number of tests performed within the 
group of risk factors. The frequencies of the minor alleles of the +35 (T/g) SNP 
(p=0.005) and +127 (C/t) SNP (p=0.040) were higher among population with Eastern 
Finnish origin when comparing to population originating from Western Finland. 
 
IL-18 polymorphisms and markers of subclinical atherosclerosis 
 
According to ANOVA adjusted with sex, BMI, age, smoking and geographical origin, the 
CCTgT haplotype associated with carotid artery IMT significantly differently among 
men and women (p=0.011 after correcting for multiple testing). Among men, the carriers 
of the CCTgT haplotype had a significantly lower IMT when compared to the non-
carriers (adjusted difference in means: -0.016mm 95% CI -0.028 to -0.004, p=0.014 after 
correcting for multiple testing). The adjusted mean values by haplotype groups were: 
0.601mm (standard error [S.E.] of 0.004mm) for non-carriers, 0.585mm (S.E. 0.005mm) 
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for heterozygous carriers and 0.596mm (S.E. 0.014mm) for homozygous carriers of the 
CCTgT haplotype. There difference in IMT between heterozygous and homozygous 
male carriers of this haplotype was not significant (corrected p=1.00). As the carriers of 
this CTCgT haplotype are the only ones carrying the minor g allele of the +415 C/g SNP 
(rs5744292), it is clear that the significant difference between the haplotype groups is 
caused by the minor g allele of the +415 C/g SNP. Among women no significant 
difference was observed (0.005 mm, 95% -0.004 to 0.014, corrected p=0.498). None of 
the other haplotypes or SNPs associated significantly with IMT among the whole study 
population and no other significant haplotype-by-sex-interactions were seen. None of the 
haplotypes or studied SNPs associated significantly with CAC or brachial artery FMD in 
the whole study population and we didn’t observe any significant haplotype-by-sex-
interactions. The exclusion of geographical origin from covariates left the results 
unchanged and thus also the observed associations remained significant.  
 
Discussion 
 
According to the novel results of the present haplotype study, the variation of the IL-18 
gene is not associated with subclinical markers of atherosclerosis among population 
based sample of healthy young adults. However among men, the carriership of a major 
haplotype (CCTgT) of the IL-18 gene appears to associate with lower IMT 
independently of risk factors. 
Thus far there are only contradictory results of the possible link between IL-18 
and IMT. In 2005, Yamagami et al. reported that higher circulating IL-18 levels 
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associated independently with greater carotid IMT among a population without a history 
of cardiovascular accidents (28). A later study by Chapman et al., conducted with a 
younger study population with lower overall atherosclerotic burden, was unable to 
replicate this finding (29). The fact that the present study lacks the data of circulating IL-
18 levels is a weakness. However, according to prior evidence, the genetic variation of 
the IL-18 gene affects the circulating levels of IL-18 (12-15). In fact, the very same 
haplotype that associated significantly with lower IMT among men in our study was also 
found to associate with lower IL-18 levels and cardiovascular mortality in a large 
haplotype study by Tiret et al.(12). It is also a possibility that the local production of IL-
18 within the atherosclerotic plaque might affect independently the overall development 
of the disease. Supporting the hypothesis, we have demonstrated that the mRNA 
expression of IL-18 in atherosclerotic plaques is dependent of IL-18 gene polymorphism 
(41). One IL-18 gene promoter region SNP (-137G/c, rs187238) was seen to associate 
with the expression of both IL-18 and IFN-γ mRNA. This polymorphism, as well as one 
other SNP (rs360719), associating with the mRNA expression of IL-18 in peripheral 
blood monocytes, is in nearly complete concordance with the one of the SNPs studied in 
the present work (rs360717) (8, 12). The minor allele of the -137 G to C polymorphism 
(rs187238) is also linked with lower risk for sudden cardiac death (SCD) among men 
(41). Despite of these findings, according to the present study, this polymorphism doesn’t 
associates with the early stages of the disease. 
In fact, most of the positive results linking IL-18 to atherosclerosis are derived 
from older and more risk factor burdened patients (mean ages of patient groups ranging 
from 54 to 69 years) with more severe atherosclerotic disease end-points e.g., acute MI, 
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CAD and SCD (12, 16-20). Thus it seems, that IL-18 has a significant role in the 
development of atherosclerosis rather in the later than in the early stage of the disease. 
Atherosclerosis also develops faster in men and this could at least partly explain why the 
association between the CCTgT haplotype and IMT was seen among men but not among 
women. The male carriers of this CCTgT haplotype (also the only one carrying the g 
allele of the +415 C/g SNP) had 0.016 mm lower IMT compared to the male non-carriers. 
Clinically, this difference in IMT was greater in comparison to the effects of some more 
well known classical risk factors such as smoking (change of 0.011 mm), male sex 
(change of 0.010 mm) and BMI (0.011 mm change for 1 SD change in BMI [=4.2kg/m
2
]) 
and systolic blood pressure (0.010 mm change of 1 SD change in BP[=14.4mmHg]) 
previously demonstrated in the same material (32). As men tend to suffer more frequently 
from cardiovascular diseases (42), and taking into consideration the size of the effect, it 
would be feasible to suggest that this finding could have clinical significance. However, 
this association should be replicated in independent populations before it can be 
considered significant. 
In addition to the lack of measurements of the circulating IL-18 levels, another 
limitation of our study is that the blood pressure values that were used to derive the 
carotid artery elasticity were measured from the brachial artery. This limitation has been 
discussed earlier in more detail (43). An obvious strength of our study is the study design. 
Our results are based on a multi-centre study with a randomly selected study population 
and the risk factor data of this study is extensive and thus provides a good background for 
a genetic association study. Furthermore, with the 5 tagSNP genotyped in the present 
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study we were able to cover more than 99% of the variation of the IL-18 gene and thus 
the associative data is comprehensive. 
In summary, according to the present haplotype study the polymorphism of the 
IL-18 gene is not associated with the development of subclinical atherosclerosis 
(measured by intima media thickness, carotid arterial elasticity or with endothelial 
function measured by flow mediated dilatation) among all young Caucasian adults. 
However, among men one major haplotype (CCTgT) seems to associate with 
substantially lower carotid artery IMT values. 
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Table I. Characteristics of the study population. 
Variable All (n=2260) Male (n=1013) Female (n=1247) P-value* 
Age (years) 31.7 ±5.0 31.7 ±5.0 31.7 ±5.0 0.933 
Body mass index (kg/m
2
) 24.91 ±4.16 25.69 ±3.79 24.27 ±4.33 <0.001 
Ever smokers, yes (%)** 959 (42.4) 493 (48.7) 466 (37.4) <0.001 
Systolic BP (mmHg) 122.0 ±14.4 129.2 ±13.5 116.2 ±12.4 <0.001 
Diastolic BP (mmHg) 73.16 ±9.0 74.99 ±9.1 71.67 ±8.7 <0.001 
Cholesterol (mmol/l) 5.16 ±0.98 5.26 ±1.03 5.09 ±0.93 <0.001 
HDL cholesterol (mmol/l) 1.29 ±0.32 1.16 ±0.28 1.40 ±0.31 <0.001 
LDL cholesterol (mmol/l) 3.27 ±0.85 3.42 ±0.92 3.16 ±0.78 <0.001 
Triglycerides (mmol/l) 1.34 ±0.85 1.53 ±0.99 1.18 ±0.68 <0.001 
Apolipoprotein A-I (g/l) 1.50 ±0.26 1.40 ±0.21 1.57 ±0.27 <0.001 
Apolipoprotein B (g/dl) 1.06 ±0.26 1.13 ±0.27 1.00 ±0.24 <0.001 
Insulin (mU/l) 7.63 ±5.21 7.52 ±5.19 7.72 ±5.22 0.382 
Glucose (mmol/l) 5.00 ±0.45 5.15 ±0.42 4.87 ±0.44 <0.001 
C-reactive protein (mg/l) 1.89 ±3.85 1.46 ±3.27 2.23 ±4.23 <0.001 
Homocysteine (µmol/l) 9.82 ±3.81 10.86 ±4.18 8.97 ±3.24 <0.001 
Values of continuous variables are expressed as mean ± standard deviation. 
Abbreviations: BP, Blood pressure; HDL, high density lipoprotein; LDL, low density 
lipoprotein.  
*Significance calculated using one-way ANOVA for continuous variables and Pearsons 
χ2-test for categorical variables. 
**This category includes daily smokers, ex-daily smokers and occasional smokers. 
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Table II. Interleukin -18 (IL-18) genotype distributions. 
SNP, rs number  IL-18 Genotype, n (%) 
 Major Homozygote Heterozygote Minor homozygotes 
    
-656 (C/a), rs1946519 673 (30.0%) 1065 (47.1 %) 506 (22.5%) 
+127 (C/t), rs360717 1125 (50.8%) 899 (40.6%) 189 (8.5%) 
+35 (T/g), rs549908 1062 (47.2%) 966 (42.9%) 223 (9.9%) 
+415 (A/g), rs5744292 1204 (57.6%) 766 (36.6%) 121 (5.8%) 
+533 (T/c)*, rs4937100 1195 (53.4%) 704 (31.4%) 340 (15.2%) 
*Genotype distribution not in Hardy Weinberg equilibrium 
Table III. Interleukin-18 (IL-18) haplotypes. 
                            IL-18 SNPs      
 -656(C/a) 
rs1946519 
+127(C/t) 
rs360717 
+35(T/g) 
rs549908 
+415(A/g) 
rs5744292 
+533(T/c) 
rs4937100 
Haplotype 
Frequency 
(SE) 
H
ap
lo
ty
pe
 
C C T A c 0.270 (0.0005) 
a t g A T 0.288 (0.0003) 
C C T g T 0.244 (0.0003) 
a C T A T 0.132 (0.0005) 
C C g A T 0.024 (0.0001) 
a C T A c 0.041 (0.0004) 
Minor allele 
Frequency 
0.462 0.288 0.313 0.240 0.312   
Abbreviations: SNPs, single nucleotide polymorphisms 
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bstract
bjective: The increased plasma concentrations of pro-atherogenic and cardiomyocyte hypertrophic cytokine interleukin 18 (IL-18) predict
ortality in patients with coronary heart disease (CHD) in addition to predicting the outcome of heart failure. The IL-18 gene has a functional
137 G/C polymorphism (rs187238) in the promoter region. The C allele carriage is associated with attenuated IL-18 production. The effect
f IL-18 genotype on SCD is unknown. We studied the association of the IL-18 gene −137 G/C polymorphism with the occurrence of sudden
ardiac death (SCD).
ethods: Using the TaqMan 5′ nuclease assay, we genotyped two independent consecutive and prospective autopsy series which were
ncluded in the Helsinki Sudden Death Study.
esults: Of the 663 men, 359 (54.1%) had the wild-type GG-genotype, 261 (39.4%) were heterozygotes (CG) and 43 (6.5%) were CC
omozygotes. Compared to the GG homozygotes, the C allele carriers (i.e. subjects having CC or CG genotypes) had a lower adjusted risk
or SCD from any cause (odds ratio [OR] 0.49; 95% confidence interval [CI], 0.31–0.77, p = 0.002), for SCD due to CHD (OR 0.51; 95% CI,
.32–0.82, p = 0.005), and for SCD caused by non-coronary heart diseases (OR 0.34; 95% CI 0.13–0.90, p = 0.030).
onclusion: IL-18 promoter −137 G/C polymorphism, which regulates the expression of IL-18, is an important predictor of SCD from any
ause as well as SCD in patients with and without underlying CHD.
2007 Elsevier Ireland Ltd. All rights reserved.
eywords: Myocardial infarction; Sudden cardiac death; Polymorphism; Genetics; Coronary heart disease
P. IntroductionSudden cardiac death (SCD) leads to the loss of
00,000–400,000 lives a year in the United States [1].
∗ Corresponding author at: Tampere University Hospital, Finn Medi 2, 3rd
loor, P.O. Box 2000, FI-33521 Tampere, Finland. Tel.: +358 3 311 74049;
ax: +358 3 311 74168.
E-mail address: jussi.hernesniemi@uta.fi (J.A. Hernesniemi).
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oi:10.1016/j.atherosclerosis.2007.07.018re-existing coronary heart disease (CHD) and its conse-
uences, e.g., acute coronary syndrome, myocardial scarring
ue to a previous infarction, and heart failure are mani-
ested in 80% of all SCD victims [1]. The second largest
roup of diseases concurrent with SCD includes dilated or
ypertrophic cardiomyopathy, both of which can develop
n the absence of CHD [1]. The other cardiac disorders,
.g., the known genetically determined ion channel abnor-
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alities and congenital heart defects account for 5–10% of
CDs [1].
A family history of myocardial infarction (MI) [2] and
udden death [3] are both associated with the risk of SCD,
ut the specific genetic risk factors of SCD involving fibrino-
en receptor and alpha(2B) adrenoceptor gene variations are
oorly known [4–6].
One interesting candidate gene for SCD might be
nterleukin-18 (IL-18), formerly known as the interferon-
IFN-) inducing factor [7]. The increased plasma concentra-
ions of this pro-atherogenic and cardiomyocyte hypertrophic
ytokine have previously been associated with the occurrence
f stable and unstable angina pectoris, MI, and acute fatal
oronary events [8–13]. However, in one previous study, no
ssociation was found between IL-18 plasma concentrations
nd coronary events [14]. IL-18 is a pleiotropic pro-
nflammatory cytokine, affecting both innate and acquired
nflammatory response [15,16], and it has been associated
ith the development of atherosclerosis by stimulating the
roduction of atherogenic IFN- [17]. Furthermore, the
evelopment of more vulnerable atherosclerotic plaques, usu-
lly associated with increased risk of acute coronary events,
eems to be instigated by the expression of IL-18 [18]. IL-18
lso appears to be involved in the development of conges-
ive heart failure due to cardiomyopathy, and patients with
ongestive heart failure have higher circulating IL-18 levels
han controls with no signs of chronic heart failure [19–21].
oreover, IL-18 levels seem to predict mortality in patients
ith congestive heart failure [21].
The promoter region of the human IL-18 gene has a com-
on single nucleotide polymorphism (SNP) at position −137
hat changes guanine to cytosine (G/C) (rs187238). This SNP
s in complete linkage disequilibrium with two other SNPs
n the IL-18 gene (located at positions +113 and +127) [22].
his polymorphism has been shown to regulate the IL-18 pro-
uction of peripheral blood monocytes and associated with
ranscriptional activity of the IL-18 gene [22–24].
To date, the association of IL-18 polymorphism with SCD
as remained unknown. Therefore, and based on previous
ata, we tested the hypothesis whether the IL-18 −137 G/C
olymorphism could be a risk factor for SCD and its subtypes
ith and without underlying CHD, using extensive autopsy
aterial from two independent autopsy series which included
total of 700 men and were carried out in the Helsinki Sudden
eath study. Furthermore, we investigated the effect of age on
his possible association, because the genetic susceptibility to
eath caused by CHD and to atherosclerosis has been shown
o decrease with advancing age [25,26].
. Material and methods.1. Subjects
The Helsinki Sudden Death study is based on the autopsy
aterial of 700 Caucasian Finnish men who had died sud-
M
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trosis 196 (2008) 643–649
enly out of hospital in the area of Helsinki (Mean age 53
ears, range 33–70 years). The material includes two inde-
endent autopsy series collected in 1981–1982 (A series,
= 400) and 1991–1992 (B series, n = 300). Because of their
nexpected sudden death occurring outside a hospital and
ften unwitnessed, all the men were subjected to a medi-
olegal autopsy, unless the deceased had suffered a clinically
iagnosed condition with a high probability of causing an
ntimely and sudden demise, such as severe chronic heart
ailure. This autopsy study covers 25.3% of all the 2850
eaths of 33–70-year-old males during the study period, cov-
ring 35.0% of all deaths which occurred due to ischemic
eart disease in the area of Helsinki. The leading cause of
eath within this study population was cardiac causes (41%,
= 288). Other causes of death were verified as other diseases
20%, n = 140) and unnatural deaths resulting from accidents
r suicides (39%, n = 272). All medicolegal autopsies were
erformed according to the same protocol at the Department
f Forensic Medicine at the University of Helsinki, and the
tudy was approved by the Ethics Committee of the depart-
ent/university.
.2. Genotyping of the IL-18 polymorphism
The cardiac muscle tissue samples collected for the
series were stored as paraffin-embedded blocks, and
he samples from the B series were stored frozen. The
NA was extracted from these samples using a method
escribed by Isola et al. [27]. The IL-18 SNP (rs187238)
as genotyped by using the 5′ nuclease assay for allelic
iscrimination with the ABI Prism 7900HT Sequence Detec-
ion System (Applied Biosystems, Foster City, CA, USA)
28]. The nucleotide sequences of the primers and the
uorogenic allele-specific oligonucleotide probes used in
CR were deduced from published sequences in the Gen-
ank database, and they were chosen and synthesized in
o-operation with Applied Biosystems. PCR reaction was
erformed according to standard protocol for TaqMan MGB
robes in a total volume of 5l. After cycling, end-point
uorescence was measured and the allelic discrimination
nalysis module carried out the genotype calling. Genotyp-
ng was successful for 663 of the 700 tissue samples (A
eries, 382 cases; B series, 281 cases). Water controls and
nown control samples were run in parallel with unknown
amples.
.3. Post-mortem veriﬁcation of old and acute
yocardial infarction
MI was verified by a macroscopic and histological exam-
nation of the myocardium. Fibrous scar tissue of the
yocardium was considered the diagnostic criterion for old
I and the presence of neutrophil granulocytes for an acute
I. The presence of a coronary thrombus was recorded
uring autopsy when coronary arteries were opened longi-
udinally.
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Table 1
General characteristics of the study subjects
Valid n All IL-18 genotype groups p-value
CG/CC (n = 304) GG (n = 359)
Age (years)a 663 53.2 ± 9.5 52.9 ± 9.5 53.4 ± 9.5 0.56
Body mass index, (kg/m2)a 663 24.7 ± 4.8 24.3 ± 4.9 25.0 ± 4.7 0.13
Alcohol use, (<60 g/d / ≥60 g/d) 432 215/217 97/97 118/120 1.00
Hypertensive, n (%) 663 101 39 (38.6%) 62 (61.4%) 0.13
Diabetic, n (%) 459 107 53 (49.5%) 54 (50.5%) 0.32
Smokers, n (%) 473 390 174 (44.6%) 216 (55.4%) 0.72
Coronary artery disease, n (%) 639 271 121 (44.6%) 150 (55.4%) 0.75
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Atatistics: p-values have been derived with analysis of variance (normally d
ontinuous variables), and chi-square test for categorical variables.
a Mean ± standard deviation.
.4. Varying causes underlying SCD
The deaths caused by cardiac diseases were divided into
wo categories by the autopsy findings—SCDs caused by
HD (80%, n = 220) and SCDs caused by non-coronary dis-
ases in the absence of CHD (20%, n = 55). Most of the men
ith CHD died of SCD due to an MI (n = 154) [death due to
cute myocardial infarct (AMI) (n = 101) or/and arrhythmias
ssociated with the scar of a prior MI (n = 53)], or CHD with-
ut AMI/prior MI (n = 64). Non-coronary SCDs were due to
ardiomyopathy, hypertrophy or dilatation of the hearth, or
alvular diseases.
.5. Collection of risk factor data
The information on common risk factors was obtained
y interviewing a close friend, spouse, or relative of the
eceased by means of a questionnaire. Complete interview
ata was available in 402 (60.6%) of the 663 cases whose
enotype was successfully determined. The interviewee was
sked whether the deceased had suffered from arterial hyper-
ension or diabetes prior to his death. Smoking habits and the
uantity/frequency of the average daily alcohol consumption
ere also inquired about. Subjects were categorized as smok-
rs and non-smokers. The ex-smokers were included in the
t
b
1
C
able 2
he number of men who had died of SCD or other causes and the percentages of C
he corresponding unadjusted and adjusted odds ratios (OR)
n CG/CC (%) Crude OR
ontrolsb 388 50.3
CD 275 39.6 0.65 (0.4
Non-CHDc 55 32.7 0.48 (0.2
CHD 220 41.4 0.70 (0.5
MI 154 39.0 0.63 (0.4
AMI 101 36.6 0.57 (0.3
AMI with thrombus 58 32.8 0.48 (0.2
AMI without thrombus 43 41.9 0.71 (0.3
bbreviations: IL-18, interleukin 18; CHD, coronary hearth disease; SCD, sudden
a Model adjusted with age, body mass index, smoking, hypertension, diabetes, an
b Death due to non-cardiac diseases or unnatural deaths.
c Death due to cardiomyopathy, cardiac hypertrophy or dilatation, or to valvular ded continuous variables), Mann–Whitney U-test (non-normally distributed
ategory of smokers for the statistical analysis. The reliabil-
ty of the risk factor data has been discussed earlier in more
etail [29].
.6. Statistical analyses
The small group of CC homozygotes in our study (n = 43,
.5%) was combined with the GC heterozygotes for statisti-
al analyses, because the risk for SCD was not significantly
ifferent between these two groups.
Logistic regression analysis was used to calculate the odds
atios for dependent variables according to genotype groups.
nalyses were carried out with and without adjustment for
utopsy data [body mass index (BMI) and age] and inter-
iew data (daily alcohol consumption, smoking, diabetes and
ypertension). Covariates were included in the model in a
tepwise manner if they were found statistically significant.
earson’s χ2-test was also used.
The combined group of men who had died of other dis-
ases and those who had died of unnatural causes was used
s a control group. This was done because the IL-18 geno-
ype group did not associate with the rate of deaths caused
y non-cardiac-related diseases or unnatural causes (Of the
30 men who had died of other diseases, 48.5% (n = 63) were
-allele carriers and of the 258 men who had died of unnat-
allele carries of the IL-18 gene −137 G/C polymorphism (rs187238) with
(95% CI) p-value Adjusted OR (95% CI)a p-value
8–0.89) 0.007 0.49 (0.31–0.77) 0.002
7–0.88) 0.016 0.34 (0.13–0.90) 0.030
0–0.98) 0.035 0.51 (0.32–0.82) 0.005
3–0.92) 0.018 0.48 (0.28–0.81) 0.006
6–0.90) 0.015 0.50 (0.28–0.90) 0.021
7–0.86) 0.014 0.40 (0.18–0.87) 0.021
8–1.35) 0.298 0.62 (0.29–1.33) 0.220
cardiac death; (A)MI, (acute)myocardial infarction.
d daily alcohol consumption.
isease in the absence of CHD.
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ral causes, 51.8% (n = 132) were C allele carriers). A value
f P < 0.05 was considered statistically significant. The com-
utations were carried out with SPSS for Windows software
Version 13.0, SPSS Inc., USA).
. Results
.1. Characteristics of the study subjects
The demographic characteristics of the entire study pop-
lation are presented in Table 1. The mean age of the study
opulation at the time of death was 53.2 ± 9.5 years (range
3–70 years). Of the 663 men, 359 (54.1%) had the wild-type
G-genotype, 261 (39.4%) were heterozygotes (CG), and 43
6.5%) were CC-homozygotes. The allelic frequencies of the
-allele and G-allele were 0.262 and 0.738, respectively. The
enotype distribution was in line with the Hardy–Weinberg
quilibrium. The genotype groups did not have any signifi-
ant associations with any common CAD risk factors or with
he occurrence of CAD within the whole study population or
mong different age groups, nor were any significant differ-
nces observed between subjects with or without interview
ata available.
.2. IL-18 polymorphism and the occurrence of SCD
rom any cause
In the entire study population, the C allele carriers had a
ower occurrence rate for SCD than GG homozygotes [crude
dds ratio, 0.65; 95% confidence interval (CI) 0.48–0.89;
= 0.007]. This association became more significant when
he analysis was adjusted for the interview data (adjusted
dds ratio 0.49; 95% CI 0.31–0.77; p = 0.002).
.3. IL-18 polymorphism and SCD in subjects with or
ithout underlying CHD
The odds ratios between the IL-18 genotype groups for
ifferent phenotypes of SCD are presented in Table 2. The C
llele carriers had a significantly lower risk for SCD due to
HD (adjusted odds ratio, 0.51; 95% CI 0.32–0.82;p = 0.005)
nd for SCD caused by non-coronary heart diseases (adjusted
dds ratio, 0.34; 95% CI 0.13–0.90, p = 0.030) when com-
ared to the GG homozygotes. The association between IL-18
enotype group and SCD due to CHD remained significant
hen the control population was limited to men with autopsy
erified CAD (n = 92) (adjusted OR, 0.45; 95% CI 0.24–0.85;
= 0.014)
Similarly, the C allele carriers had a lower occurrence
ate for SCD due to MI (adjusted odds ratio, 0.48; 95% CI
.28–0.81; p = 0.006). They were also at a significantly lower
isk for AMI (adjusted odds ratio, 0.50; 95% CI 0.28–0.90;
= 0.021). This difference became even more pronounced
hen the analysis was limited to the AMI victims who had
uffered an autopsy-verified coronary thrombus (adjusted
dds ratio, 0.40; 95% CI 0.18–0.87; p = 0.021).
d
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.4. IL-18 polymorphism and the age-dependency of
CD
In logistic regression analyses, the risk of the C allele
arriers for SCD from any cause, and for almost all other
ubtypes (see Section 3.3 and Table 2) of SCD, was lower
han that of the GG homozygotes. These associations were
ndependent of age (data not shown). However, there was a
ignificant genotype-by-age interaction with the risk of SCD
ue to MI (crude age-by-genotype group interactionp = 0.028
nd corresponding adjusted interaction p = 0.037 by logistic
egression analysis). Therefore, we formed two categories of
qual size by dividing the overall study population by the
ean age (53 years). In the younger age group (age <53
ears), the C allele was strongly protective against SCD due
o MI: of the 35 younger men, 26 (74.3%) were GG homozy-
otes and only 9 were (25.7%) C allele carriers (crude odds
atio, 0.34; 95% CI 0.14–0.68; p = 0.004 and adjusted odds
atio, 0.16; 95% CI 0.05–0.51; p = 0.002). In the older age
roup, 68 (57.1%) of the 119 men who had died of SCD due
o MI were GG homozygous and 51 (42.9%) were C allele
arriers. This difference was not statistically significant.
.5. IL-18 and SCD in separate and independent
utopsy series
The C allele carriers seemed to be underrepresented
mong SCD victims in both independent autopsy series col-
ected 10 years apart (A and B, please see Section 2 for the
escription of the autopsy series. In the A series, the differ-
nce was statistically significant (p = 0.039 by two sided exact
earson’s χ2-test). In the B series, there was a similar but not
ignificant trend (p = 0.085 by two sided exact Pearson’s χ2-
est) (Fig. 1). IL-18 genotype associated with the occurrence
f various phenotypes of SCD similarly in both series, but the
ssociations were not significant due to smaller sample sizes.
he major conclusions are therefore based on combined data
rom series A and B.
. Discussion
The major result of the present study was that a promoter
egion SNP (G-to-C) of the IL-18 gene at position −137
rs187238) associates with the occurrence (rate) of SCD. The
allele carriers had a lower occurrence rate for SCD when
ompared to the GG homozygotes. As a confirmation of this
esult, the same trend was evident in two independent autopsy
eries collected 10 years apart, which were combined to form
he present study population. The C allele carriers remained
t a lower risk for SCD caused by CHD and by non-coronary
eart diseases even after stratification.One reason for the selection of the IL-18 gene as a candi-
ate gene for SCD was its clearly demonstrated functionality.
reviously, this polymorphism has been shown to regulate the
roduction of IL-18 from peripheral blood monocytes [23].
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tig. 1. The number of sudden cardiac death (SCD) victims and those who h
L-18 genotype group in two consecutive and prospective autopsy series (A
y employing the two-sided exact Pearson chi-square test. Numbers in pare
urthermore, Liang et al. [22] found this polymorphism to
ssociate with decreased transcriptional activity of the IL-18
ene. The results of a previous haplotype study by Giedraitis
t al. [24] are also in line with this finding, in addition to
emonstrating that a change at position −137 from G to
changes the H4TF-1 nuclear factor binding site for an
nknown factor found in the GM-CSF promoter. The same
aplotype study also showed that the mRNA expression of
therogenic IFN- correlated significantly with the expres-
ion of IL-18 mRNA in GG homozygous patients but failed
o correlate with patients with the C allele [24].
IL-18 is a pro-atherogenic cytokine associated with the
ccurrence of various cardiac complications [8–11,30]. In
ight of these previous findings, we can suggest that the
ecreased occurrence of SCD in the C allele carriers in our
tudy is most likely associated with their impaired IL-18 pro-
uction. Previously high IL-18 levels have been associated
ith the occurrence angina pectoris, MI, and fatal coronary
vents [9–13]. Furthermore, in a haplotype study by Tiret et
l. [12], genetic variability of the IL-18 gene was shown to
ssociate with serum IL-18 levels and cardiovascular mortal-
ty in CAD patients. In this earlier study, one of the haplotypes
hich were in almost complete linkage with the SNP stud-
ed in the present study was not significantly associated with
ither serum IL-18 levels or cardiovascular mortality. How-
ver, a similar tendency towards a lower hazard ratio for
ardiovascular mortality was observed. Only one previous
tudy has failed to find any association between plasma IL-18
evels and coronary events [14].
IL-18 has been associated with the many factors promot-
ng the instability of atherosclerotic plaques – e.g., secretion
f IFN- and matrix metalloproteinases [31,32] – in addition
o being directly associated with the development of unsta-
le plaques [18]. The instability of atherosclerotic plaques
ay result in an accelerated development of coronary stenosis
33,34], but it also makes the patients prone to SCD [35].
d
I
c
dfrom other causes such as other diseases or unnatural death (Controls) by
981–1982 and B series 1991–1992). p-values for both series were obtained
are %.
In present study, we observed that the lower risk of the C
llele carriers for SCD due to MI was age dependent. After
ge stratification we found that younger (<53 years) middle-
ged C allele carriers had significantly lower occurrence rate
or SCD due to MI when compared to the GG homozygotes.
his effect was no longer seen among older men. Previous
tudies have shown that genetic susceptibility to atheroscle-
osis and to death caused by CHD decreases with advancing
ge [25,26]. Most likely, the burden of accumulating envi-
onmental risk factor becomes more dominant with age than
he effect of genetic factors.
In our study, the majority of the non-coronary SCDs were
ue to cardiomyopathy, hypertrophy, or dilatation of the heart.
nterestingly, IL-18 has previously been connected with the
athology of all of these diseases. The literature has reported
eart failure patients to have higher circulating IL-18 levels
hen compared to controls [19,20]. Moreover, IL-18 plasma
evels have been associated with the severity of heart failure
nd its clinical outcome [21]. In a study by Chandrasekar et al.
36], IL-18 was proven to induce cardiomyocyte hypertrophy
ia increased transcription and expression of atrial natriuretic
eptide (ANP). Prior to this, Seta et al. [20] had also reported
positive dose-dependent correlation between IL-18 stimu-
ation and ANP mRNA production. Despite its role in ANP
roduction, IL-18 may increase the risk of heart failure and
CD by increasing the pro-inflammatory response within
he myocardium as a result of enhancing the expression
f endothelial cell adhesion molecules and the production
f such pro-inflammatory mediators as IL-1, IL-8, tumor
ecrosis factor  (TNF), and inducible nitric oxide [21]. Of
hese mediators, nitric oxide and TNF are associated with
he modulation of contractile function and the loss of car-
iomyocytes [21]. Moreover, it has been demonstrated that
L-18 up-regulates membrane Fas ligand expression and may
ontribute to Fas-mediated apoptosis of Fas-expressing car-
iomyocytes [21]. Interestingly, this pathway has been related
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o cardiomyocyte apoptosis [37] and even to cardiomyocyte
rrythmogenicity [38]. In line with these earlier findings, we
bserved a clear association between IL-18 polymorphism
nd the occurrence of SCDs which had not been induced by
predisposing CHD.
The obvious limitation of our study is the absence of infor-
ation about serum IL-18, cholesterol and other lipid values
f the deceased men. Furthermore, we were unable to obtain
omplete interview data on all subjects due to the fact that our
ubjects were victims of sudden, unexpected out-of-hospital
eaths. All of the subjects were Caucasian men, and these
esults are thus not directly applicable to women and all ethnic
roups as such. The possible confounding effect of medi-
al therapies, for example the use of statins on the results
f the present study, is also unclear, because in the present
tudy reliable medical history of the study subjects was not
btained. On the other hand, this study was based on a large
umber of autopsies with reliable post-mortem verification
f various causes of death, coronary narrowing, myocardial
nfarctions and thrombi. This study includes nearly all SCDs
hich occurred in the Helsinki area during the time of the
utopsy series and, therefore, is quite representative of the
opulation at risk of SCD.
It is generally required that genetic association results be
epeatable in two independent samples. One strength of the
resent study is that it is based on two independent autopsy
eries collected 10 years apart. The major results were there-
ore also analyzed separately for these independent series.
here was no contradiction in the results of the two separate
utopsy series. The same association between IL-18 genotype
roup and the occurrence of SCD persisted in both indepen-
ent series, albeit it was not always as significant as it was in
he analysis conducted for the entire study population. This
ifference was due to smaller sample sizes and, therefore,
owers statistical power of the separate series. This led us to
ase the major conclusions of the study on the combined data
rom series A and B.
In the present study, the C allele of the IL-18 gene promoter
egion SNP (−137C/G, rs187238), previously associated
ith decreased production of IL-18 under inflammatory stim-
lation, also associates with a lower risk of SCD. This finding
upports the hypothesis that inflammatory mechanisms are
nvolved in the development of atherosclerosis and the insti-
ation of fatal cardiac complications and SCD.
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Aims The interleukin 18 (IL-18) gene has a single nucleotide promoter region (2137) G-to-C polymorphism (rs187238)
which leads to attenuated transcriptional activity of the gene and to lower production of pro-atherogenic IL-18. The
C allele of this polymorphism is associated with a lower risk of sudden cardiac death (SCD). We examined the
process by which this polymorphism alters the risk of SCD and coronary artery disease (CAD) by analysing the inter-
actions between this polymorphism and environmental factors.
Methods
and results
TaqMan 50 nuclease assay was used to genotype the study population of the Helsinki Sudden Death Study, comprising
medicolegal autopsies of 700 men. According to adjusted logistic regression analysis, there was a significant inter-
action between IL-18 genotype and hypertension impacting on the risk of SCD due to coronary heart disease
(CHD) (P ¼ 0.011) and the severity of autopsy-verified CAD (P ¼ 0.026). Among GG homozygotes, hypertension
was a major risk factor for SCD due to CHD [adjusted odds ratio (OR) 3.75 with 95% CI 1.78–7.91, P, 0.001]
and hypertension also associated with larger coronary atherosclerotic plaque areas (P ¼ 0.002) and the occurrence
of complicated plaques (adjusted OR 8.38 with 95% CI 2.39–29.33, P, 0.001). Among C allele carriers, hyperten-
sion was not a significant risk factor for CHD-related SCD or CAD and did not associate with the development of
coronary atherosclerotic plaques. According to gene expression analysis of atherosclerotic tissue samples obtained
from live patients, hypertension also interacted significantly with IL-18 genotype affecting the expression of IL-18
(P ¼ 0.030) mRNA and interferon-g mRNA (P ¼ 0.004).
Conclusion Hypertension interacts with IL-18 gene promoter 2137 G/C polymorphism, affecting the risk of SCD and the devel-
opment of coronary atherosclerosis.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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Introduction
Sudden cardiac death (SCD) is a major killer in the developed
nations.1–3 For example, according to a report by the US
Center of Disease Control (CDC), a total of 462 340 SCDs
occurred in the USA in 1999, and 341 780 (74%) of these cases
were classified as out-of-hospital deaths.1 The underlying cause of
most SCDs (80%) is pre-existing coronary heart disease (CHD),
* Corresponding author. Tel: þ358 3 311 74049, Fax: þ358 3 311 74168, Email: jussi.hernesniemi@uta.fi
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expressed as acute coronary syndrome, myocardial scarring due to
a previous infarction or heart failure.3
The major risk factors for CHD include hypertension, smoking,
male sex, obesity, and diabetes.4 Many of the same factors, such as
smoking, hypertension, and sex, also increase the risk of SCD, but
on an individual scale the risk of SCD is hard to predict.5–7 Even
less is known about the specific genetic factors associated with
SCD, although family history of SCD, primary cardiac arrest, and
myocardial infarction (MI) are known to increase the risk.7–9
The problem most likely lies in the complex aetiology of CHD
and different phenotypes of SCD.10 The interactions between tra-
ditional risk factors (e.g. hypertension and smoking) and genetic
variation may explain individual differences in the predisposition
for coronary artery disease (CAD) and SCD.
The human interleukin 18 (IL-18) gene has a common single
nucleotide polymorphism (SNP, rs187238) located at the promo-
ter region in position 2137 (G/C). We have previously shown that
the C allele carriers of this polymorphism have a lower risk for
SCD caused by CHD.11 This polymorphism is in complete
linkage disequilibrium with two other SNPs (þ113T/G and
þ127C/T),12 and it decreases the transcriptional activity of the
gene and the production of IL-18.12–14 IL-18 is a pro-inflammatory
and pro-atherogenic cytokine, and it has been directly associated
with the development of unstable atherosclerotic plaques.15–18
The production of IL-18 leads to the secretion of interferon-g
(IFN-g) and matrix metalloproteinases (MMPs), factors which are
associated with instability in atherosclerotic plaques.19,20 The
development of unstable plaques increases the risk of acute
cardiac events and may also lead to the development of
coronary stenosis.21–23 Similarly, IL-18 genetic variability and
increased plasma concentrations of IL-18 have previously been
associated with the occurrence of MI and acute fatal coronary
events.16,24–28
The mechanism by which IL-18 genotype affects the occurrence
of SCD remains unclear. It is possible that this genetic effect is due
to an altered predisposition to traditional risk factors. We decided
to examine whether traditional risk factors interact with IL-18
thus possibly impacting the occurrence of autopsy-verified CAD
and SCD.
Methods
Subjects
Current study consists of two separate studies: The Helsinki Sudden
Death Study (HSDS) and the Tampere Vascular Study (TVS). HSDS
is an autopsy study comprising two independent autopsy series col-
lected in 1981–1982 (A series, n ¼ 400), and 1991–1992 (B series,
n ¼ 300). The autopsies were performed on Finnish Caucasian men
(mean age of 53 years, range 33–70 years). All the men were sub-
jected to a medicolegal autopsy because of their unexpected and
often unwitnessed sudden death occurring outside a hospital. A med-
icolegal autopsy was not performed if the deceased had a previous
clinical diagnosis of CAD complicated by, for example, severe
chronic heart failure. All medicolegal autopsies were performed
according to the same protocol at the Department of Forensic Medi-
cine at the University of Helsinki, and the study was approved by the
Ethics Committees of the Department and the University. The details
of this study have been described in detail earlier.29 The TVS material
consists of arterial samples of atherosclerotic lesions (types V–VI)30
from carotid arteries (n ¼ 9), femoral arteries (n ¼ 4), and the
aortas (n ¼ 7) of 20 patients subjected to vascular surgical procedures
and healthy control samples of the left interior thoracic artery and the
left interior mammary artery of patients (n ¼ 6) undergoing coronary
artery bypass surgery in Divisions of Vascular and Cardiothoracic
Surgery, Tampere University Hospital.31 Genome wide expression
analysis (GWEA) was performed on all the samples. Of the patients,
15 were GG homozygotes, 9 GC heterozygotes, and 1 was a CC
homozygote. The patients were divided into two groups: GG homozy-
gotes and C allele carriers. The expression levels of IL-18 receptor a
(IL-18Ra), IFN-g, and IL-12 have been previously measured using real-
time polymerase chain reaction (PCR) for a separate publication, and
these measurements were incorporated into the data to obtain
more accurate results.31
Genotyping of the IL-18 polymorphism
The DNA samples were genotyped using the 50 nuclease assay for
allelic discrimination with the ABI Prism 7900HT Sequence Detection
System (Applied Biosystems, Foster City, CA, USA). Genotyping of the
IL-18 SNP (rs187238) was successful for 663 (94.7%) of the 700 tissue
samples in the HSDS and 25 (96.2%) of the 26 tissue samples in the
TVS. The method of genotyping by PCR has been described in detail
earlier.11 Random duplicates were used as a quality control.
Post mortem verification and classification
of varying causes underlying sudden
cardiac death
Of all the SCDs in the present material, 220 (80%) were caused by
CHD. Most frequently, the cause of death was acute or old MI (n ¼
154). Of these deaths, 101 were caused by an acute MI, 53 were
associated with the scar of a prior MI and were most probably due
to arrhythmias, and 64 men suffered a CHD-related SCD with no
MI aetiology. Myocardial infarction was verified by means of a macro-
scopic and histological examination of the myocardium. The presence
of a coronary thrombus was recorded during autopsy, when coronary
arteries were opened longitudinally.
Autopsy measurement of coronary stenosis
and atherosclerosis
At autopsy, a silicon rubber cast was made from the three main epicar-
dial coronary arteries (the left anterior descending, left circumflex, and
right coronary artery). The degree of coronary stenosis was deter-
mined from these rubber models. The cut-off value for the classifi-
cation of CAD was over 50% stenosis in any part of one or several
main coronary arteries. In order to analyse the areas of different
types of atherosclerotic lesions and overall atherosclerosis, the coron-
ary arteries were fixed in 10% buffered formalin and stained for fat by
the Sudan IV staining method. The methods of these measurements
have been described previously.32
Collection of risk factor data in the HSDS
A close friend, spouse, or relative of the deceased was interviewed by
means of a questionnaire to obtain risk factor data. Complete inter-
view data on risk factors were available in 402 (60.6%) of the 663
cases whose IL-18 genotype was successfully determined.32 Risk
factor data included the following variables: hypertensive (yes/no), dia-
betic (yes/no), smoker (yes/no) (smokers and ex-smokers were com-
bined into the category of smokers for the statistical analysis), daily
alcohol consumption, and body mass index (BMI). Body mass index
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was calculated from the autopsy data. The victim was considered
hypertensive if his hypertension had been diagnosed clinically by a
physician and/or he was medically treated for hypertension, or if it
was known that hypertensive blood pressure (BP) values had been
measured from the subject prior to his death.
RNA isolation and genome wide expression
analysis
The fresh tissue samples (n ¼ 26) were immediately soaked to RNA-
Later solution (Ambion Inc., Austin, TX, USA) and total-RNA was iso-
lated with Trizol reagent (Invitrogen, Carlsbad, CA, USA) and
RNAEasy Kit (Qiagen, Valencia, CA, USA). The GWEA Microarray
experiments were performed by using Sentrixw Human-8 Expression
BeadChips analysing over 23 000 known genes and gene candidates
(Illumina, San Diego, CA, USA) according to the instructions given
by the manufacturer. BeadChips were scanned with Illumina BeadArray
Reader. The method has been more accurately described in our earlier
work.31 The accuracy of Illumina Sentrixw Human-8 Expression Bead-
Chips microarray methodology to measure the gene expression was
verified by real-time quantitative TaqMan PCR through quantifying
the expression of 20 genes with both methods.33
Statistical analyses
Because of the small number of CC homozygotes (n ¼ 43, 6.5%) in the
HSDS, they were combined with the GC heterozygotes to form a
group of C allele carriers for statistical analyses. However, the analyses
were also repeated without pooling the genotypes.
In order to compare the characteristics between genotype groups,
we used Pearson’s x2-test for categorical variables and the Mann–
Whitney U test for continuous variables. Binary logistic regression
analysis was used to calculate the IL-18 genotype-by-risk-factor inter-
actions. Analyses for each genotype group by risk factor interaction
were carried out with and without adjustment for autopsy data (BMI
and age) and interview data (alcohol consumption, smoking, diabetes,
and hypertension). Covariates were included in the model in a step-
wise manner. Only statistically significant (P, 0.05) covariates were
accepted in the final adjusted model. If the interaction between
IL-18 genotype group and a risk factor was found significant, the
effect of the risk factor on the occurrence of SCD was studied separ-
ately using unadjusted and adjusted binary logistic regression analysis
(stepwise procedure for accepting significant covariates) stratifying
the population by IL-18 genotypes.
The control group consisted of men who had died of other diseases
and men who had died of unnatural causes. This was included because
the IL-18 genotype group did not associate with the rate of deaths
caused by non-cardiac-related diseases or unnatural causes.
In the TVS material, the expression levels of IL-18 mRNA and IFN-g
mRNA were compared over IL-18 genotype groups, and patients with
or without hypertension using adjusted analysis of variance (ANOVA).
All ANOVAs were adjusted with the mRNA expression of surface
structures expressed by antigen presenting cells (APC) [CD80 and
CD86 transcript variant 1 (v1) and CD86 transcript variant 2 (v2)]
and by T-cells (CD4, CD28, and CTLA-4).34 Macrophages which act
also as APCs are major producers of IL-18 and T cells are major pro-
ducers of IFN-g.19 Only significant covariates were selected into the
model by a backward elimination procedure. This allowed us to
compare the expression of IL-18 and IFN-g between samples with
different inflammatory background, and it was necessary because the
current material consist of atherosclerotic samples from different vas-
cular beds with variation in inflammatory background. The expression
of the mRNA of these factors is subjected to inflammatory stimuli.34
Thus, they do not represent directly the quantity of the T-cells or
APCs in the samples. However, at the same time, they provide
some adjustment on the inflammatory activity within the samples. All
analyses were repeated with log-transformation of the continuous vari-
ables, but this did not improve the predictive value of the analyses
(measured by pseudo R2-value), and thus the results of the analyses
performed with crude values are reported. The study population
was divided into two groups by median systolic arterial pressure
(140 mmHg) in order to study the effect of hypertension on the
dependent variables.
In both studies, the significance P-value , 0.05 was considered stat-
istically significant. Values of significance on all non-parametric tests are
presented as asymptomatic and two-tailed. The computations were
carried out with SPSS for Windows software (Version 14.0, SPSS
Inc., TX, USA).
Results
Characteristics of the study subjects
in the HSDS
The mean age of the study population at the time of death was
53.2+ 9.5 years (range 33–70 years). The characteristics of the
study population are presented in Table 1. The genotype frequen-
cies in the order of GG-GC-CC were: 359 (54.1%), 261 (39.4%),
and 43 (6.5%). The allelic frequencies were 0.262 for the C allele
and 0.738 for the G allele. The genotype distribution was in
accordance with the Hardy–Weinberg equilibrium (P ¼ 0.89 by
x2-test). The genotype groups did not have any significant associ-
ations with any common CAD risk factors or with the occurrence
of CAD, nor were there any significant differences (observed)
between subjects with or without interview data available (data
not shown).
The interactions between risk factors and
IL-18 gene polymorphism on the risk
of sudden cardiac death and coronary
artery disease
According to unadjusted binary logistic regression analysis, IL-18
genotype group interacted significantly with hypertension (crude
P ¼ 0.009 and adjusted P ¼ 0.011) as regards to the effect on
the risk of SCD. After applying the Bonferroni correction, the
interaction remained significant (crude P ¼ 0.045 and adjusted
P ¼ 0.055). When the IL-18 genotype information was entered
into the analysis without pooling CG heterozygotes and CC
homozygotes, the result remained significant (crude P ¼ 0.022
and adjusted P ¼ 0.029). Interactions with daily alcohol consump-
tion (P ¼ 0.600), BMI (P ¼ 0.075), smoking (P ¼ 0.998), or dia-
betes (P ¼ 0.943) were not statistically significant.
Similarly, in unadjusted binary regression analysis of the occur-
rence of CAD, there was a statistically significant interaction
between IL-18 genotype group and hypertension (P ¼ 0.020),
which remained significant after an adjustment for other risk
factors (P ¼ 0.026). After Bonferroni correction, the interaction
was no longer significant (crude P ¼ 0.100 and adjusted P ¼
0.130). Interactions with daily alcohol consumption (P ¼ 0.701),
BMI (P ¼ 0.833), smoking (P ¼ 0.805), and diabetes (P ¼ 0.316)
were not statistically significant.
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The effect of hypertension on the risk of
sudden cardiac death and coronary artery
disease among IL-18 genotypes
Because of the statistically significant genotype-group-by-
hypertension interaction, we divided the study population accord-
ing to IL-18 genotype. Among GG homozygotes and C allele
carriers, hypertensive men were statistically significantly older and
had higher BMI compared with normotensive men (Table 2). The
same associations were also observed separately among the 226
GC heterozygotes (P ¼ 0.023 for age and P ¼ 0.001 for BMI), but
no longer among the 43 CC homozygous men (n ¼ 0.927 for age
and P ¼ 0.118 for BMI). No other statistically significant differences
were observed between hypertensive and normotensive men in
either genotype group. Among SCD victims, 23.9% (n ¼ 55) had
suffered from hypertension. In the control group, the corresponding
number was 10.4% (n ¼ 43).
Hypertension was a major risk factor of SCD and CAD among
GG homozygotes, but not among combined group of C allele car-
riers or among GC heterozygotes or CC homozygotes, when the
genotypes were analysed separately (Table 3). Among GG homo-
zygotes, hypertension associated significantly with SCD due to
CHD (adjusted OR 3.75, P ¼ 0.0005; Figure 1), SCD due to old
or acute MIs (SCD due to arrhythmias caused by an old MI scar
and/or AMI) (adjusted OR 4.56, P ¼ 0.0002), fatal acute MI
(adjusted OR 4.69, P ¼ 0.0004), and with CAD (adjusted OR
3.08, P ¼ 0.0027; Figure 1). Among the CC homozygotes, the
effect of hypertension on the risk of SCD and CAD was evaluated
by Fisher’s exact x2-test because only five men had suffered from
hypertension, one of them had suffered SCD, and only two had
CAD. According to the x2-test, hypertension was not associated
with SCD due to CHD (P ¼ 0.632), SCD due to old or acute MI
(P ¼ 1.00), fatal acute MI (P ¼ 1.00), or with CAD (P ¼ 1.00).
The effect of hypertension on the
different atherosclerotic plaque areas
in the HSDS
In order to study how hypertension affects the atherosclerotic
plaque formation and composition among IL-18 genotype
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Table 2 Characteristics of hypertensive and normotensive men among GG homozygotes and C allele carriers of the
IL-18 -137G/C polymorphism
GG homozygotes P-Value C allele carriers P-Value
Hypertensive
(n 5 62)
Normotensive
(n 5 297)
Hypertensive
(n 5 39)
Normotensive
(n 5 265)
Age (years)a 56.4 (9.5) 53.8 (9.7) 0.007 56.0 (9.4) 52.4 (9.5) 0.029
Body mass index (kg/m2)a 26.8 (4.2) 24.6 (4.7) 0.001 26.5 (4.4) 23.9 (4.9) 0.002
Alcohol use (portions/day)b 6.9 (9.4) 7.8 (8.4) 0.533 5.4 (6.1) 8.2 (9.4) 0.081
Diabetic, n (%) 16 (25.8) 38 (19.9) 0.373 11 (28.2) 42 (25.1) 0.839
Smokers, n (%) 50 (84.7) 166 (82.6) 0.844 30 (78.9) 144 (82.3) 0.646
P-values have been derived with analysis of variance, the Mann–Whitney U test, and the chi-square test for categorical variables.
aMean+ standard deviation.
bMean+ standard error of mean.
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Table 1 General characteristics of the study subjects
Valid n All IL-18 genotype groups
GG (n5 359) GC/CC (n5 304) P-Value
Age (years)a 663 53.2+9.5 53.4+9.5 52.9+9.5 0.56
Body mass index (kg/m2)a 663 24.7+4.8 25.0+4.7 24.3+4.9 0.13
Alcohol use (portions/day) 432 7.6+8.8 7.6+8.6 7.7+9.0 0.91
Hypertensive, n (%) 663 101 (15.2%) 62 (17.3%) 39 (12.8%) 0.13
Diabetic, n (%) 459 107 (23.3%) 54 (21.3%) 53 (25.7%) 0.32
Smokers, n (%) 473 390 (82.5%) 216 (83.1%) 174 (81.7%) 0.72
Coronary artery disease, n (%) 639 271 (42.4%) 150 (43.1%) 121 (41.6%) 0.75
Sudden cardiac death victims, n (%)b 608 220 (36.2%) 129 (40.1%) 91 (31.8%) 0.04
P-values have been derived with analysis of variance, the Mann–Whitney U test, and the chi-square test.
aMean+standard deviation.
bCoronary heart disease-related sudden cardiac death victims.
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groups, we focused on the control group. This was done to avoid
the evident selection bias presented by the significantly different
mortality to CHD-related SCD among different IL-18 genotype
groups. Among GG homozygotes, according to ANOVA adjusted
with autopsy data (BMI and age), the coronary arteries of hyper-
tensive men were more afflicted by overall atherosclerosis
Figure 1 The effect of hypertension on the risk of sudden cardiac death (SCD) and coronary artery disease (CAD) among the GG homo-
zygotes and C allele carriers of the IL-18 gene 2137G/C polymorphism. Odds ratios (OR) are derived by logistic regression adjusted with
traditional risk factors for CAD.
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Table 3 The effect of hypertension on the risk of sudden cardiac death and coronary artery disease among GG
homozygotes, C allele carriers and GC heterozygotes of the IL-18 2137 (G/C) polymorphism
Unadjusted OR (95% CI) P-Value Adjusted OR (95% CI) P-Value
GG homozygotes
SCD by CHD 4.21 (2.28–7.78) ,0.00001 3.75 (1.78–7.91) 0.0005
SCD with MI aetiology 5.02 (2.63–9.57) ,0.000001 4.56 (2.05–10.11) 0.0002
SCD by fatal acute MI 4.75 (2.33–9.68) 0.00002 4.69 (2.01–10.95) 0.0004
CAD 4.42 (2.40–8.13) ,0.000002 3.08 (1.48–6.41) 0.0027
CG heterozygotes
SCD by CHD 0.35 (0.04–3.45) 0.369 0.75 (0.28–2.00) 0.565
SCD with MI aetiology 1.69 (0.71–3.99) 0.233 1.06 (0.36–3.10) 0.922
SCD by fatal acute MI 1.88 (0.68–5.14) 0.222 1.30 (0.40–4.22) 0.661
CAD 1.54 (0.73–3.23) 0.259 0.83 (0.32–2.11) 0.687
C allele carriers
SCD by CHD 1.19 (0.57–2.46) 0.643 0.78 (0.32–1.91) 0.583
SCD with MI aetiology 1.43 (0.64–3.18) 0.390 0.88 (0.32–2.40) 0.805
SCD by fatal acute MI 1.66 (0.66–4.20) 0.282 1.14 (0.39–3.37) 0.814
CAD 1.48 (0.73–2.97) 0.276 0.78 (0.32–1.89) 0.581
P-values have been derived with regression analysis. Autopsy data (BMI and age) and interview data (alcohol consumption, smoking, diabetes, and hypertension) were used to
adjust the analyses. Covariates were included in the model in a stepwise manner. Only statistically significant (P, 0.05) covariates were accepted in the final adjusted model.
SCD, sudden cardiac death; CHD, coronary heart disease; MI, myocardial infarction; CAD, coronary artery disease.
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(measured as the relative surface area covered by atherosclerotic
lesions) [11.71% (SE 1.72) vs. 6.18% (SE 0.48), P ¼ 0.002] when
compared with normotensive men. Hypertensive men also had
larger relative areas of fatty streaks [7.14% (SE 1.34) vs. 4.21%
(SE 0.40), P ¼ 0.026] and fibrotic plaques [4.57% (SE 0.66) vs.
1.97% (SE 0.21), P, 0.001]. According to adjusted regression
analysis, hypertension was also a significant risk factor for the
occurrence of complicated plaques (OR 8.38 with 95% CI 2.39–
29.33, P, 0.001, covariates: BMI and age).
Among C allele carriers, hypertension was not associated with
the overall atherosclerotic burden [9.34% (SE 1.08) vs. 8.38% (SE
0.72), P ¼ 0.701], relative surface areas of fatty streaks [6.80%
(SE 1.03) vs. 5.17% (SE 0.50), P ¼ 0.306], surface areas of fibrotic
plaques [2.53% (SE 0.62) vs. 3.21% (SE 0.43), P ¼ 0.268], or with
the occurrence of complicated plaques (OR 2.07 with 95% CI
0.73–5.89, P ¼ 0.174). In addition, when the groups of GC hetero-
zygotes and CC homozygotes were analysed separately, hyperten-
sion did not associate significantly with the plaque areas or with
the occurrence of complicated plaques.
The effect of IL-18 genotype and
hypertension on the expression of IL-18
and IFN-g in atherosclerotic arterial
samples (TVS)
According to adjusted ANOVA, the effect of hypertension on the
expressions of IL-18 mRNA and IFN- g mRNA were modulated by
the IL-18 genotype [P ¼ 0.030 (IL-18) and P ¼ 0.004 (IFN- g) for
the interactions]. Among GG homozygotes, hypertension did not
associate with the expression level of intracellular precursor
IL-18 mRNA (0.89-fold increase, P ¼ 0.217), whereas among
C allele carriers hypertension augmented the expression of intra-
cellular precursor IL-18 mRNA (1.31-fold increase, P ¼ 0.001).
Almost inversely, among GG homozygotes hypertension associ-
ated with a higher expression level of pro-atherosclerotic IFN-g
(1.58-fold increase, P ¼ 0.006), whereas among C allele carriers
hypertension seemed to associate with a lower expression level
of IFN-g (0.58-fold increase, P ¼ 0.047).
In the atherosclerotic samples obtained from GG homozygotes,
the expression levels of the intracellular precursor IL-18 mRNA
were lower (0.68-fold increase, P, 0.001), but the expression
levels of IFN-g mRNA were higher (1.85-fold increase, P,
0.001) when compared with the atherosclerotic samples of the
C allele carriers. Furthermore, according to unadjusted Mann–
Whitney U test, the expression levels of the IL-18 mRNA
seemed to be significantly higher in the healthy control samples
when compared with the atherosclerotic samples (1.33-fold
increase, P ¼ 0.052).
Significant covariates associating with the expression of IL-18
mRNA were: CD80 (P ¼ 0.006), CD86v1 (P ¼ 0.012), CD4 (P ¼
0.013), CD86v2 (P ¼ 0.010), Caspase-1 variant a (P ¼ 0.023),
and Caspase-1 variant e (P ¼ 0.009). The expression levels of
Caspase-1 (Casp-1) variants were also introduced to this model
because Casp-1 cleaves the IL-18 precursor protein into biologi-
cally active IL-18 resulting in the secretion of mature IL-18
protein. This intrinsic processing likely affects the amount of
intracellular IL-18 precursor mRNA, which has a stable mRNA
structure and is constitutively and intracellulary stored.35
Significant covariates associating with the expression of IFN-g
mRNA were: CD80 (P, 0.001), CD86v1 (P, 0.001), CD4 (P ¼
0.014), CTLA-4 (P ¼ 0.010), IL-12 (P ¼ 0.004), and IL-18Ra (P ¼
0.003). The expression levels of IL-12 and IL-18Ra were also
included into this model because IL-12 in synergy with IL-18 aug-
ments the production of IFN-g and IL-18Ra plays an important
role in IL-18 signalling.35 The expression of IL-18 binding protein,
Casp-1va, and Casp-1ve was also added to the analysis, but
these covariates were not significant in the model and thus were
not used for further adjustment.
Discussion
According to the present study, the IL-18 genotype significantly
modifies the association of arterial hypertension with the occur-
rence of SCD due to CHD. We found that arterial hypertension
was a major risk factor for SCD and severe CAD among GG
homozygotes, but not among C allele carriers of the 2137 (G/C)
polymorphism (rs187238). When we studied the risk of SCD
due to MI (SCD due to arrhythmias caused by an old MI scar
and/or AMI) or the risk of fatal acute MI, the results were even
more pronounced despite the lower sample sizes of the sub-
groups. The results of the autopsy data of the independent
control group showed that hypertension associates significantly
with development of overall coronary atherosclerosis as well as
with the occurrence of complicated plaques among GG homozy-
gotes, but not among C allele carriers. To confirm and investigate
further this interaction, we performed detailed analysis of gene
expression in atherosclerotic samples from live patients of the
TV study. The results showed that the effect of hypertension on
the expressions of IL-18 mRNA and IFN-g mRNA is modulated
by the IL-18 genotype.
Previously, it has been shown that circulating IL-18 levels are
higher among patients with unstable angina pectoris and among
MI victims.24,26,36 Among CAD patients, higher IL-18 levels are
associated with a higher risk of a future fatal coronary event.25
Higher IL-18 levels have also been found to predict future coron-
ary events among healthy middle-aged men.37 The studied promo-
ter G-to-C polymorphism of the IL-18 gene has been proven
functional with the C allele, associating with lower transcriptional
activity of the IL-18 gene and thus resulting in an attenuated pro-
duction of IL-18.12–14 Supporting these previous results, recent
haplotype studies have shown that the variation in the IL-18
gene associates with circulating IL-18 levels.16,38 The same
studies also showed that a major haplotype which is the sole
carrier of the 2137C allele associates with lower IL-18 levels
and with cardiovascular mortality during a follow-up of 5.9 years.
One other major haplotype, the only one carrying the G allele
of the A-to-G polymorphism at position þ183, was similarly
associated with the same endpoints. Other haplotypes or SNPs
of this gene were not found to associate with circulating IL-18
levels or cardiovascular mortality.16,38 Based on these previous
results, it seems clear that IL-18 gene variation affects cardiovascu-
lar mortality. However, according to our new results, the
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association between this polymorphism and CHD-related SCD
seems more complex.
High BP values have previously been associated with high circu-
lating IL-18 concentrations.39,40 Furthermore, circulating IL-18
values along with greater intima media thickness values could
be treated effectively by lowering morning BP peaks with a
12 month treatment with the unselective b-blocker carvedilol.40
Nevertheless, this does not explain why hypertension seems
to associate with the risk for SCD only among IL-18 GG
homozygotes.
In the present study, we found that IL-18 genotype significantly
modulates the effect of hypertension on the expression of IL-18
mRNA and IFN-g mRNA in atherosclerotic tissue samples
obtained from live patients. It is especially noteworthy that
among GG homozygotes, hypertension associated with higher
expression level of the pro-atherosclerotic IFN-g. In the group
of C allele carriers, hypertension actually associated with lower
expression level of IFN-g despite the fact that among them hyper-
tension did associate with a higher expression level of the intra-
cellular IL-18 mRNA. Previously, it has been shown that
b2-adrenergic receptor stimulation activates both basal and induci-
ble IL-18 promoter activity in endothelial cells leading to upregula-
tion of IL-18 mRNA expression, and more stable IL-18 mRNA.41
Also, it has been shown in an in vitro study that aldosterone in car-
diomyocytes, through the production of angiotensin II and
endothelin-1, increase IL-18 mRNA and protein expression.42
Unfortunately, it is not possible to deduct more conclusions
from our expression analysis results because the regulation of
the different genetic pathways is highly complex, and thus more
accurate and extensive data would be required.
Hypertension might also have a more general effect on the occur-
rence of SCD and formation of atherosclerosis. The overall
pro-inflammatory effects of higher BP on the vessel wall43 may lead
to increased production of mature IL-18 by endothelial cells and
macrophages. Also the C allele carriers might be better protected
against this because of their impaired production of IL-18.12–14
Furthermore, Sahar et al.44 have shown that pre-treatment of vascular
smooth muscle cells with angiotensin II increases the expression of
the ligand-binding subunit of IL-18Ra of the IL-18 receptor, and
thus leads to IL-18-mediated induction of the transcription factor
nuclear factor-kB (pathway leading to the expression of several
pro-inflammatory cytokines and chemokines and the production of
pro-inflammatory cytokines such as IL-6 and IL-8).
A major limitation of our study is the fact that we do not have
the genotype data concerning the þ183A/G polymorphism
(rs5744292) which has also been found to significantly affect circu-
lating IL-18 levels. However, as the haplotype carrying the þ183G
allele is also associated with attenuated production of IL-18, it only
emphasizes our results because these two SNPs do not co-exist in
a same haplotype.16 Therefore, among GG homozygotes of the
2137G/C polymorphism, there are more G allele carriers of the
þ183A/G polymorphism than among the C allele carriers.16,38 Fur-
thermore, we had no data on the serum IL-18, cholesterol, and
other lipid values of the deceased men. In addition, we were
unable to obtain complete interview data on all subjects, and
thus we were unable to analyse the possible effect of pre-mortem
medication on the IL-18 genotype-by-hypertension interaction.
The information on hypertension in the present study was based
on interview data which cannot be considered a valid data based
on recorded clinical measurements. However, previous studies
have shown that the validity of interview data concerning hyper-
tension is high,45,46 and moreover, it is more likely for hypertensive
men to have been misdiagnosed as normotensive, than normoten-
sive men as hypertensive. This suggests that the reliability of our
results would not be significantly weakened by this limitation.
More likely, our results would be more pronounced if the accuracy
of the diagnosis would be better. Other limitations concerning the
study population have been discussed earlier.11 The strength of the
present study is the fact that it comprises almost all SCDs which
occurred in the Helsinki region during the time of the collection
of the autopsy series, making our study population a valid repre-
sentative of a population at the risk of SCD.
In conclusion, our results suggest that the effect of hypertension
on the development of CHD leading to an untimely SCD and the
development of overall coronary atherosclerosis as well as the
occurrence of complicated plaques is modulated by the IL-18
gene promoter region 2137G/C polymorphism. Hypertension
seems to be a major risk factor for these endpoints among GG
homozygous men, but not among C allele carriers.
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